Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.7.1.153 - phosphatidylinositol-4,5-bisphosphate 3-kinase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
Acidosis impairs insulin receptor substrate-1-associated phosphoinositide 3-kinase signaling in muscle cells: consequences on proteolysis.
Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy.
Lipopolysaccharide directly inhibits bicarbonate absorption by the renal outer medullary collecting duct.
Phosphoinositide 3-kinase accelerates calpain-dependent proteolysis of fodrin during hypoxic cell death.
Phosphoinositide 3-kinase accelerates necrotic cell death during hypoxia.
The Metabolic Mechanisms of Breast Cancer Metastasis.
Acquired Immunodeficiency Syndrome
'How can I halt thee?' The puzzles involved in autophagic inhibition.
PIK3CA mutation in a mixed dysembryoplastic neuroepithelial tumor and rosette forming glioneuronal tumor, a case report and literature review.
Acute Coronary Syndrome
Endothelial Microparticles From Acute Coronary Syndrome Patients Induce Premature Coronary Artery Endothelial Cell Aging and Thrombogenicity: Role of the Ang II/AT1 Receptor/NADPH Oxidase-Mediated Activation of MAPKs and PI3-Kinase Pathways.
Acute Kidney Injury
Renal ischemia/reperfusion and ATP depletion/repletion in LLC-PK(1) cells result in phosphorylation of FKHR and FKHRL1.
Telluric Acid Ameliorates Endotoxemic Kidney Injury in Mice: Involvement of TLR4, Nrf2, and PI3K/Akt Signaling Pathways.
Acute Lung Injury
Lack of phosphoinositide 3-kinase-gamma attenuates ventilator-induced lung injury.
Preventive and therapeutic effects of phosphoinositide 3-kinase inhibitors on acute lung injury.
Adenocarcinoma
Adenosquamous gallbladder carcinoma: Multigene hotspot mutational profiling reveals a monoclonal origin of the two components.
Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors.
Amplification of CCND1, EMS1, PIK3CA, and ERBB oncogenes in ethmoid sinus adenocarcinomas.
An oncogenic, somatic mutation of PIK3CA identified in 2 primary malignancies: clear cell renal cell carcinoma and prostate adenocarcinoma in the same patient.
ARID1A gene mutation in ovarian and endometrial cancers (Review).
Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer.
Clinicopathological, molecular features and prognosis of colorectal cancer with mucinous component.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase.
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Detection of oncogenic mutations in cervical carcinoma using method High Resolution Melting (HRM).
Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes.
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.
Distinctive Patterns of CTNNB1 (?-Catenin) Alterations in Salivary Gland Basal Cell Adenoma and Basal Cell Adenocarcinoma.
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy.
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes.
Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.
Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma.
GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy.
Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications.
Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients.
Hepatoid Adenocarcinoma of the Lung: A Systematic Review of the Literature From 1981 to 2020.
Hepatoid adenocarcinoma of the stomach with PIK3Ca mutation during pregnancy: A case report with molecular profile.
Hot spot mutations in Finnish non-small cell lung cancers.
Human Papillomavirus-Associated Adenocarcinoma of the Base of Tongue: Potentially Actionable Genetic Changes.
Identification of novel prognosis-related genes in the endometrial cancer immune microenvironment.
Immunohistochemistry features and molecular pathology of appendiceal neoplasms.
Impact of Somatic Mutations in Non-Small-Cell Lung Cancer: A Retrospective Study of a Chinese Cohort.
Improved survival associated with somatic PIK3CA mutations in copy-number low endometrioid endometrial adenocarcinoma.
Inhibitory effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Integration of gene profile to explore the hub genes of lung adenocarcinoma: A quasi-experimental study.
Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of Epstein-Barr virus).
Involvement of ERK1/2, p38 MAPK, and PI3K/Akt signaling pathways in the regulation of cell cycle progression by PTHrP in colon adenocarcinoma cells.
KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages.
KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
MicroRNAs associated with initiation and progression of colonic polyp: A feasibility study.
Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas.
Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
Mucinous Adenocarcinoma of the Rectum: A Whole Genome Sequencing Study.
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Mutational analysis of PI3K/AKT and RAS/RAF pathway activation in malignant salivary gland tumours with a new mutation of PIK3CA.
Mutations of PIK3CA in gastric adenocarcinoma.
N-terminal domains of the class ia phosphoinositide 3-kinase regulatory subunit play a role in cytoskeletal but not mitogenic signaling.
Next-Generation Sequencing in Salivary Gland Basal Cell Adenocarcinoma and Basal Cell Adenoma.
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.
Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.
p85? is a microRNA target and affects chemosensitivity in pancreatic cancer.
Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110?.
Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review.
Phase I Study of the Anti-Angiogenic Antibody Bevacizumab and the mTOR / Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin.
Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics.
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
PIK3CA mutation status in Japanese lung cancer patients.
PIK3CA mutations and copy number gains in human lung cancers.
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
PIK3CA mutations in small bowel adenocarcinoma.
PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis.
Retinoic acid signaling through PI 3-kinase induces differentiation of human endometrial adenocarcinoma cells.
Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer.
Sodium butyrate-mediated differentiation of colorectal cancer cells: regulation of PKCbetaII by PI 3-kinase.
Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer.
Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
The FOXO1-miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma.
The Landscape of PIK3CA Mutations in Colorectal Cancer.
The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
The PI 3-kinase-Rac-p38 MAP kinase pathway is involved in the formation of signet-ring cell carcinoma.
The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas.
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review.
Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
[Construction of recombinant adenovirus vector expressing shRNAs targeting COX-2, AKT1 and PIK3R1 gene and its inhibition effect on proliferation of human gastric adenocarcinoma]
[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
[New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "à la carte" treatment?].
Adenocarcinoma of Lung
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
AKT1 and AKT2 mutations in lung cancer in a Japanese population.
Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma.
Analysis of genomic variation in lung adenocarcinoma patients revealed the critical role of PI3K complex.
Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens.
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Concealed driver in lung adenocarcinoma with single PIK3CA mutation: a case report and single-center genotyping review.
Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.
Differential molecular markers of primary lung tumors and metastatic sites indicate different possible treatment selections in patients with metastatic lung adenocarcinoma.
EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.
Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas.
Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population.
Integration of gene profile to explore the hub genes of lung adenocarcinoma: A quasi-experimental study.
Lung Adenocarcinoma Biomarker Incidence in Hispanic Versus Non-Hispanic White Patients.
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
miR?10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma.
Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas.
Mutational analysis of EGFR and related signaling pathway genes in lung Adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.
NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.
Oncogene-mediated human lung epithelial cell transformation produces adenocarcinoma phenotypes in vivo.
PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma.
Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
PTEN is a Potent Suppressor of Small Cell Lung Cancer.
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers.
Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Targeted next-generation sequencing in cytology specimens for molecular profiling of lung adenocarcinoma.
The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition.
Tyrosine kinase-dependent, phosphatidylinositol 3'-kinase, and mitogen-activated protein kinase-independent signaling pathways prevent lung adenocarcinoma cells from anoikis.
Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients.
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
Adenocarcinoma, Clear Cell
ARID1A gene mutation in ovarian and endometrial cancers (Review).
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Adenocarcinoma, Follicular
FOXO3a: a novel player in thyroid carcinogenesis?
Adenocarcinoma, Mucinous
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Clinicopathological, molecular features and prognosis of colorectal cancer with mucinous component.
Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact.
Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
Genotype-phenotype associations in breast pathology: Achievements of the past quarter century.
Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
P53 and PIK3CA Mutations in KRAS/HER2 Negative Ovarian Intestinal-Type Mucinous Carcinoma Associated with Mature Teratoma.
PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Adenofibroma
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Adenoma
Activity and PI3-kinase dependent trafficking of the intestinal anion exchanger downregulated in adenoma depend on its PDZ interaction and on lipid rafts.
Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors.
Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers.
Frequent PIK3CA activating mutations in nipple adenomas.
Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.
MicroRNAs associated with initiation and progression of colonic polyp: A feasibility study.
Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas.
Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA.
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Oncogenic PIK3CA mutations in colorectal cancers and polyps.
Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation.
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
Adenoma, Pleomorphic
Different correlations between tumor size and cancer-related gene profiles according to histologic type of salivary gland tumor.
Malignant transformation of salivary gland pleomorphic adenoma: proof of principle.
PIK3CA mutations and PTEN loss in salivary duct carcinomas.
Adenomatous Polyposis Coli
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
H-Ras activation promotes cytoplasmic accumulation and phosphoinositide 3-OH kinase association of beta-catenin in epidermal keratinocytes.
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Mutations of the PIK3CA gene in hereditary colorectal cancers.
PIK3CA and APC mutations are synergistic in the development of intestinal cancers.
Adenomatous Polyps
Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.
Adenomyoepithelioma
CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.
Adenomyosis
MiR-10b Directly Targets ZEB1 and PIK3CA to Curb Adenomyotic Epithelial Cell Invasiveness via Upregulation of E-Cadherin and Inhibition of Akt Phosphorylation.
Adenoviridae Infections
Corneal cell survival in adenovirus type 19 infection requires phosphoinositide 3-kinase/Akt activation.
Agammaglobulinemia
A novel monoallelic gain of function mutation in p110? causing atypical activated phosphoinositide 3-kinase ? syndrome (APDS-1).
Autosomal Recessive Agammaglobulinemia Due to a Homozygous Mutation in PIK3R1.
Common Variable Immunodeficiency and Other Immunodeficiency Syndromes in Bronchiectasis.
De novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly.
Gain-of-function mutation in PIK3R1 in a patient with a narrow clinical phenotype of respiratory infections.
Albinism, Oculocutaneous
Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family.
Alzheimer Disease
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.
A pilot study on the effect of lactoferrin on Alzheimer's disease pathological sequelae: Impact of the p-Akt/PTEN pathway.
Caffeic acid phenethyl ester rescued streptozotocin-induced memory loss through PI3-kinase dependent pathway.
Fasudil hydrochloride ameliorates memory deficits in rat model of streptozotocin-induced Alzheimer's disease: Involvement of PI3-kinase, eNOS and NF?B.
p110? PI 3-kinase inhibition perturbs APP and TNF? trafficking, reduces plaque burden, dampens neuroinflammation and prevents cognitive decline in an Alzheimer's disease mouse model.
Phosphatidylinositol 3-kinase: increased activity and protein level in amyotrophic lateral sclerosis.
Phosphoinositide 3-kinase inhibitor AS605240 ameliorates streptozotocin-induced Alzheimer's disease like sporadic dementia in experimental rats.
Rho-associated kinases contribute to the regulation of tau phosphorylation and amyloid metabolism during neuronal plasticity.
Targeting disease through novel pathways of apoptosis and autophagy.
Weighted burden analysis of exome-sequenced late-onset Alzheimer's cases and controls provides further evidence for a role for PSEN1 and suggests involvement of the PI3K/Akt/GSK-3? and WNT signalling pathways.
Amyotrophic Lateral Sclerosis
Survival activity of troglitazone in rat motoneurones.
VEGF protects spinal motor neurons against chronic excitotoxic degeneration in vivo by activation of PI3-K pathway and inhibition of p38MAPK.
Anaphylaxis
Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function.
Anemia
Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
Aneurysm
Abnormal mechanosensing and cofilin activation promote the progression of ascending aortic aneurysms in mice.
Angiolipoma
Frequent activating PIK3CA mutations in sporadic angiolipoma.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Activated phosphoinositide 3-kinase delta syndrome misdiagnosed as anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report.
Anus Neoplasms
Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes.
EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors.
Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.
Arrhythmias, Cardiac
Ouabain attenuates cardiotoxicity induced by other cardiac steroids.
Phosphoinositide 3-kinase ? protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases.
[Animal in vivo model of arrhythmia for genes target identification for 5-amino-exo-3-azatricyclo[5.2.1.0(2,6)]decan-4-one].
Arteriovenous Malformations
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Functional assessment of two variants of unknown significance in TEK by endothelium-specific expression in zebrafish embryos.
Arthritis
Abrogation of antibody-induced arthritis in mice by a self-activating viridin prodrug and association with impaired neutrophil and endothelial cell function.
PI3K{gamma} regulates cartilage damage in chronic inflammatory arthritis.
Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils.
Arthritis, Experimental
ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice.
PI3K{gamma} regulates cartilage damage in chronic inflammatory arthritis.
Arthritis, Rheumatoid
Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors.
Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
Discovery of novel PI3-kinase ? specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.
Discovery of Orally Efficacious Phosphoinositide 3-Kinase ? Inhibitors with Improved Metabolic Stability.
Inhibition of Phosphoinositide 3-Kinase Ameliorates Dextran Sodium Sulfate-Induced Colitis in Mice.
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
Novel phosphoinositide 3-kinase ?,? inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis.
PBT-6, a Novel PI3KC2? Inhibitor in Rheumatoid Arthritis.
Phosphoinositide 3-kinase ? regulates migration and invasion of synoviocytes in rheumatoid arthritis.
Phosphoinositide 3-kinase signalling and FoxO transcription factors in rheumatoid arthritis.
Targeting phosphoinositide 3-kinase: moving towards therapy.
[Therapeutic potential of phosphoinositide 3-kinase inhibitors in rheumatoid arthritis]
Arthus Reaction
Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcgamma receptor activation and immune complex-induced inflammation.
Asthma
Advances in development of phosphatidylinositol 3-kinase inhibitors.
Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase gamma-deficient mice.
An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model.
Anti-malarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway.
Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT.
Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase ? Syndrome from the USIDNET Cohort.
Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease.
Defining Bronchial Asthma with Phosphoinositide 3-Kinase Delta Activation: Towards Endotype-Driven Management.
Distinct phosphoinositide 3-kinases mediate mast cell degranulation in response to G-protein-coupled versus FcepsilonRI receptors.
Dual ERK and phosphatidylinositol 3-kinase pathways control airway smooth muscle proliferation: differences in asthma.
Essential role of phosphoinositide 3-kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation.
FIZZ1 promotes airway remodeling through the PI3K/Akt signaling pathway in asthma.
Histone deacetylase-2 and airway disease.
Increased expression of PI-3K in asthmatic rat T lymphocytes.
Inhibition of phosphoinositide 3-kinase {delta} attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model.
Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
Interleukin 13 increases contractility of murine tracheal smooth muscle by a phosphoinositide 3-kinase p110delta-dependent mechanism.
Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma.
Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations.
Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches.
Phosphoinositide 3-kinase {delta} inhibitor suppresses IL-17 expression in a murine asthma model.
PI 3-kinase inhibition: a therapeutic target for respiratory disease.
PI3-Kinase Regulates Eosinophil and Neutrophil Degranulation in Patients with Allergic Rhinitis and Allergic Asthma Irrespective of Allergen Challenge Model.
PI3K and Notch signal pathways coordinately regulate the activation and proliferation of T lymphocytes in asthma.
PI3K gamma-deficient mice have reduced levels of allergen-induced eosinophilic inflammation and airway remodeling.
PI3K inhibition in inflammation: Toward tailored therapies for specific diseases.
PI3K? contributes to ER stress-associated asthma through ER-redox disturbances: the involvement of the RIDD-RIG-I-NF-?B axis.
Signalling through Class I PI3Ks in mammalian cells.
Tangeretin has anti-asthmatic effects via regulating PI3K and Notch signaling and modulating Th1/Th2/Th17 cytokine balance in neonatal asthmatic mice.
Targeting phosphoinositide 3-kinase ? for allergic asthma.
Astrocytoma
A Screen for Novel Phosphoinositide 3-kinase Effector Proteins.
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.
Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor.
Cross-talk between phospholipase C and phosphoinositide 3-kinase signalling pathways.
Differential effects of GH and GH-releasing peptide-6 on astrocytes.
Differential in vitro neurotoxicity of the flame retardant PBDE-99 and of the PCB Aroclor 1254 in human astrocytoma cells.
Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications.
Malignant astrocytoma cell attachment and migration to various matrix proteins is differentially sensitive to phosphoinositide 3-OH kinase inhibitors.
MicroRNA-542-3p Suppresses Tumor Cell Invasion via Targeting AKT Pathway in Human Astrocytoma.
Muscarinic receptor-mediated activation of p70 S6 kinase 1 (S6K1) in 1321N1 astrocytoma cells: permissive role of phosphoinositide 3-kinase.
Muscarinic receptors mediate phospholipase C-dependent activation of protein kinase B via Ca2+, ErbB3, and phosphoinositide 3-kinase in 1321N1 astrocytoma cells.
Muscarinic-receptor-mediated inhibition of insulin-like growth factor-1 receptor-stimulated phosphoinositide 3-kinase signalling in 1321N1 astrocytoma cells.
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Phosphatidylinositol 3'-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells.
Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases.
Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Synchronous rosette-forming glioneuronal tumor and diffuse astrocytoma with molecular characterization: a case report.
Ataxia
Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells.
Ataxia Telangiectasia
A phosphatidylinositol 3-kinase inhibitor wortmannin induces radioresistant DNA synthesis and sensitizes cells to bleomycin and ionizing radiation.
ATM activation accompanies histone H2AX phosphorylation in A549 cells upon exposure to tobacco smoke.
DNA-dependent protein kinase and related proteins.
DNA-dependent protein kinase regulates lysosomal AMP-dependent protein kinase activation and autophagy.
Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC.
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Human UPF1 interacts with TPP1 and telomerase and sustains telomere leading-strand replication.
Relationship of the ataxia-telangiectasia protein ATM to phosphoinositide 3-kinase.
SMG1 heterozygosity exacerbates haematopoietic cancer development in Atm null mice by increasing persistent DNA damage and oxidative stress.
Atherosclerosis
Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis.
Early growth response gene-1 expression in vascular smooth muscle cells effects of insulin and oxidant stress.
Fluid-Phase Pinocytosis of LDL by Macrophages: A Novel Target to Reduce Macrophage Cholesterol Accumulation in Atherosclerotic Lesions.
Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes.
Glucosamine enhances platelet-derived growth factor-induced DNA synthesis via phosphatidylinositol 3-kinase pathway in rat aortic smooth muscle cells.
Inhibition of Phosphoinositide 3-Kinase Ameliorates Dextran Sodium Sulfate-Induced Colitis in Mice.
Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice.
p110Delta Inhibits Monocyte Infiltration by Thioglycollate-Induced Periotoneal Inflammation but Not HCD-Induced Inflammation and Atherosclerosis in APOE KO Mice.
The interleukin-33-mediated inhibition of expression of two key genes implicated in atherosclerosis in human macrophages requires MAP kinase, phosphoinositide 3-kinase and nuclear factor-?B signaling pathways.
Tissue-specific impairment of insulin signaling in vasculature and skeletal muscle of fructose-fed rats.
Atrial Fibrillation
Cardiotoxicity of Novel Targeted Hematological Therapies.
Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.
Autoimmune Diseases
Attenuation of phosphoinositide 3-kinase ? signaling restrains autoimmune disease.
Auto-immune disorders in a child with PIK3CD variant and 22q13 deletion.
Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists.
Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
Inhibition of phosphoinositide 3-kinase delta attenuates experimental autoimmune encephalomyelitis in mice.
Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells.
Phosphoinositide 3-Kinase Gamma (PI3Kgamma) Inhibitors for the Treatment of Inflammation and Autoimmune Disease.
Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.
Phosphoinositide 3-kinase p110delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses.
PI3K? drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation.
Role of phosphoinositide 3-kinase signaling in autoimmunity.
Targeting phosphatidylinositol 3-kinase gamma (PI3K?): Discovery and development of its selective inhibitors.
The PI3K? inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sj?gren's syndrome.
WITHDRAWN: Phosphoinositide 3-Kinase Gamma (PI3Kgamma) Inhibitors for the Treatment of Inflammation and Autoimmune Disease.
Autoimmune Lymphoproliferative Syndrome
A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity).
Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: An intriguing challenge.
Bacterial Infections
Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection.
Phosphoinositide 3-kinase family in channel catfish and their regulated expression after bacterial infection.
Barrett Esophagus
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Biliary Tract Neoplasms
PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.
Blister
Bleb-driven chemotaxis of Dictyostelium cells.
CIB1 synergizes with EphrinA2 to regulate Kaposi's sarcoma-associated herpesvirus macropinocytic entry in human microvascular dermal endothelial cells.
ESCRT-I Protein Tsg101 Plays a Role in the Post-macropinocytic Trafficking and Infection of Endothelial Cells by Kaposi's Sarcoma-Associated Herpesvirus.
Interaction of c-Cbl with myosin IIA regulates Bleb associated macropinocytosis of Kaposi's sarcoma-associated herpesvirus.
Kaposi's sarcoma-associated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection.
Bone Resorption
c-Src is required for stimulation of gelsolin-associated phosphatidylinositol 3-kinase.
Class IA phosphatidylinositol 3-kinase regulates osteoclastic bone resorption through Akt-mediated vesicle transport.
Effects of wortmannin analogs on bone in vitro and in vivo.
Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength.
Important roles of PI3Kgamma in osteoclastogenesis and bone homeostasis.
Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice.
Phosphatidylinositol 3-kinase association with the osteoclast cytoskeleton, and its involvement in osteoclast attachment and spreading.
Brain Diseases
Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders.
Brain Edema
Inhibition of FOXO3a/BIM signaling pathway contributes to the protective effect of salvianolic acid A against cerebral ischemia/reperfusion injury.
Brain Injuries
BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway.
Immunoreactive Akt, PI3-K and ERK protein kinase expression in ischemic rat brain.
Brain Ischemia
Insulin blocks cytochrome c release in the reperfused brain through PI3-K signaling and by promoting Bax/Bcl-XL binding.
Phosphoinositide 3-Kinase ? Restrains Neurotoxic Effects of Microglia After Focal Brain Ischemia.
Phosphoinositide 3-kinase-gamma expression is upregulated in brain microglia and contributes to ischemia-induced microglial activation in acute experimental stroke.
Role of phosphoinositide 3-kinase in ischemic postconditioning-induced attenuation of cerebral ischemia-evoked behavioral deficits in mice.
Brain Neoplasms
5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.
Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer.
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer.
Impact of somatic mutations on patterns of metastasis in colorectal cancer.
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.
Mutation of the PIK3CA gene in anaplastic thyroid cancer.
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
The dual PI3K/mTOR-pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases.
The Phosphoinositide 3-Kinase Signaling Pathway as a Therapeutic Target in Grade IV Brain Tumors.
The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma.
Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors.
Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting a treatment outcomes of non-small cell lung cancer.
Breast Carcinoma In Situ
Lobular breast cancer: Clinical, molecular and morphological characteristics.
PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
Breast Neoplasms
3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer.
A butterfly effect in cancer.
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.
A comparative survey of functional footprints of EGFR pathway mutations in human cancers.
A Comparison Between Full-COLD PCR/HRM and PCR Sequencing for Detection of Mutations in Exon 9 of PIK3CA in Breast Cancer Patients.
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
A microscopic landscape of the invasive breast cancer genome.
A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
A novel carcinogenic PI3K? mutation suggesting the role of helical domain in transmitting nSH2 regulatory signals to kinase domain.
A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation.
A novel Phosphatidylinositol 3-Kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes.
A Novel PIK3CA Hotspot Mutation in Isfahanian Breast Cancer Patients.
A Novel Workflow to Enrich and Isolate Patient-Matched EpCAM(high) and EpCAM(low/negative) CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer.
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.
A Phase Ib Study of Alpelisib (BYL719), a PI3K?-specific Inhibitor, with Letrozole in ER+/HER2-Negative Metastatic Breast Cancer.
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer.
A PI3K p110?-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.
A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.
A simple and robust real-time qPCR method for the detection of PIK3CA mutations.
A single nucleotide polymorphism in PIK3CA gene is inversely associated with P53 protein expression in breast cancer.
A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.
A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.
Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer.
Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer.
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
Activation of HIF-1? by ?-Opioid Receptors Induces COX-2 Expression in Breast Cancer Cells and Leads to Paracrine Activation of Vascular Endothelial Cells.
Activation of IGF1R/p110?/AKT/mTOR confers resistance to ?-specific PI3K inhibition.
Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells.
Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells.
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-? signaling axes.
AKT1 E17K Inhibits Cancer Cell Migration by Abrogating ?-Catenin Signaling.
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Alpelisib to treat breast cancer.
Alpelisib-Induced Diabetic Ketoacidosis.
Alpelisib: First Global Approval.
Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients.
Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Analysis of PIK3CA mutations in breast cancer subtypes.
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.
Antagonists of the serotonin receptor 5A target human breast tumor initiating cells.
Anthricin Isolated from Anthriscus sylvestris (L.) Hoffm. Inhibits the Growth of Breast Cancer Cells by Inhibiting Akt/mTOR Signaling, and Its Apoptotic Effects Are Enhanced by Autophagy Inhibition.
Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis.
Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility.
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
Association between the lengths of GT dinucleotide repeat in the PIK3CA gene with breast cancer risk.
Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.
Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer.
Available and emerging molecular markers in the clinical management of breast cancer.
BAG-1/SODD, HSP70 and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma.
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110? and p110? activities in tumor cell lines and xenograft models.
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
Benefits versus risk profile of buparlisib for the treatment of breast cancer.
Beta-Tocotrienol Exhibits More Cytotoxic Effects than Gamma-Tocotrienol on Breast Cancer Cells by Promoting Apoptosis via a P53-Independent PI3-Kinase Dependent Pathway.
Bilateral Breast Radiation Associated Angiosarcoma After Radiotherapy for Bilateral Invasive Ductal Adenocarcinoma.
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.
Biomarkers in Her2- Positive Disease.
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy.
Biphasic papillary and lobular breast carcinoma with PIK3CA and IDH1 mutations.
BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model.
BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.
Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.
Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
CD44/HA signaling mediates acquired resistance to a PI3K? inhibitor.
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
cDNA cloning of a third human C2-domain-containing class II phosphoinositide 3-kinase, PI3K-C2gamma, and chromosomal assignment of this gene (PIK3C2G) to 12p12.
Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation.
Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology.
Ceramide Kinase Is Upregulated in Metastatic Breast Cancer Cells and Contributes to Migration and Invasion by Activation of PI 3-Kinase and Akt.
Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.
Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer.
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer.
Chromatin regulation at the intersection of estrogen receptor and PI3K pathways in breast cancer.
Classifying cancer genome aberrations by their mutually exclusive effects on transcription.
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer.
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer.
Clinical-Pathologic Analysis of Breast Cancer With PIK3CA Mutations in Chinese Women.
Clinico-pathological Features of PIK3CA Mutation in HER2-Positive Breast Cancer of Indian Population.
Clinicopathological Characteristics of PIK3CA Mutation and Amplification in Korean Patients with Breast Cancers.
Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA Mutation.
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of BRCA1-related breast cancer.
Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis.
Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer.
Comparison of Three Real-Time PCR Assays for the Detection of PIK3CA Somatic Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Breast Carcinomas.
Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells.
Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.
Comprehensive Cohort Analysis of Mutational Spectrum in Early Onset Breast Cancer Patients.
Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.
Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer.
Convergent loss of PTEN leads to clinical resistance to a PI(3)K? inhibitor.
Cooperation between Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation.
Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.
Cooperative oncogenic effect and cell signaling crosstalk of co?occurring HER2 and mutant PIK3CA in mammary epithelial cells.
Coordinate expression of the PI3-kinase downstream effectors serum and glucocorticoid-induced kinase (SGK-1) and Akt-1 in human breast cancer.
Copy number variation in ACHE/EPHB4 (7q22) and in BCHE/MME (3q26) genes in sporadic breast cancer.
Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer.
Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(-) advanced breast cancer: results from BOLERO-2.
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.
Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth.
Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Detection of PIK3CA Mutations in Breast Cancer Bone Metastases.
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis.
Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Detection of tumor PIK3CA status in Metastatic Breast Cancer using Peripheral Blood.
Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas.
Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110?/PIK3CA but not by HER2 or mutant AKT1.
Distinct epithelial-to-mesenchymal transitions induced by PIK3CA H1047R and PIK3CB.
Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells.
Disulfiram Treatment Facilitates Phosphoinositide 3-Kinase Inhibition in Human Breast Cancer Cells In vitro and In vivo.
DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations.
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K? inhibitors.
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer.
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer.
Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Efficacy of buparlisib in treating breast cancer.
Efficacy of PI3K inhibitors in advanced breast cancer.
EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy.
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Enhanced PI3K p110? signaling confers acquired lapatinib resistance that can be effectively reversed by a p110?-selective PI3K inhibitor.
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism.
Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product.
ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
ErbB2-positive mammary tumors can escape PI3K-p110? loss through downregulation of the Pten tumor suppressor.
ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
Estrogen receptor ? induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells.
Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.
Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001).
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant.
Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.
Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1.
Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.
Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases.
Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation.
Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
FAM83 family oncogenes are broadly involved in human cancers: an integrative multi-omics approach.
Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Frequent PIK3CA mutations in radial scars.
Function of MiR-152 As a Tumor Suppressor in Human Breast Cancer By Targeting PIK3CA.
Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance.
Functional role of alpha-actinin, PI 3-kinase and MEK1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast carcinoma cells.
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
Gene expression and pathologic response to neoadjuvant chemotherapy in breast cancer.
Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway.
Genetic Alterations in Benign Breast Biopsies of Subsequent Breast Cancer Patients.
Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours.
Genetic landscape of breast cancer and mutation tracking with circulating tumor DNA in Chinese women.
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Genetic variants in the mTOR pathway and interaction with body size and weight gain on breast cancer risk in African-American and European American women.
Genetically engineered ER? positive breast cancer mouse models.
Genomic profile of advanced breast cancer in circulating tumour DNA.
Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations, and immune activation.
Growth inhibition of MCF-7 human breast cancer cells by progesterone is associated with cell differentiation and phosphorylation of Akt protein.
GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer.
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
High-resolution genomic and expression analyses of copy number alterations in breast tumors.
High-Resolution Melting Analysis as a Sensitive Prescreening Diagnostic Tool to Detect KRAS , BRAF , PIK3CA , and AKT1 Mutations in Formalin-Fixed, Paraffin-Embedded Tissues.
High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer.
Highlights from the 38th SABCS annual meeting, 8th - 12th December 2015, San Antonio, USA.
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression.
Hypoxia-inducible factor-1alpha expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas.
Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease.
Identification of effective natural PIK3CA H1047R inhibitors by computational study.
Identification of frequent somatic mutations in inflammatory breast cancer.
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells.
Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA.
Identification of upregulated phosphoinositide 3-kinase ? as a target to suppress breast cancer cell migration and invasion.
Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.
Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.
Impact of next-generation sequencing (NGS) for primary endocrine resistance in breast cancer patients.
Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors.
Improving the performance of somatic mutation identification by recovering circulating tumor DNA mutations.
In silico investigation of heparanase-correlated genes in breast cancer subtypes.
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis.
Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.
Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3K? inhibition through the transcriptional regulation of ER?.
Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells.
Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells.
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Inhibitors of STAT3, ?-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review.
Initiating breast cancer by PIK3CA mutation.
Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line.
Insulin-dependent leptin expression in breast cancer cells.
Insulin-like growth factor binding protein-3 stimulates phosphatidylinositol 3-kinase in MCF-7 breast carcinoma cells.
Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase-independent pathway.
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
Integrating mutation and gene expression cross-sectional data to infer cancer progression.
Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer.
Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells.
Interaction of insulin-like growth factor-I and insulin resistance-related genetic variants with lifestyle factors on postmenopausal breast cancer risk.
Intermittent high dose scheduling of AZD8835, a novel selective inhibitor of PI3K? and PI3K?, demonstrates treatment strategies for PIK3CA-dependent breast cancers.
Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach.
Investigation of somatic PIK3CA gene mutations in breast cancer patients.
Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells.
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells.
Juvenile papillomatosis of the breast (Swiss cheese disease) has frequent associations with PIK3CA and/or AKT1 mutations.
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.
Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.
Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies.
Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer.
LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer.
Liquid Biopsy in Breast Cancer: A Focused Review.
Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer.
Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.
Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis.
Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment.
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Management of toxicity to isoform ?-specific PI3K inhibitors.
Mango polyphenolics suppressed tumor growth in breast cancer xenografts in mice: role of the PI3K/AKT pathway and associated microRNAs.
Manic episode occurring during investigational treatment with pan-class I phosphoinositide 3-kinase inhibitor in a patient with breast cancer.
Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model.
Mechanisms of FGFR3 actions in endocrine resistant breast cancer.
Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer.
Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CAH1047R accompanied with pro-tumorigenic secretome.
Metabolic Imaging Detects Resistance to PI3K? Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer.
Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line.
MEX3A promotes development and progression of breast cancer through regulation of PIK3CA.
Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1.
Mislocalization of the cell polarity protein Scribble promotes mammary tumorigenesis and is associated with basal breast cancer.
Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
Molecular Characterization of Apocrine Salivary Duct Carcinoma.
Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients.
Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Molecular Testing in Breast Cancer.
Molecular Testing in Breast Cancer: Current Status and Future Directions.
More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.
mTORC1 inhibition is required for sensitivity to PI3K p110? inhibitors in PIK3CA-mutant breast cancer.
Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells.
Multiplex detection of DNA mutations by the fluorescence fingerprint spectrum technique.
Multiplexed assays for detection of mutations in PIK3CA.
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
Mutant PIK3CA Induces EMT in a Cell Type Specific Manner.
Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.
Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.
Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Mutation of the PIK3CA gene in ovarian and breast cancer.
Mutation of the PTCH1 gene predicts recurrence of breast cancer.
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.
Mutational Hotspot in Exon 20 of PIK3CA in Breast Cancer Among Singapore Chinese.
Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics.
Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women.
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.
Mutations in PIK3CA Sensitize Breast Cancer Cells to Physiologic Levels of Aspirin.
N-substituted hydroxynaphthalene imino-oxindole derivatives as new class of PI3-kinase inhibitor and breast cancer drug: Molecular validation and structure-activity relationship studies.
N-WASP activation by a beta1-integrin-dependent mechanism supports PI3K-independent chemotaxis stimulated by urokinase-type plasminogen activator.
Nanopore Identification of Single Nucleotide Mutations in Circulating Tumor DNA by Multiplexed Ligation.
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
Network Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome.
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.
Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.
Novel Method for PIK3CA Mutation Analysis: Locked Nucleic Acid-PCR Sequencing.
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Novel Mutations in Neuroendocrine Carcinoma of the Breast: Possible Therapeutic Targets.
Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets.
NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects.
Oncogenic PIK3CA mutations in lobular breast cancer progression.
Oncogenic PIK3CA mutations increase dependency on the mRNA cap methyltransferase, RNMT, in breast cancer cells.
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
OPENchip: an on-chip in situ molecular profiling platform for gene expression analysis and oncogenic mutation detection in single circulating tumour cells.
Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer.
Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.
Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.
Overexpression of PIK3CA impacts global survival of patients with HER2 subtype breast carcinoma.
p130Cas interacts with estrogen receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells.
p53 Loses grip on PIK3CA expression leading to enhanced cell survival during platinum resistance.
pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation.
Particular molecular and ultrastructural aspects in invasive mammary carcinoma.
Pathway-driven discovery of rare mutational impact on cancer.
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.
PDGF regulated migration of mesenchymal stem cells towards malignancy acts via the PI3K signaling pathway.
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K? Inhibition.
Pharmacological explorations of eco-friendly amide substituted (Z)-?-enaminones as anti-breast cancer drugs.
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Phase I Study of the Anti-Angiogenic Antibody Bevacizumab and the mTOR / Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin.
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
PHLPP2 gene L1016S (rs61733127) and PIK3R1 gene Met326Ile (rs3730089) polymorphisms are associated with the risk of colon and breast cancers.
Phospatidylinositol 3-kinase expression in human breast cancer.
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator.
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer.
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth.
Phosphoinositide 3-kinase and INPP4B in human breast cancer.
Phosphoinositide 3-kinase assay in breast cancer cell extracts.
Phosphoinositide 3-kinase inhibition in the treatment of hormone receptor-positive breast cancer.
Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na(+)/H(+) exchange, motility, and invasion induced by serum deprivation.
Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?
Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?
Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells.
Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ER?-positive tumors.
PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer.
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
PI3K inhibition to overcome endocrine resistance in breast cancer.
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
PI3K mutations in breast cancer: prognostic and therapeutic implications.
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ--Implications for Progression to Invasive Breast Carcinoma.
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.
PI3K-p110? mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85?.
PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer.
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects.
PI3K? links integrin activation and PI(3,4)P2 production during invadopodial maturation.
PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(l-Glutamic Acid)-Combretastatin A4 Conjugate in Metastatic Breast Cancer.
PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System.
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.
PIK3CA and PTEN Genes Expressions in Breast Cancer.
PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.
PIK3CA cancer mutations display gender and tissue specificity patterns.
PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.
PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
PIK3CA gene amplification and PI3K p110? protein expression in breast carcinoma.
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
PIK3CA gene mutations in breast carcinoma in Malaysian patients.
PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies.
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
PIK3CA Genotype and Treatment Decisions in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
PIK3CA in Breast Carcinoma: A Mutational Analysis of Sporadic and Hereditary Cases.
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
PIK3CA mutation associates with improved outcome in breast cancer.
PIK3CA mutation detected by liquid biopsy in patients with metastatic breast cancer.
PIK3CA mutation enrichment and quantitation from blood and tissue.
PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups.
PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype.
PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come.
PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
PIK3CA mutation predicts resistance to breast cancer therapy.
PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ER? serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive early breast cancer.
PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT.
PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance.
PIK3CA mutations and downstream effector p-mTOR expression: implication for prognostic factors and therapeutic targets in triple negative breast cancer.
PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis.
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.
PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis.
PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer.
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer.
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis.
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
PIK3CA mutations in breast cancer are associated with poor outcome.
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data.
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients
PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum.
PIK3CA mutations in in situ and invasive breast carcinomas.
PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
PIK3CA mutations may be discordant between primary and corresponding metastatic disease in Breast Cancer.
PIK3CA Mutations mostly Begin to Develop in Ductal Carcinoma of the Breast.
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2 and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.
PIK3CA oncogenic mutations in neoadjuvant treatments for breast cancer.
PIK3CA rs7640662 (C/G) single nucleotide polymorphism lacks association with breast cancer cases in Persians.
PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations.
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.
PIK3R1 underexpression is an independent prognostic marker in breast cancer.
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer.
PIKing the right patient.
Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer.
Plasma PIK3CA Mutation Testing in Advanced Breast Cancer Patients for Personalized Medicine: A Value Proposition.
Potential Anticancer Effect of Calcium-mediated Src Degradation on Hormone-dependent Breast Cancer.
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.
Precision cell-free DNA extraction for liquid biopsy by integrated microfluidics.
Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood.
Precision medicine for metastatic breast cancer--limitations and solutions.
Precision medicine for metastatic breast cancer.
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer.
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
Prognosis of women with early breast cancer and PIK3CA mutations.
Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer.
Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis.
Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer.
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting.
Proximity ligation assay to detect and localize the interactions of ER? with PI3-K and Src in breast cancer cells and tumor samples.
PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the ?-catenin signaling pathway.
PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone.
Ramentaceone, a Naphthoquinone Derived from Drosera sp., Induces Apoptosis by Suppressing PI3K/Akt Signaling in Breast Cancer Cells.
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring.
Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c.
Regulation of macrophage inhibitory factor (MIF) by epidermal growth factor receptor (EGFR) in the MCF10AT model of breast cancer progression.
Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2.
Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer.
Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia.
Relationship Between PIK3CA Amplification and P110? and CD34 Tissue Expression as Angiogenesis Markers in Iranian Women with Sporadic Breast Cancer.
Relationship of PIK3CA mutation and pathway activity with anti-proliferative response to aromatase inhibition.
Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB.
Rlip Depletion Suppresses Growth of Breast Cancer.
RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells.
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives.
Role of E542 and E545 missense mutations of PIK3CA in breast cancer: A comparative Computational approach.
Role of estrogen receptor (ER) alpha in insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells.
Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells.
S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis.
Science Signaling Podcast for 21 February 2017: Pentraxin-3 in basal-like breast cancer.
Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors.
Secretion of Mutant DNA and mRNA by the Exosomes of Breast Cancer Cells.
Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells.
Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
Sensitization of breast cancer cells to radiation by trastuzumab.
Serine phosphorylation of paxillin by heregulin-beta1: role of p38 mitogen activated protein kinase.
SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.
Signaling-dependent nuclear export of estradiol receptor controls cell cycle progression in breast cancer cells.
Signet-ring cell/histiocytoid carcinoma in the axilla: A case report with genetic analysis using next-generation sequencing.
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers.
Significant prognostic values of differentially expressed-aberrantly methylated hub genes in breast cancer.
Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Single-cell resolved imaging reveals intra-tumor heterogeneity in glycolysis, transitions between metabolic states, and their regulatory mechanisms.
Solid Papillary Breast Carcinomas Resembling the Tall Cell Variant of Papillary Thyroid Neoplasms (Solid Papillary Carcinomas with Reverse Polarity) Harbor Recurrent Mutations Affecting IDH2 and PIK3CA: A Validation Cohort.
Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
Somatic mutation profiling in BRCA-negative breast and ovarian cancer patients by multigene panel sequencing.
Somatic mutations in the notch, NF-KB, PIK3CA, and hedgehog pathways in human breast cancers.
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.
Specific requirement for the p85-p110alpha phosphatidylinositol 3-kinase during epidermal growth factor-stimulated actin nucleation in breast cancer cells.
Standardized uptake value (SUVmax) in 18F-FDG PET/CT is correlated with the total number of main oncogenic anomalies in cancer patients.
Structural prediction, whole exome sequencing and molecular dynamics simulation confirms p.G118D somatic mutation of PIK3CA as functionally important in breast cancer patients.
Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai.
Subclonal diversification of primary breast cancer revealed by multiregion sequencing.
Suppression of epidermal growth factor receptor-mediated ?-catenin nuclear accumulation enhances the anti-tumor activity of phosphoinositide 3-kinase inhibitor in breast cancer.
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Surgical resection of breast cancers: Molecular analysis of cancer stem cells in residual disease.
Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells.
Synergistic interactions with PI3K inhibition that induce apoptosis.
Systematic functional characterization of resistance to PI3K inhibition in breast cancer.
Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types.
Tackling Resistance to PI3K Inhibition by Targeting the Epigenome.
Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples.
Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells.
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Targeting HER2 heterogeneity in early-stage breast cancer.
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
Targeting PIK3CA in HER2-positive breast cancer: what are the opportunities and the challenges?
Targeting the Phosphatidyl Inositol 3-Kinase Signaling Pathway in Breast Cancer.
Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer.
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.
Telocinobufagin inhibits the epithelial-mesenchymal transition of breast cancer cells through the phosphoinositide 3-kinase/protein kinase B/extracellular signal-regulated kinase/Snail signaling pathway.
Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
The anticancer activities of Vernonia amygdalina Delile. Leaves on 4T1 breast cancer cells through phosphoinositide 3-kinase (PI3K) pathway.
The cancer genetics and pathology of male breast cancer.
The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.
The Correlation of Mutations and Expressions of Genes within the PI3K/Akt/mTOR Pathway in Breast Cancer-A Preliminary Study.
The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
The distinct clinicopathological and prognostic implications of PIK3CA mutations in breast cancer patients from Central China.
The dual PI3K/mTOR-pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases.
The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
The Gene Mutation Spectrum of Breast Cancer Analyzed by Semiconductor Sequencing Platform.
The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients.
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis.
The interaction of p130Cas with PKN3 promotes malignant growth.
The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.
The molecular contribution of TNF-? in the link between obesity and breast cancer.
The Occurrence of Genetic Alterations during the Progression of Breast Carcinoma.
The paradox of cancer genes in non-malignant conditions: implications for precision medicine.
The PIK3CA gene is mutated with high frequency in human breast cancers.
The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis.
The promise of combining inhibition of PI3K and PARP as cancer therapy.
The role of adapter protein Shc in estrogen non-genomic action.
The role of insulin receptor substrate-1 in transformation by v-src.
The role of phosphoinositide 3-kinase in breast cancer: an overview.
The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors.
The sensitivity and efficacy method of PIK3CA exon 9 E545A as a high diagnostic accuracy in breast cancer.
The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.
Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer.
Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.
Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
Understanding the histogenesis of a HRAS-PIK3R1 co-driven metastatic metaplastic breast carcinoma associated with squamous metaplasia of lactiferous ducts.
Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients.
Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer.
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor ?.
VEGF-A165 Induces Human Aortic Smooth Muscle Cell Migration by Activating Neuropilin-1-VEGFR1-PI3K Axis.
Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer.
Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis.
[Activation of HIF-1 by bFGF in breast cancer: role of PI-3K and MEK1/ERK pathways.]
[Activation of phosphatidylinositol 3-kinase in human breast carcinoma]
[Correlation between the incidence of PIK3CA mutations in breast cancer and histopathological characteristics of the tumor].
[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].
[PI3K/AKT pathway activation and therapeutic consequences in breast cancer].
[PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
[What's new liquid biopsy-PIK3CA testing in breast cancer].
Breast Neoplasms, Male
PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.
Bronchiectasis
Activated phosphoinositide 3-kinase ? syndrome in a patient with a former diagnosis of common variable immune deficiency, bronchiectasis, and lymphoproliferative disease.
Common Variable Immunodeficiency and Other Immunodeficiency Syndromes in Bronchiectasis.
Brucellosis
RNAi screen of endoplasmic reticulum-associated host factors reveals a role for IRE1alpha in supporting Brucella replication.
Burkitt Lymphoma
Cross-linking of surface IgM in the Burkitt's lymphoma cell line ST486 provides protection against arsenite- and stress-induced apoptosis that is mediated by ERK and phosphoinositide 3-kinase signaling pathways.
Hydrogen peroxide in the Burkitt's lymphoma cell line Raji provides protection against arsenic trioxide-induced apoptosis via the phosphoinositide-3 kinase signalling pathway.
Immunocytochemical detection of phosphatidylinositol 3 kinase in Burkitt lymphoma cells.
Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation.
Carcinogenesis
A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.
A PIK3CA transgenic mouse model with chemical carcinogen exposure mimics human oral tongue tumorigenesis.
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma.
Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells.
Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes.
Activation of phosphoinositide 3-kinase by the NBS1 DNA repair protein through a novel activation motif.
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Activation of WNT/?-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin.
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
Algorithm-Based Meta-Analysis Reveals the Mechanistic Interaction of the Tumor Suppressor LIMD1 With Non-Small-Cell Lung Carcinoma.
Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
An insulin-like growth factor-mediated, phosphatidylinositol 3' kinase-independent survival signaling pathway in beta tumor cells.
An integrated strategy for revealing the pharmacological changes based on metabolites profiling and network pharmacology: Arctiin as an example.
APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma.
Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
Atypical Endometrial Hyperplasia, Low-grade: "Much ADO About Nothing".
B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells.
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.
Biological functions of cytokeratin 18 in cancer.
BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy.
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
Cancer Genetic Network Inference Using Gaussian Graphical Models.
Carcinogenesis of PIK3CA.
Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell lines.
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chemopreventive Effects of Licorice and Its Components.
Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment.
Commentary on Essential roles of PI(3)K-p110beta in cell growth, metabolism, and tumorigenesis Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ, Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.
Copper Promotes Tumorigenesis by Activating the PDK1-AKT Oncogenic Pathway in a Copper Transporter 1 Dependent Manner.
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
Cribriform-morular variant of papillary thyroid carcinoma: a study of 3 cases featuring the PIK3CA mutation.
Deletion of p53 and Hyper-Activation of PIK3CA in Keratin-15+ Stem Cells Lead to the Development of Spontaneous Squamous Cell Carcinoma.
Detection of PIK3R1 (L449S) Mutation in a Patient with Ovarian Cancer: A Case Report.
Differences in Somatic Mutation Profiles between Korean Gastric Cancer and Gastric Adenoma Patients.
Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model.
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Dolastatin, along with Celecoxib, stimulates apoptosis by a mechanism involving oxidative stress, membrane potential change and PI3-K/AKT pathway down regulation.
Endometrial cancer cells exhibit high expression of p110? and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.
Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer.
Flavonoids as Protein Kinase Inhibitors for Cancer Chemoprevention: Direct Binding and Molecular Modeling.
Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.
Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.
Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.
Gene expression profiling analysis contributes to understanding the association between non-syndromic cleft lip and palate, and cancer.
Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway.
Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
Genetic and pharmacologic dissection of ras effector utilization in oncogenesis.
Genetic factors in ovarian carcinoma.
Genetics of hepatobiliary carcinogenesis.
Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.
HER2 Tyrosine Kinase Inhibitors in the Sensitization to Cancers Resistant to HER2 Antibodies.
Identification and Validation of PIK3CA as a Marker Associated with Prognosis and Immune Infiltration in Renal Clear Cell Carcinoma.
Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.
Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit.
Initiating breast cancer by PIK3CA mutation.
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway.
Interaction between IGF2-PI3K axis and cancer-associated-fibroblasts promotes anal squamous carcinogenesis.
Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma.
KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer.
KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC).
LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA.
Loss of cardiac phosphoinositide 3-kinase p110 alpha results in contractile dysfunction.
Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases.
Microarray analysis reveals that leptin induces autocrine/paracrine cascades to promote survival and proliferation of colon epithelial cells in an Apc genotype-dependent fashion.
MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27(Kip1.).
MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA.
MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA.
MiR-142-5p Suppresses Tumorigenesis by Targeting PIK3CA in Non-Small Cell Lung Cancer.
miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling.
Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas.
Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation.
Molecular mechanisms linking endometriosis under oxidative stress with ovarian tumorigenesis and therapeutic modalities.
Molecular profiles of benign and (pre)malignant endometrial lesions.
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations.
Mutant PIK3CA Induces EMT in a Cell Type Specific Manner.
Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women.
Mutation of the PIK3CA oncogene in human cancers.
Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.
Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Mutational Hotspot in Exon 20 of PIK3CA in Breast Cancer Among Singapore Chinese.
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.
Myricetin is a potent chemopreventive phytochemical in skin carcinogenesis.
Neuroendocrine tumors resistant to mammalian target of rapamycin inhibitors: A difficult conversion from biology to the clinic.
Newly recognized non-adenomatous lesions associated with enteric carcinomas in inflammatory bowel disease - Report of six rare and unique cases.
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
Nuclear PTEN deficiency causes microcephaly with decreased neuronal soma size and increased seizure susceptibility.
Nuclear upregulation of class I phosphoinositide 3-kinase p110? correlates with high 47S rRNA levels in cancer cells.
Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer.
Oncogene amplification pattern in adenoid cystic carcinoma of the salivary glands.
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma.
Oncogenic PIK3CA mutations in colorectal cancers and polyps.
OncomiRs: the discovery and progress of microRNAs in cancers.
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
PDK1 Signaling Toward PLK1-MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted Therapy.
Phosphatidylinositol-3-kinase ? catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients.
Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ER?-positive tumors.
PI3K enters beta-testing.
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.
PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation.
PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia.
PIK3CA as an oncogene in cervical cancer.
PIK3CA Cooperates with KRAS to Promote MYC Activity and Tumorigenesis via the Bromodomain Protein BRD9.
PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer.
PIK3CA gene aberrancy and role in targeted therapy of solid malignancies.
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
PIK3CA gene amplification and PI3K p110? protein expression in breast carcinoma.
PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma.
PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis.
PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients.
PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells.
PIK3CA Is Regulated by CUX1, Promotes Cell Growth and Metastasis in Bladder Cancer via Activating Epithelial-Mesenchymal Transition.
PIK3CA mutation and amplification in human lung cancer.
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
PIK3CA Mutations are Common in Many Tumor Types and are Often Associated With Other Driver Mutations.
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.
PIK3CA Mutations mostly Begin to Develop in Ductal Carcinoma of the Breast.
PIK3CA somatic mutation in sinonasal teratocarcinosarcoma.
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
PKCiota promotes ovarian tumor progression through deregulation of cyclin E.
Prevalence and architecture of posttranscriptionally impaired synonymous mutations in 8,320 genomes across 22 cancer types.
Preventive Effects of Calcitriol on the Development of Capsular Invasive Carcinomas in a Rat Two-Stage Thyroid Carcinogenesis Model.
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review.
Prostate Power Play: Does Pik3ca Accelerate Pten-Deficient Cancer Progression?
Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer.
PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression.
PTEN loss and activation of K-RAS and ?-catenin cooperate to accelerate prostate tumourigenesis.
PTEN regulates apoptotic cell death through PI3-K/Akt/GSK3? signaling pathway in DMH induced early colon carcinogenesis in rat.
Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis.
Relative quantification of PIK3CA gene expression level in fine-needle aspiration biopsy thyroid specimens collected from patients with papillary thyroid carcinoma and non-toxic goitre by real-time RT-PCR.
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation.
RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer.
Role of microRNA-296-3p in the malignant transformation of sinonasal inverted papilloma.
Role of RAS in the Regulation of PI 3-Kinase.
Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis.
SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.
Should individual PI3 kinase isoforms be targeted in cancer?
Shp2 Deletion in Hepatocytes Suppresses Hepatocarcinogenesis Driven by Oncogenic ?-Catenin, PIK3CA and MET.
Somatic mutation in PIK3CA is a late event in cervical carcinogenesis.
SOX2 recruits KLF4 to regulate nasopharyngeal carcinoma proliferation via PI3K/AKT signaling.
Src Cooperates with Oncogenic Ras in Tumourigenesis via the JNK and PI3K Pathways in Drosophila epithelial Tissue.
Stopping ras in its tracks.
SUMOylation modulates the stability and function of PI3K-p110?.
Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
Targetable "driver" mutations in non small cell lung cancer.
Targeting molecules to medicine with mTOR, autophagy, and neurodegenerative disorders.
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
The combination of NVP-BEZ235 and rapamycin regulates nasopharyngeal carcinoma cell viability and apoptosis via the PI3K/AKT/mTOR pathway.
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
The phosphoinositide 3-kinase pathway and cancer.
The phosphoinositide 3-kinase pathway and therapy resistance in cancer.
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.
The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression.
The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.
The PIK3CA gene is mutated with high frequency in human breast cancers.
The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors.
The target therapy of ovarian clear cell carcinoma.
The Wnt/?-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation.
Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
TP53, SPOP and PIK3CA Genes Status in Prostate Cancer.
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer.
Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP.
Transgenic mouse models of breast cancer.
[Activation of phosphatidylinositol 3-kinase in human breast carcinoma]
[Advanced research of mTOR and lung carcinoid tumors].
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
[Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol]
[Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma]
Carcinoid Tumor
Analysis of the molecular features of rectal carcinoid tumors to identify new biomarkers that predict biological malignancy.
Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors.
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours.
Carcinoma
3q26 Amplifications in Cervical Squamous Carcinomas.
A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3K? inhibition in controlling tumor growth.
A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
A Novel Approach for the Genetic Analysis of Biliary Tract Cancer Specimens Obtained Through Endoscopic Ultrasound-Guided Fine Needle Aspiration Using Targeted Amplicon Sequencing.
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer.
A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome.
A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells.
A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.
Absence of hotspot mutations in exons 9 and 20 of the PIK3CA gene in human oral squamous cell carcinoma in the Greek population.
Activated Mutant p110? Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion.
Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta.
Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
AIB1 Promotes DNA Replication by JNK Repression and AKT Activation during Cellular Stress.
Akt activation, but not extracellular signal-regulated kinase activation, is required for SDF-1alpha/CXCR4-mediated migration of epitheloid carcinoma cells.
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
Amplicon profiles in ovarian serous carcinomas.
An oncogenic, somatic mutation of PIK3CA identified in 2 primary malignancies: clear cell renal cell carcinoma and prostate adenocarcinoma in the same patient.
Analysis of cellular phosphatidylinositol (3,4,5)-trisphosphate levels and distribution using confocal fluorescent microscopy.
Analysis of genes involved in the PI3K/Akt pathway in radiation- and MNU-induced rat mammary carcinomas.
Analysis of Intestinal Metaplasia Without Dysplasia in the Urinary Bladder Reveal Only Rare Mutations Associated With Colorectal Adenocarcinoma.
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical and molecular single institution study.
Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3-kinase/protein kinase B/glycogen synthase kinase 3? signaling pathway.
Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.
Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
Association of PIK3CA gene mutations with head and neck squamous cell carcinomas.
AXL mediates resistance to PI3K? inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
BER gene polymorphisms associated with key molecular events in bladder cancer.
Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.
Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma.
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Cancer Implications for Patients with Endometriosis.
Capn4 regulates migration and invasion of ovarian carcinoma cells via targeting osteopontin-mediated PI3K/AKT signaling pathway.
CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
cDNA expression library screening revealed novel functional genes involved in clear cell carcinogenesis of the ovary in vitro.
Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation.
Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia.
Cerebellar Metastasis From Ovarian Carcinoma Harboring PIK3CA-Activating Mutation: A "Clear" Explanation for an Unexpected "Vertigo".
Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Class I PI3K in oncogenic cellular transformation.
Clear cell carcinoma of the ovary: a clinical and molecular perspective.
Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
Clinical implication of oncogenic somatic mutations in early-stage cervical cancer with radical hysterectomy.
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma.
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Clinicopathologic Significance of HNF-1?, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.
Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.
Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.
Clonality of basal cell carcinoma arising in an epidermal nevus. New insights provided by molecular analysis.
Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signaling.
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas.
Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.
Combined mutational analysis of RAS, BRAF, PIK3CA, and TP53 genes in Taiwanese patients with oral squamous cell carcinoma.
Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas.
Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.
Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact.
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Comprehensive Mutation Analysis of PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1 Genes is Suggestive of a Non- Neoplastic Nature of Phenytoin Induced Gingival Overgrowth.
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.
Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
Copy number loss of variation_91720 in PIK3CA predicts risk of esophageal squamous cell carcinoma.
Cripto-1 induces phosphatidylinositol 3'-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells.
Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase.
Deletion of p53 and Hyper-Activation of PIK3CA in Keratin-15+ Stem Cells Lead to the Development of Spontaneous Squamous Cell Carcinoma.
Detection of oncogenic mutations in cervical carcinoma using method High Resolution Melting (HRM).
Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR.
Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients.
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
Different correlations between tumor size and cancer-related gene profiles according to histologic type of salivary gland tumor.
Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA.
Discovering functional evolutionary dependencies in human cancers.
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Distinct ?-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas.
Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Distinguishing the progression of an endometrioma: Benign or malignant?
Divergent molecular profile of PIK3CA gene in arsenic-associated bladder carcinoma.
Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro.
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
Dual HER2\PIK3CA targeting overcomes single-agent acquired resistance in HER2 amplified uterine serous carcinoma cell lines in vitro and in vivo.
Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma.
Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals.
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma.
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
Effects of miR-455 on PIK3R1 gene expression regulation and kidney cancer cell functions.
Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance.
EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma.
EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
ERBB2 kinase domain mutation in a gastric cancer metastasis.
ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.
Establishment and genomic characterization of gingivobuccal carcinoma cell lines with smokeless tobacco associated genetic alterations and oncogenic PIK3CA mutation.
Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin.
Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
Exosomal miRNAs as Novel Pharmacodynamic Biomarkers for Cancer Chemopreventive Agent Early Stage Treatments in Chemically Induced Mouse Model of Lung Squamous Cell Carcinoma.
Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma.
Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.
Expression of Phosphoinositide 3-Kinase p110? and p110? Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma.
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.
Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma.
Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.
Genetic alterations of the PIK3CA oncogene in human oral squamous cell carcinoma in an Indian population.
Genetic association between PIK3CA gene and oral squamous cell carcinoma: a case control study conducted in Chongqing, China.
Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma.
Genome wide analysis of pathogenic SH2 domain mutations.
Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients.
Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.
Genotype-phenotype associations in breast pathology: Achievements of the past quarter century.
Genotypic analysis of esophageal squamous cell carcinoma by molecular cytogenetics and real-time quantitative polymerase chain reaction.
Global gene expression profiling of a mouse model of ovarian clear cell carcinoma caused by ARID1A and PIK3CA mutations implicates a role for inflammatory cytokine signaling.
Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors.
GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing.
High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features.
High frequency of PIK3CA and TERT promoter mutations in fibromatosis-like spindle cell carcinomas.
High Frequency of PIK3CA Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients.
Histologic features and genomic alterations of primary colorectal adenocarcinoma predict growth patterns of liver metastasis.
Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment.
Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies.
Hot spot mutations in Finnish non-small cell lung cancers.
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.
Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway.
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells.
Hypoxia-induced epithelial-mesenchymal transition is regulated by phosphorylation of GSK3-? via PI3 K/Akt signaling in oral squamous cell carcinoma.
Identification and Validation of PIK3CA as a Marker Associated with Prognosis and Immune Infiltration in Renal Clear Cell Carcinoma.
Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses.
Identification of protein kinase C as an intermediate in Na,K-ATPase Beta-subunit mediated lamellipodia formation and suppression of cell motility in carcinoma cells.
Identification of somatic gene mutations in penile squamous cell carcinoma.
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.
Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
Immunohistochemistry features and molecular pathology of appendiceal neoplasms.
In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).
Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.
Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac.
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival.
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Integrated Molecular Characterization of Uterine Carcinosarcoma.
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Invasive ductal carcinoma arising in borderline phyllode tumor: A potential role of PIK3CA mutation.
Involvement of PTEN/Akt signaling in capsular invasive carcinomas developed in a rat two-stage thyroid carcinogenesis model after promotion with sulfadimethoxine.
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.
KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers.
KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC).
Landscape of genomic alterations in cervical carcinomas.
LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma.
Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells.
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Loss of HDAC-Mediated Repression and Gain of NF-?B Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Mammary Epithelial-Myoepithelial Carcinoma: Report of a Case With HRAS and PIK3CA Mutations by Next-Generation Sequencing.
Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.
Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas.
Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases.
Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib.
MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma.
miR-490-5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA.
Mixed and Ambiguous Endometrial Carcinomas: A Heterogenous Group of Tumors With Different Clinicopathologic and Molecular Genetic Features.
Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression.
Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas.
Molecular Characteristics of Basaloid Squamous Cell Carcinoma of the Esophagus: Analysis of KRAS, BRAF, and PIK3CA Mutations and LINE-1 Methylation.
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations.
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases.
Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.
Molecular heterogeneity of pancreatic intraductal papillary mucinous neoplasms and implications for novel endoscopic tissue sampling strategies.
Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes.
Molecular Pathology of Endometrial Carcinoma: Practical aspects from the diagnostic and therapeutical view points.
Molecular profiles of benign and (pre)malignant endometrial lesions.
Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin.
Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma.
MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress.
Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors.
Mutation analysis of CTNNB1 gene and the ras pathway genes KRAS, NRAS, BRAF, and PIK3CA in eyelid sebaceous carcinomas.
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma.
Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma.
Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma (HNSCC).
Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women.
Mutation of the PIK3CA gene in ovarian and breast cancer.
Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.
Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.
Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.
Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma - occurence and prognostic significance.
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors.
New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications.
Newly recognized non-adenomatous lesions associated with enteric carcinomas in inflammatory bowel disease - Report of six rare and unique cases.
Next generation sequencing of cervical high grade dysplasia and invasive squamous cell carcinoma: A case study.
Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
No significant association between PIK3CA mutation and survival of esophageal squamous cell carcinoma: A meta-analysis.
Non-invasive papillary urothelial carcinoma of the vagina: molecular analysis of a rare case identifies clonal relationship to non-invasive urothelial carcinoma of the bladder.
Novel insights on the malignant transformation of endometriosis into ovarian carcinoma.
Novel Method for PIK3CA Mutation Analysis: Locked Nucleic Acid-PCR Sequencing.
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Oligonucleotide PIK3CA/Chromosome 3 Dual in Situ Hybridization Automated Assay with Improved Signals, One-Hour Hybridization, and No Use of Blocking DNA.
Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling.
Oncocytoma-like renal tumor with transformation toward high-grade oncocytic carcinoma: a unique case with morphologic, immunohistochemical, and genomic characterization.
Oncogenic mutation of PIK3CA in small cell lung carcinoma: A potential therapeutic target pathway for chemotherapy-resistant lung cancer.
Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients.
Oncogenic mutations in gastric cancer with microsatellite instability.
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma.
One-Step Synthesis of Tunable Zinc-Based Nanohybrids as an Ultrasensitive DNA Signal Amplification Platform.
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Ovarian clear cell carcinoma with an immature teratoma component showing ARID1A deficiency and an identical PIK3CA mutation.
Ovarian clear cell carcinoma--bad endometriosis or bad endometrium?
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma.
p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC).
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Phosphatidylinositol 3'-kinase, mTOR, and Glycogen synthase kinase-3 beta mediated regulation of p21 in human urothelial carcinoma cells.
Phosphatidylinositol 3-kinase activity is required for hepatocyte growth factor-induced mitogenic signals in epithelial cells.
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.
PI3-kinase pathway biomarkers in oral cancer and tumor immune cells.
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
PI3K/AKT pathway activation in bladder carcinogenesis.
PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
PI3K/PTEN/AKT Genetic Mouse Models of Endometrial Carcinoma.
PI3K/PTEN/AKT/mTOR pathway genetic variations are associated with the clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
PI3KCA Mutations in Uterine Cervix Carcinoma.
PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.
PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma.
PIK3CA and p53 Mutations by Next Generation Sequencing in Lymphoepithelioma-Like Carcinoma of the Endometrium.
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney.
PIK3CA and TFRC Located in 3q Are New Prognostic Factors in Esophageal Squamous Cell Carcinoma.
PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma.
PIK3CA as an oncogene in cervical cancer.
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
PIK3CA gene amplification in Japanese non-small cell lung cancer.
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
PIK3CA gene mutations and amplifications in Chinese patients with ovarian clear cell carcinoma.
PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.
PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma.
PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.
PIK3CA in ovarian clear cell carcinoma.
PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells.
PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.
PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer.
PIK3CA mutation in Chinese patients with lung squamous cell carcinoma.
PIK3CA mutation in HPV-associated OPSCC patients receiving deintensified chemoradiation.
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
PIK3CA mutation status in Japanese lung cancer patients.
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
PIK3CA mutations and copy number gains in human lung cancers.
PIK3CA mutations and PTEN loss in salivary duct carcinomas.
PIK3CA Mutations and Their Impact on Survival Outcomes of Patients with Cervical Cancer: A Systematic Review.
PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome.
PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
PIK3CA mutations in advanced ovarian carcinomas.
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
PIK3CA mutations in in situ and invasive breast carcinomas.
PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
PIK3CA Mutations mostly Begin to Develop in Ductal Carcinoma of the Breast.
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma.
PIK3CA, HRAS and KRAS Gene Mutations in Human Penile Cancer.
PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.
PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3?/CTNNB1 signaling pathway.
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.
Prevalence of high-risk human papillomavirus infection and cancer gene mutations in nonmalignant tonsils.
Preventive Effects of Calcitriol on the Development of Capsular Invasive Carcinomas in a Rat Two-Stage Thyroid Carcinogenesis Model.
Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids.
Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma.
Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer.
Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review.
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas.
Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes.
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas.
PTEN deficiency contributes to the development and progression of head and neck cancer.
Pulmonary epithelial-myoepithelial carcinoma without AKT1, HRAS or PIK3CA mutations: a case report.
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
Re: PIK3CA Mutation Spectrum in Urothelial Carcinoma Reflects Cell Context-Dependent Signaling and Phenotypic Outputs.
Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland.
Regulation of squamous cell carcinoma antigen production by E-cadherin mediated cell-cell adhesion in squamous cell carcinoma cell line.
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
RNA Interference-Mediated Silencing of the Phosphatidylinositol 3-Kinase Catalytic Subunit Attenuates Growth of Human Ovarian Cancer Cells in vitroand in vivo.
Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Screening for PIK3CA mutations among Saudi women with ovarian cancer.
Search for mutations in signaling pathways in head and neck squamous cell carcinoma.
Sequence Mutations and Amplification of PIK3CA and AKT2 Genes in Purified Ovarian Serous Neoplasms.
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Silencing of miR-17-5p suppresses cell proliferation and promotes cell apoptosis by directly targeting PIK3R1 in laryngeal squamous cell carcinoma.
Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
Somatic mutation in PIK3CA is a late event in cervical carcinogenesis.
Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Somatic mutations of the ERBB4 kinase domain in human cancers.
Stage IV Epstein-Barr Virus-Associated Early Gastric Cancer and Comparative Analysis of Genetic Alterations in Primary and Metastatic Tumors.
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.
Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002.
Tall cell carcinoma of the breast with reversed polarity (TCCRP) with mutations in the IDH2 and PIK3CA genes: a case report.
Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract.
Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.
Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
Targeted sequencing of burn scar-related squamous cell carcinomas identified PIK3CA amplification.
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC).
Targeting phosphoinositide 3-kinase signalling in lung cancer.
Targeting the phosphoinositide 3-kinase p110-? isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
Taselisib (GDC-0032), a Potent ?-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.
The C-terminal flanking peptide (CTFP) of progastrin inhibits apoptosis via a PI3-kinase-dependent pathway.
The conundrum of the Epstein-Barr virus-associated gastric carcinoma in the Americas.
The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas.
The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
The EDA-containing cellular fibronectin induces epithelial-mesenchymal transition in lung cancer cells through integrin ?9?1-mediated activation of PI3-K/AKT and Erk1/2.
The evolving genomic landscape of urothelial carcinoma.
The fibronectin EDA splicing variant induces epithelial-mesenchymal transition in lung cancer cells through integrin {alpha}9{beta}1-mediated activation of PI3-K and Erk.
The frequent co-expression of the oncogenes PIK3CA and PAK1 in oral carcinomas.
The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma.
The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel.
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.
The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck.
The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.
The prevalence of PIK3CA mutations in gastric and colon cancer.
The Prognostic Value of PIK3CA Copy Number Gain in Penile Cancer.
The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas.
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma.
There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
Translational Genomics and Recent Advances in Oral Squamous Cell Carcinoma.
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
Type I to Type II Ovarian Carcinoma Progression: Mutant Trp53 or Pik3ca Confers a More Aggressive Tumor Phenotype in a Mouse Model of Ovarian Cancer.
Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis.
Unilateral synchronous papillary renal neoplasm with reverse polarity and clear cell renal cell carcinoma: a case report with KRAS and PIK3CA mutations.
Up-regulation of PIK3CA promotes metastasis in gastric carcinoma.
Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
Vascular Endothelial Growth Factor Induces CXCL1 Chemokine Release via JNK and PI-3K-Dependent Pathways in Human Lung Carcinoma Epithelial Cells.
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
[Correlation between the incidence of PIK3CA mutations in breast cancer and histopathological characteristics of the tumor].
[Endometriosis-related ovarian tumors].
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
[Inhibitory Effect of N-Terminal 24 Amino Acids of the p55 Gamma, a Regulatory Subunit of Phosphoinositide 3-Kinase, on Proliferation of Colon Carcinoma Cell Line HT29.]
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
[PI 3-kinase activity is necessary for F9 mouse embryonic carcinoma cell proliferation]
[The expression of PIK3CA in nasopharyngeal carcinoma].
Carcinoma in Situ
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses.
Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas.
PIK3CA Mutations mostly Begin to Develop in Ductal Carcinoma of the Breast.
Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids.
Carcinoma, Adenoid Cystic
Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.
Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma.
PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney.
The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma.
Carcinoma, Adenosquamous
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma.
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
High rate of PIK3CA mutations but no TP53 mutation in low-grade adenosquamous carcinoma of the breast.
Next generation sequencing of the nidus of early (adenosquamous proliferation rich) radial sclerosing lesions of the breast reveals evidence for a neoplastic precursor lesion.
Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review.
Carcinoma, Basal Cell
Clonality of basal cell carcinoma arising in an epidermal nevus. New insights provided by molecular analysis.
Carcinoma, Ductal
Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Invasive ductal carcinoma arising in borderline phyllode tumor: A potential role of PIK3CA mutation.
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Molecular Testing in Breast Cancer: Current Status and Future Directions.
Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ--Implications for Progression to Invasive Breast Carcinoma.
PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
PIK3CA in Breast Carcinoma: A Mutational Analysis of Sporadic and Hereditary Cases.
PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT.
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
PIK3CA mutations in in situ and invasive breast carcinomas.
PIK3CA Mutations mostly Begin to Develop in Ductal Carcinoma of the Breast.
PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas.
Carcinoma, Ductal, Breast
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
Carcinoma, Embryonal
Early stage-specific inhibitions of cardiomyocyte differentiation and expression of Csx/Nkx-2.5 and GATA-4 by phosphatidylinositol 3-kinase inhibitor LY294002.
Carcinoma, Endometrioid
Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma.
Activated Mutant p110? Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion.
Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.
Clinicopathological and molecular characteristics of endometrial neuroendocrine carcinomas reveal preexisting endometrial carcinoma origin.
Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact.
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Current and future strategies for treatment of ovarian clear cell carcinoma.
Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression.
Genetic analysis and phosphoinositide 3-kinase/protein kinase B signaling pathway status in ovarian endometrioid borderline tumor samples.
Molecular Pathology of Endometrial Carcinoma: Practical aspects from the diagnostic and therapeutical view points.
Molecular profiles of benign and (pre)malignant endometrial lesions.
Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
Phase I Study of the Anti-Angiogenic Antibody Bevacizumab and the mTOR / Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin.
PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia.
PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients.
Carcinoma, Hepatocellular
A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type.
Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients.
Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumor formation in mice via AKT2/mTORC1 cascade.
Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis.
Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
ARID2, p110?, p53, and ?-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications.
AT-rich interactive domain 2, p110?, p53, and ?-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications.
BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy.
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Clinicopathological characteristics of PIK3CA and HBx mutations in Korean patients with hepatocellular carcinomas.
Cross-Species Suppression of Hepatoma Cell Growth and Migration by a Schistosoma japonicum MicroRNA.
Direct association of heat shock protein 20 (HSPB6) with phosphoinositide 3-kinase (PI3K) in human hepatocellular carcinoma: regulation of the PI3K activity.
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Effect of sidt2 Gene on Cell Insulin Resistance and Its Molecular Mechanism.
Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma.
Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling.
FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients.
Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the suppression of the phosphoinositide 3-kinase (PI3K)/AKT pathway.
Hepatitis B virus X protein promotes vimentin expression via LIM and SH3 domain protein 1 to facilitate epithelial-mesenchymal transition and hepatocarcinogenesis.
Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling.
Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
Insulin-induced activation of phosphoinositide 3-kinase in Fao cells.
Involvement of phosphoinositide 3-kinase in regulation of adhesive activity of highly metastatic hepatoma cells.
Jianpijiedu fang improves survival of hepatocarcinoma mice by affecting phosphatase and tensin homolog, phosphoinositide 3-kinase, and focal adhesion kinase.
Low Frequency of PIK3CA Gene Mutations in Hepatocellular Carcinoma in Chinese Population.
MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.
MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA.
miR-128-3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients.
MiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K/SGK3/?-catenin signaling pathways.
miR-502 inhibits cell proliferation and tumor growth in hepatocellular carcinoma through suppressing phosphoinositide 3-kinase catalytic subunit gamma.
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Overexpression of PIK3R1 promotes hepatocellular carcinoma progression.
Participation of a MEK-independent pathway in MAP kinase activation and modulation of cell growth in mouse hepatoma cell lines.
Phosphatidylinositol 3-kinase is required for the regulation of hepatitis B surface antigen production and mitogen-activated protein kinase activation by insulin but not by TPA.
Phosphatidylinositol 3-kinase modulates IL-18-induced nuclear factor-kappa B activation.
PI3-kinase inhibition synergistically promoted the anti-tumor effect of lupeol in hepatocellular carcinoma.
PI3-Kinase Inhibitor LY294002 Repressed the Expression of Thrombin-Activatable Fibrinolysis Inhibitor in Human Hepatoma HepG2 Cells.
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
PIK3CA mutations in hepatocellular carcinoma in Korea.
PIK3CA polymorphisms associated with susceptibility to hepatocellular carcinoma.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
Role of hepatitis B virus X protein in regulating LIM and SH3 protein 1 (LASP-1) expression to mediate proliferation and migration of hepatoma cells.
Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Stephtetrandrine A-D, bisbenzylisoquinoline alkaloids from Stephania tetrandra.
Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.
The hypoglycaemic activity of fenugreek seed extract is mediated through the stimulation of an insulin signalling pathway.
The phosphoinositide 3-kinase pathway and glycogen synthase kinase-3 positively regulate the activity of metal-responsive transcription factor-1 in response to zinc ions.
[Expression and mutations of PIK3CA gene in hepatocellular carcinomas]
Carcinoma, Intraductal, Noninfiltrating
APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer.
Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.
Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
Genomic landscape of ductal carcinoma in situ and association with progression.
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model.
Intratumor Heterogeneity of Synchronous In Situ and Invasive Breast Carcinoma Revealed Using Multi-region Exome Sequencing.
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Molecular Testing in Breast Cancer: Current Status and Future Directions.
Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.
PI-3 kinase activity is necessary for ERK1/2-induced disruption of mammary epithelial architecture.
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ--Implications for Progression to Invasive Breast Carcinoma.
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
PIK3CA mutations in in situ and invasive breast carcinomas.
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma.
Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma.
Carcinoma, Large Cell
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
Carcinoma, Lewis Lung
Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals.
Carcinoma, Lobular
Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast.
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas.
Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations.
Lobular breast cancer: Clinical, molecular and morphological characteristics.
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT.
PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
Signet-ring cell/histiocytoid carcinoma in the axilla: A case report with genetic analysis using next-generation sequencing.
Whole exome sequencing of rare aggressive breast cancer histologies.
Carcinoma, Mucoepidermoid
Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations.
Carcinoma, Neuroendocrine
Clinicopathological and molecular characteristics of endometrial neuroendocrine carcinomas reveal preexisting endometrial carcinoma origin.
Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
Carcinoma, Non-Small-Cell Lung
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.
Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer.
Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
BYL719, a selective inhibitor of phosphoinositide 3-Kinase ?, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer.
Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI 3-kinase in KRAS mutant lung cancer.
Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
EMT twists the road to PI3K.
Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation.
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma.
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC).
Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies.
Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.
MiR-142-5p Suppresses Tumorigenesis by Targeting PIK3CA in Non-Small Cell Lung Cancer.
MiR-486-5p Serves as a Good Biomarker in Nonsmall Cell Lung Cancer and Suppresses Cell Growth With the Involvement of a Target PIK3R1.
Molecular profiling of non-small cell lung cancer.
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
PI3K expression predicts overall survival in lung adenocarcinoma.
PIK3CA gene amplification in Japanese non-small cell lung cancer.
PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
PIK3CA mutations and copy number gains in human lung cancers.
PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis.
Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
Prognostic significance of phosphoinositide 3-kinase p110? and p110? isoforms in non-small cell lung cancer.
Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer.
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy.
Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer.
Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Targeted therapies in development for non-small cell lung cancer.
The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA.
The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer.
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
The Proto-oncogene PKC? regulates the alternative splicing of Bcl-x pre-mRNA.
The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.
Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer.
Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review.
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
[Correlation between expression of TUBB3/STMN1 and EGFR signaling pathway in non-small cell lung cancer].
[Research Advances of Pan-negative Type of Non-small Cell Lung Cancer].
Carcinoma, Ovarian Epithelial
Amphiregulin increases migration and proliferation of epithelial ovarian cancer cells by inducing its own expression via PI3-kinase signaling.
Correlation between SNPs of PIK3CA, ERBB2 3'UTR, and their interactions with environmental factors and the risk of epithelial ovarian cancer.
Epithelial Mutations in Endometriosis: Link to Ovarian Cancer.
Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer.
MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB.
Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models.
The effects of common genetic variants in oncogenes on ovarian cancer survival.
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
Carcinoma, Papillary
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.
Immunophenotypic and genomic characterization of papillary carcinomas of the breast.
Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.
Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.
Solid Papillary Breast Carcinomas Resembling the Tall Cell Variant of Papillary Thyroid Neoplasms (Solid Papillary Carcinomas with Reverse Polarity) Harbor Recurrent Mutations Affecting IDH2 and PIK3CA: A Validation Cohort.
Carcinoma, Renal Cell
A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome.
An oncogenic, somatic mutation of PIK3CA identified in 2 primary malignancies: clear cell renal cell carcinoma and prostate adenocarcinoma in the same patient.
Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma.
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro.
Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma.
Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma.
GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation.
MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma.
miR-490-5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA.
PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3?/CTNNB1 signaling pathway.
Unilateral synchronous papillary renal neoplasm with reverse polarity and clear cell renal cell carcinoma: a case report with KRAS and PIK3CA mutations.
Carcinoma, Signet Ring Cell
Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase.
Carcinoma, Small Cell
Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.
Carcinoma, Squamous Cell
3q26 Amplifications in Cervical Squamous Carcinomas.
A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3K? inhibition in controlling tumor growth.
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer.
A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
Association of PIK3CA gene mutations with head and neck squamous cell carcinomas.
AXL mediates resistance to PI3K? inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Clinical implication of oncogenic somatic mutations in early-stage cervical cancer with radical hysterectomy.
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.
Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signaling.
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
Deletion of p53 and Hyper-Activation of PIK3CA in Keratin-15+ Stem Cells Lead to the Development of Spontaneous Squamous Cell Carcinoma.
Detection of oncogenic mutations in cervical carcinoma using method High Resolution Melting (HRM).
Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR.
Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA.
Discovering functional evolutionary dependencies in human cancers.
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Exosomal miRNAs as Novel Pharmacodynamic Biomarkers for Cancer Chemopreventive Agent Early Stage Treatments in Chemically Induced Mouse Model of Lung Squamous Cell Carcinoma.
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.
Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients.
Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.
Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors.
Hot spot mutations in Finnish non-small cell lung cancers.
Identification of somatic gene mutations in penile squamous cell carcinoma.
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Involvement of phosphoinositide 3-kinase in insulin- or IGF-1-induced membrane ruffling.
Molecular Characteristics of Basaloid Squamous Cell Carcinoma of the Esophagus: Analysis of KRAS, BRAF, and PIK3CA Mutations and LINE-1 Methylation.
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations.
Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes.
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.
New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors.
Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Oligonucleotide PIK3CA/Chromosome 3 Dual in Situ Hybridization Automated Assay with Improved Signals, One-Hour Hybridization, and No Use of Blocking DNA.
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma.
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Phosphoinositide 3-kinase as an upstream regulator of the small GTP-binding protein Rac in the insulin signaling of membrane ruffling.
PI3-kinase pathway biomarkers in oral cancer and tumor immune cells.
PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
PI3K/PTEN/AKT/mTOR pathway genetic variations are associated with the clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
PIK3CA gene amplification in Japanese non-small cell lung cancer.
PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer.
PIK3CA mutation in Chinese patients with lung squamous cell carcinoma.
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
PIK3CA mutation status in Japanese lung cancer patients.
PIK3CA mutations and copy number gains in human lung cancers.
PIK3CA Mutations and Their Impact on Survival Outcomes of Patients with Cervical Cancer: A Systematic Review.
PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome.
PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.
Prevalence of high-risk human papillomavirus infection and cancer gene mutations in nonmalignant tonsils.
Prevention of Tumor Growth Driven by PIK3CA and HPV Oncogenes by Targeting mTOR Signaling with Metformin in Oral Squamous Carcinomas Expressing OCT3.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma.
PTEN deficiency contributes to the development and progression of head and neck cancer.
Regulation of squamous cell carcinoma antigen production by E-cadherin mediated cell-cell adhesion in squamous cell carcinoma cell line.
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Search for mutations in signaling pathways in head and neck squamous cell carcinoma.
Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Targeted sequencing of burn scar-related squamous cell carcinomas identified PIK3CA amplification.
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC).
Taselisib (GDC-0032), a Potent ?-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas.
The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel.
The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck.
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
The Prognostic Value of PIK3CA Copy Number Gain in Penile Cancer.
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
Translational Genomics and Recent Advances in Oral Squamous Cell Carcinoma.
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
Carcinoma, Transitional Cell
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC).
Carcinosarcoma
Detection of PIK3CA E545A mutation in circulating tumor DNA of a patient affected by uterine carcinosarcoma.
Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Molecular characterization of carcinosarcomas arising in the uterus and ovaries.
Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease.
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
Use of mutation profiles to refine the classification of endometrial carcinomas.
Cardiomegaly
Basal and IGF-I-dependent regulation of potassium channels by MAP kinases and PI3-kinase during eccentric cardiac hypertrophy.
Cardiotoxicity of Novel Targeted Hematological Therapies.
Chronic blockade of class I PI3-kinase attenuates Ang II-induced cardiac hypertrophy and autophagic alteration.
Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy.
Cross-talk between MAPKs and PI-3K pathways alters the functional density of I(K) channels in hypertrophied hearts.
Decreased p110alpha catalytic activity accompanies increased myocyte apoptosis and cardiac hypertrophy in leptin deficient ob/ob mice.
Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies.
Dual role of cyclic GMP in cardiac cell survival.
FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K.
H11 has dose-dependent and dual hypertrophic and proapoptotic functions in cardiac myocytes.
Local angiotensin II aggravates cardiac remodeling in hypertension.
Ouabain prevents pathological cardiac hypertrophy and heart failure through activation of phosphoinositide 3-kinase ? in mouse.
Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cbeta2 in the regulation of physiologic developmental hypertrophy and heart function.
Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure.
Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure.
Protein Kinases as Drug Development Targets for Heart Disease Therapy.
Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy.
Role of PI3-Kinase in Angiotensin II-Induced Cardiac Hypertrophy: Class I Versus Class III.
Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy.
The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection.
The role of leptin in the ventricular remodeling process and its mechanism.
[The antagonistic effect of PI3K-gamma inhibitor AS605240 on cardiac hypertrophy and cardiac fibrosis induced by isoproterenol in rats].
Cardiomyopathies
Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice.
Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells.
H3K9ac modification was involved in doxorubicin induced apoptosis by regulating Pik3ca transcription in H9C2 cells.
Phosphoinositide 3-kinase (p110?) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction.
Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure.
Temporally controlled overexpression of cardiac-specific PI3K{alpha} induces enhanced myocardial contractility--a new transgenic model.
Cardiomyopathy, Dilated
Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies.
Cardiotoxicity
Upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo.
Cardiovascular Diseases
Phosphoinositide 3-kinase: friend and foe in cardiovascular disease.
Role of PI3 kinase gamma in excitation-contraction coupling and heart disease.
Tissue-specific impairment of insulin signaling in vasculature and skeletal muscle of fructose-fed rats.
Cataract
Alterations in lens protein tyrosine phosphorylation and phosphatidylinositol 3-kinase signaling during selenite cataract formation.
Cerebral Infarction
Inhibition of FOXO3a/BIM signaling pathway contributes to the protective effect of salvianolic acid A against cerebral ischemia/reperfusion injury.
Cerebrovascular Disorders
The Role of NLRP3 Inflammasome in Cerebrovascular Diseases Pathology and Possible Therapeutic Targets.
Cervical Intraepithelial Neoplasia
Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia.
Cholangiocarcinoma
A Novel Approach for the Genetic Analysis of Biliary Tract Cancer Specimens Obtained Through Endoscopic Ultrasound-Guided Fine Needle Aspiration Using Targeted Amplicon Sequencing.
Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation.
High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases.
KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.
Kras-driven heterotopic tumor development from hepatobiliary organoids.
Molecular characteristics of biliary tract cancer.
Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.
Neurotensin promotes cholangiocarcinoma metastasis via the EGFR/AKT pathway.
Polypoid Undifferentiated Carcinoma With Osteoclast-like Giant Cells Arising in the Distal Common Bile Duct: A Rare Case Report.
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion.
Cholecystitis
Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.
Cholera
Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma.
Requirement of phosphatidylinositol 3-kinase activity for bradykinin stimulation of NF-kappaB activation in cultured human epithelial cells.
Suppression of insulin-stimulated phosphatidylinositol 3-kinase activity by the beta3-adrenoceptor agonist CL316243 in rat adipocytes.
Cholestasis
Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17?-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C.
Chondroma
Carcinogenesis of PIK3CA.
Chondrosarcoma
By activating matrix metalloproteinase-7, shear stress promotes chondrosarcoma cell motility, invasion and lung colonization.
Fluid shear promotes chondrosarcoma cell invasion by activating matrix metalloproteinase 12 via IGF-2 and VEGF signaling pathways.
Interleukin-1? and cyclic AMP mediate the invasion of sheared chondrosarcoma cells via a matrix metalloproteinase-1-dependent mechanism.
Chordoma
Chordoma-Current Understanding and Modern Treatment Paradigms.
Development of a Novel Orthotopic Primary Human Chordoma Xenograft Model: A Relevant Support for Future Research on Chordoma.
Prognostic and Therapeutic Markers in Chordomas: A Study of 287 Tumors.
Ciliopathies
Inpp5e suppresses polycystic kidney disease via inhibition of PI3K/Akt-dependent mTORC1 signaling.
Coinfection
Opportunistic coinfection with Pneumocystis jirovecii and Coccidioides immitis associated with idelalisib treatment in a patient with chronic lymphocytic leukaemia.
Colitis
Agammaglobulinemia and absent B lineage cells in a patient lacking the p85? subunit of PI3K.
Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110?.
Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.
Inhibition of Phosphoinositide 3-Kinase Ameliorates Dextran Sodium Sulfate-Induced Colitis in Mice.
Loss of Phosphoinositide 3-Kinase p110? is Protective in the Acute Phase but Detrimental in the Resolution Phase of Hapten-Induced Colitis.
Phosphoinositide 3-Kinase P110?-Signaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation.
Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
The absence of functional PI3Kgamma prevents leukocyte recruitment and ameliorates DSS-induced colitis in mice.
The Drosophila larva as a tool to study gut-associated macrophages: PI3K regulates a discrete hemocyte population at the proventriculus.
Colitis, Ulcerative
Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.
How autophagy controls the intestinal epithelial barrier.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Colitis-Associated Neoplasms
Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer.
Colonic Neoplasms
A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells.
Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells.
Activation of NF-kappaB binding in HT-29 colon cancer cells by inhibition of phosphatidylinositol 3-kinase.
Analysis of Intestinal Metaplasia Without Dysplasia in the Urinary Bladder Reveal Only Rare Mutations Associated With Colorectal Adenocarcinoma.
Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations.
Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies.
Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).
Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk.
Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma.
Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line.
Brush border phosphatidylinositol 3-kinase mediates epidermal growth factor stimulation of intestinal NaCl absorption and Na+/H+ exchange.
Calcium intake and colon cancer risk subtypes by tumor molecular characteristics.
Cancer immunology-analysis of host and tumor factors for personalized medicine.
Case report of ascending colon cancer and multiple jejunal GISTs in a patient with neurofibromatosis type 1 (NF1).
Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.
Clinicopathological and molecular differences in colorectal cancer according to location.
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women.
Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location.
Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model.
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
DNA testing and molecular screening for colon cancer.
Dolastatin, along with Celecoxib, stimulates apoptosis by a mechanism involving oxidative stress, membrane potential change and PI3-K/AKT pathway down regulation.
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways.
Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Epigallocatechin-3-gallate inhibits proliferation and triggers apoptosis in colon cancer via the hedgehog/phosphoinositide 3-kinase pathways.
ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells.
Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study.
Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.
Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.
Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma.
Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the ?GBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo.
Knockin of mutant PIK3CA activates multiple oncogenic pathways.
Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells.
Mechanical force modulates global gene expression and beta-catenin signaling in colon cancer cells.
Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily.
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.
Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
Mir-30d suppresses cell proliferation of colon cancer cells by inhibiting cell autophagy and promoting cell apoptosis.
miRNA-29a inhibits colon cancer growth by regulation of the PTEN/Akt/GSK3? and Wnt/?-catenin signaling pathways.
Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients.
Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.
Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis.
Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients.
Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
Pharmacological Inhibition of Casein Kinase 2 Enhances the Effectiveness of PI3K Inhibition in Colon Cancer Cells.
PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac.
PIK3CA and APC mutations are synergistic in the development of intestinal cancers.
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
PIK3CA mutations predict local recurrences in rectal cancer patients.
PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer.
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Prognostic impact of mutation profiling in patients with stage II and III colon cancer.
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review.
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis.
PTHrP increases xenograft growth and promotes integrin alpha6beta4 expression and Akt activation in colon cancer.
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells.
Screening key genes and miRNAs in early-stage colon adenocarcinoma by RNA-sequencing.
Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.
Sphingosine kinase 1 promotes malignant progression in colon cancer and independently predicts survival of patients with colon cancer by competing risk approach in South asian population.
Targeted inhibition of the phosphoinositide 3-kinase impairs cell proliferation, survival, and invasion in colon cancer.
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Targeting ?-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations.
The double life of p85.
The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation.
The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells.
The influence of the CHIEF pathway on colorectal cancer-specific mortality.
The interplay between GRP78 expression and Akt activation in human colon cancer cells under celecoxib treatment.
The prevalence of PIK3CA mutations in gastric and colon cancer.
The prognostic value of Microsatellite Instability, KRAS, BRAF and PIK3CA mutations in stage II colon cancer patients.
The transforming functions of PI3-kinase-gamma are linked to disruption of intercellular adhesion and promotion of cancer cell invasion.
The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway.
WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear ?-Catenin depend on active PI3K signaling.
[Effects of K-ras gene mutation on colon cancer cell line Caco-2 metastasis by regulating E-cadherin/beta-catenin/p120 protein complex formation and RhoA protein activity]
[Molecular analysis of sporadic colon cancer].
Colorectal Neoplasms
5-fluorouracil enhances the anti-tumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers.
A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
A functional variant at miR-520a binding site in PIK3CA alters susceptibility to colorectal cancer in a Chinese Han population.
A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection.
A PIK3CA pyrosequencing-based assay that excludes pseudogene interference.
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
A small cog in a big wheel: PIK3CA mutations in colorectal cancer.
Activation of WNT/?-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.
AKT1 E17K in Colorectal Carcinoma is Associated with BRAF V600E but not MSI-H status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors.
An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer.
An oncogenic gene, SNRPA1, regulates PIK3R1, VEGFC, MKI67, CDK1 and other genes in colorectal cancer.
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients.
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
Aspirin and colorectal cancer: back to the future.
Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?
Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex!
Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).
Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.
Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma.
Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
Aurora-A expression is independently associated with chromosomal instability in colorectal cancer.
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS.
Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.
BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737.
BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.
BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Calcium intake and colon cancer risk subtypes by tumor molecular characteristics.
Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.
Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer.
Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer.
Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer.
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.
Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
Colorectal cancer in Chinese patients: current and emerging treatment options.
Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo.
Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas.
Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Combination of TNF-? and graphene oxide-loaded BEZ235 to enhance apoptosis of PIK3CA mutant colorectal cancer cells.
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer.
Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA.
Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
Consecutive and automatic detection of multi-gene mutations from colorectal cancer samples by coupling droplet array-based capillary electrophoresis and PCR-RFLP.
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway.
Deactivation of Glutaminolysis Sensitizes PIK3CA-Mutated Colorectal Cancer Cells to Aspirin-Induced Growth Inhibition.
Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women.
Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR.
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
Differences in gene mutations according to gender among patients with colorectal cancer.
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers.
Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer.
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer.
ENKUR Is Involved in the Regulation of Cellular Biology in Colorectal Cancer Cells via PI3K/Akt Signaling Pathway.
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.
Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer.
Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study.
Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.
Experimental verification of a predicted novel microRNA located in human PIK3CA gene with a potential oncogenic function in colorectal cancer.
Expression profile and biological function of miR-455-5p in colorectal carcinoma.
Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.
Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue.
Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer.
Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.
Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.
Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Gene heterogeneity in metastasis of colorectal cancer to the lung.
Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers.
Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II.
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.
Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.
How autophagy controls the intestinal epithelial barrier.
IGF1/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells.
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ? 2 line cetuximab-based therapy of colorectal cancer patients.
Impact of KRAS, BRAF, PIK3CA, TP53 status and intra-individual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation.
In silico approach to target PI3K/Akt/mTOR axis by selected Olea europaea phenols in PIK3CA mutant colorectal cancer.
Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors.
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.
Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2.
Insulin induction instigates cell proliferation and metastasis in human colorectal cancer cells.
Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer.
Investigation of the expression levels of CPEB4, APC, TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and CTNNB1 genes in different stage colorectal tumors
Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the ?GBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo.
Knockin of mutant PIK3CA activates multiple oncogenic pathways.
KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: A single-site report.
KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages.
KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer.
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer.
KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.
KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer.
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications.
Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer.
Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in PIK3CA-Mutant Colorectal Cancer.
Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.
Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation.
MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.
miR-486-5p regulates the migration and invasion of colorectal cancer cells through targeting PIK3R1.
miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling.
Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.
Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.
Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications.
MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.
Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of PIK3CA mutations.
Multiplexed assays for detection of mutations in PIK3CA.
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer.
Mutation of the PIK3CA gene in ovarian and breast cancer.
Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients.
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.
Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer.
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.
New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways.
Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.
NRAS mutations are rare in colorectal cancer.
NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer.
Nuclear accumulation of ?-catenin and forkhead box O3a in colon cancer: Dangerous liaison.
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.
Oncogenic PIK3CA mutations in colorectal cancers and polyps.
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
Optimal detection of clinically relevant mutations in colorectal carcinoma: sample pooling overcomes intra-tumoral heterogeneity.
Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients.
Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation.
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers.
PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.
PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.
PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.
PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma.
PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
PIK3CA cancer mutations display gender and tissue specificity patterns.
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
PIK3CA gene mutations in breast carcinoma in Malaysian patients.
PIK3CA in Colorectal Cancer.
PIK3CA mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis.
PIK3CA mutation and colorectal cancer precision medicine.
PIK3CA mutation and methylation influences the outcome of colorectal cancer.
PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.
PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.
PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer.
PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population.
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors.
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers.
PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer.
Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth.
Polymorphic GT dinucleotide repeat in the PIK3CA gene and risk of colorectal cancer.
Portrait of the PI3K/AKT pathway in colorectal cancer.
Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific.
Possibility of molecular targeting therapy for the treatment of cancer of unknown primary origin by analysis of intracellular signaling molecules.
Potential biomarker for aspirin use in colorectal cancer therapy.
Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status.
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Predictors of Lymph Node Count in Colorectal Cancer Resections: Data From US Nationwide Prospective Cohort Studies.
Prevalence and characteristics of PIK3CA mutation in mismatch repair-deficient colorectal cancer.
Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients.
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review.
Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.
Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer.
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab.
PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.
PTEN-deficient cancers depend on PIK3CB.
Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissue.
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.
Recent therapeutic advances in the treatment of colorectal cancer.
Relationship between mismatch repair protein, RAS, BRAF, PIK3CA gene expression and clinicopathological characteristics in elderly colorectal cancer patients.
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution.
Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737.
Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation.
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience.
Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.
Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
Smoking Status at Diagnosis and Colorectal Cancer Prognosis According to Tumor Lymphocytic Reaction.
Sodium butyrate-mediated differentiation of colorectal cancer cells: regulation of PKCbetaII by PI 3-kinase.
Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Studies on the expression patterns of class I PI3K catalytic subunits and its prognostic significance in colorectal cancer.
Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients.
Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.
Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer.
Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations.
Target-Enriched Next-Generation Sequencing Reveals Differences between Primary and Secondary Ovarian Tumors in Formalin-Fixed, Paraffin-Embedded Tissue.
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Targeting glutamine metabolism in PIK3CA mutant colorectal cancers.
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.
The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation.
The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer.
The Landscape of PIK3CA Mutations in Colorectal Cancer.
The Molecular Landscape of Synchronous Colorectal Cancer Reveals Genetic Heterogeneity.
The phosphoinositide 3-kinase inhibitor LY294002, decreases aminoacyl-tRNA synthetases, chaperones and glycolytic enzymes in human HT-29 colorectal cancer cells.
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
The prevalence of PIK3CA mutations in gastric and colon cancer.
The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer.
The role of microRNAs involved in PI3-kinase signaling pathway in colorectal cancer.
The roles of microbial products in the development of colorectal cancer: a review.
The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients.
Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan.
Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.
Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report.
Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
[A study of the relationship between the mutation of PIK3CA, PTEN and the occurrence of liver metastasis of colorectal cancer: survival analysis].
[Aspirin and colorectal cancer].
[Biochip detection of KRAS, BRAF, and PIK3CA somatic mutations in colorectal cancer patients].
[Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
[Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
[Predictive biomarkers for anti-EGFR antibodies].
Colorectal Neoplasms, Hereditary Nonpolyposis
Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer.
Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Common Variable Immunodeficiency
Activated phosphoinositide 3-kinase ? syndrome in a patient with a former diagnosis of common variable immune deficiency, bronchiectasis, and lymphoproliferative disease.
Advances and highlights in primary immunodeficiencies in 2017.
Common Variable Immunodeficiency and Other Immunodeficiency Syndromes in Bronchiectasis.
Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome.
Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence.
Corneal Injuries
Corneal epithelial wound healing increases the expression but not long lasting activation of the p85alpha subunit of phosphatidylinositol-3 kinase.
Corneal Neovascularization
The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization.
Coronary Disease
Advances in development of phosphatidylinositol 3-kinase inhibitors.
Coronary Occlusion
Attenuation of infarction in cynomolgus monkeys: preconditioning and postconditioning.
COVID-19
Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19.
Suppression of SARS-CoV-2 infection in ex-vivo human lung tissues by targeting class III phosphoinositide 3-kinase.
Craniopharyngioma
Adamantinomatous Craniopharyngioma in an Adult: A Case Report with NGS Analysis.
Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors.
Crohn Disease
How autophagy controls the intestinal epithelial barrier.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Cystadenofibroma
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Cystadenoma
High Frequency of PIK3CA Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients.
Cystadenoma, Mucinous
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
Cystic Fibrosis
How autophagy controls the intestinal epithelial barrier.
Cystitis
Endogenous PI3K/Akt and NMDAR act independently in the regulation of CREB activity in lumbosacral spinal cord in cystitis.
In vivo regulation of brain-derived neurotrophic factor in dorsal root ganglia is mediated by nerve growth factor-triggered Akt activation during cystitis.
Suppression of the PI3K pathway in vivo reduces cystitis-induced bladder hypertrophy and restores bladder capacity examined by magnetic resonance imaging.
Cysts
A combination of molecular markers and clinical features improve the classification of pancreatic cysts.
A Review of the Diagnosis and Management of Premalignant Pancreatic Cystic Lesions.
Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma.
Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids.
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Dementia
Phosphoinositide 3-kinase inhibitor AS605240 ameliorates streptozotocin-induced Alzheimer's disease like sporadic dementia in experimental rats.
Dengue
Use of a tandem affinity purification assay to detect interactions between West Nile and dengue viral proteins and proteins of the mosquito vector.
Dent Disease
The phosphoinositide 3-kinase inhibitor alpelisib restores actin organization and improves proximal tubule dysfunction in vitro and in a mouse model of Lowe syndrome and Dent disease.
deoxycytidine kinase deficiency
The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma.
Dermatitis, Exfoliative
Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.
Diabetes Complications
Increased platelet aggregation in diabetic patients with microangiopathy despite good glycemic control.
Diabetes Mellitus
Association analysis of the variant in the regulatory subunit of phosphoinositide 3-kinase (p85alpha) with Type 2 diabetes mellitus and hypertension in the Chinese Han population.
Association of PI3K/AKT/mTOR pathway genetic variants with type 2 diabetes mellitus in Chinese.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior.
Impaired glucose transport and protein kinase B activation by insulin, but not okadaic acid, in adipocytes from subjects with Type II diabetes mellitus.
Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes.
Insulin Resistance: Pathophysiology and Rationale for Treatment.
Role and mechanism of PI3K/AKT/FoxO1/PDX-1 signaling pathway in functional changes of pancreatic islets in rats after severe burns.
The expression of the p85alpha subunit of phosphatidylinositol 3-kinase is induced by activation of the peroxisome proliferator-activated receptor gamma in human adipocytes.
The Rap-B-Raf signalling pathway is activated by glucose and glucagon-like peptide-1 in human islet cells.
Up-regulation of microRNA-203 inhibits myocardial fibrosis and oxidative stress in mice with diabetic cardiomyopathy through the inhibition of PI3K/Akt signaling pathway via PIK3CA.
[Role of phosphatidylinositol 3-kinase in platelet aggregation in type 1 diabetes mellitus]
Diabetes Mellitus, Type 1
Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production.
Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice.
[Role of phosphatidylinositol 3-kinase in platelet aggregation in type 1 diabetes mellitus]
Diabetes Mellitus, Type 2
Alterations in insulin-induced postreceptor signaling in adipocytes of the Otsuka Long-Evans Tokushima fatty rat strain.
Association analysis of the variant in the regulatory subunit of phosphoinositide 3-kinase (p85alpha) with Type 2 diabetes mellitus and hypertension in the Chinese Han population.
Association of PI3K/AKT/mTOR pathway genetic variants with type 2 diabetes mellitus in Chinese.
Association of the polymorphisms in the 5'-untranslated region of PTEN gene with type 2 diabetes in a Japanese population.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Dysfunction of human subcutaneous FAT arterioles in obesity associated or not with Type 2 diabetes.
Epidermal growth factor and transforming growth factor alpha mimic the effects of insulin in human fat cells and augment downstream signaling in insulin resistance.
Frequency of mutations of insulin receptor gene in Japanese patients with NIDDM.
Gene encoding the catalytic subunit p110beta of human phosphatidylinositol 3-kinase: cloning, genomic structure, and screening for variants in patients with type 2 diabetes.
Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway.
Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index.
Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance--is insulin resistance initiated in the adipose tissue?
Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes.
In vitro and in vivo studies of a naturally occurring variant of the human p85alpha regulatory subunit of the phosphoinositide 3-kinase: inhibition of protein kinase B and relationships with type 2 diabetes, insulin secretion, glucose disappearance constant, and insulin sensitivity.
Insulin action in skeletal muscle from patients with NIDDM.
Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation.
Insulin Resistance: Pathophysiology and Rationale for Treatment.
Insulin signal transduction in skeletal muscle from glucose-intolerant relatives of type 2 diabetic patients [corrected].
Insulin signaling and action in fat cells: associations with insulin resistance and type 2 diabetes.
Lipid phosphatases as drug discovery targets for type 2 diabetes.
Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats.
Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes.
Pi 3-kinase and its up- and down-stream modulators as potential targets for the treatment of type II diabetes.
PIK3R1 gene polymorphisms are associated with type 2 diabetes and related features in the Turkish population.
Promoter polymorphisms -359T/C and -303A/G of the catalytic subunit p110beta gene of human phosphatidylinositol 3-kinase are not associated with insulin secretion or insulin sensitivity in finnish subjects.
Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes.
Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice.
Spinal cord injury causes insulin resistance associated with PI3K signaling pathway in hypothalamus.
[Insulin resistance - its causes and therapy possibilities].
Diabetes, Gestational
Expression of PI3-K, PKB and GSK-3 ? in the skeletal muscle tissue of gestational diabetes mellitus.
Phosphatidylinositol 3-kinase redistribution is associated with skeletal muscle insulin resistance in gestational diabetes mellitus.
The association of leukocyte phosphatidylinositol 3-kinase delta overexpression with gestational diabetes mellitus (GDM).
Diabetic Cardiomyopathies
Phosphoinositide 3-Kinase Therapy in Diabetic Cardiomyopathy: Unravelling an Enigma.
Protein Kinases as Drug Development Targets for Heart Disease Therapy.
Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110?) signaling.
Up-regulation of microRNA-203 inhibits myocardial fibrosis and oxidative stress in mice with diabetic cardiomyopathy through the inhibition of PI3K/Akt signaling pathway via PIK3CA.
Diabetic Nephropathies
Elabela protects against podocyte injury in mice with streptozocin-induced diabetes by associating with the PI3K/Akt/mTOR pathway.
Thyroid Hormone Ameliorates Diabetic Nephropathy in a Mouse Model of Type II Diabetes.
Zinc Attenuates Tubulointerstitial Fibrosis in Diabetic Nephropathy Via Inhibition of HIF Through PI-3K Signaling.
Diabetic Neuropathies
Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease?
Diphtheria
Phosphorylation, desensitization and internalization of human alpha1B-adrenoceptors induced by insulin-like growth factor-I.
Drug-Related Side Effects and Adverse Reactions
For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors.
Dyslipidemias
Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver.
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
Dyspnea
Oral sildenafil as a treatment option for lymphatic malformations in PIK3CA-related tissue overgrowth syndromes.
Encephalitis
PI3-Kinase p110? Deficiency Modulates T Cell Homeostasis and Function and Attenuates Experimental Allergic Encephalitis in Mature Mice.
Encephalitis, Japanese
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Encephalomyelitis
Absence of PI3Kgamma leads to increased leukocyte apoptosis and diminished severity of experimental autoimmune encephalomyelitis.
Inhibition of phosphoinositide 3-kinase delta attenuates experimental autoimmune encephalomyelitis in mice.
Encephalomyelitis, Autoimmune, Experimental
Absence of PI3Kgamma leads to increased leukocyte apoptosis and diminished severity of experimental autoimmune encephalomyelitis.
Inhibition of phosphoinositide 3-kinase delta attenuates experimental autoimmune encephalomyelitis in mice.
Endodermal Sinus Tumor
The genetic landscape of 87 ovarian germ cell tumors.
Endometrial Hyperplasia
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Autophagy in the physiological endometrium and cancer.
PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Endometrial Neoplasms
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.
A Unique Spectrum of Somatic PIK3CA (p110{alpha}) Mutations Within Primary Endometrial Carcinomas.
Activated Mutant p110? Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion.
Akt activity in endometrial cancer cells: regulation of cell survival through cIAP-1.
Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.
Alteration of tumor associated neutrophils by PIK3CA expression in endometrial carcinoma from TCGA data.
Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Autophagy in the physiological endometrium and cancer.
Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium.
Class I Phosphoinositide 3-Kinase PIK3CA/p110? and PIK3CB/p110? Isoforms in Endometrial Cancer.
Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Correction: High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability.
Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532].
Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
Dual HER2\PIK3CA targeting overcomes single-agent acquired resistance in HER2 amplified uterine serous carcinoma cell lines in vitro and in vivo.
Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study.
Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
Expression of metabolically targeted biomarkers in endometrial carcinoma.
Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.
FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features.
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.
Genome-wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays.
Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway.
Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma.
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability.
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.
Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.
Identification of a Gene Panel for Endometrioid Endometrial Cancer: a Possible Prognostic Value?
Infrequent loss of SMARCA4, SMARCA2, and SMARCB1 expression in uterine mesenchymal tumors.
Lack of correlation between leptin receptor expression and PI3-K/Akt signaling pathway proteins immunostaining in endometrioid-type endometrial carcinomas.
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors.
LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway.
Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas.
Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Molecular characteristics of endometrial cancer coexisting with peritoneal malignant mesothelioma in Li-Fraumeni-like syndrome.
Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.
Molecular profiling of endometrial malignancies.
Mutation Frequencies in Endometrial Cancer Patients of Different Ethnicities and Tumor Grades: An Analytical Study.
Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
New routes to old places: PIK3R1 and PIK3R2 join PIK3CA and PTEN as endometrial cancer genes.
Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens.
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations.
PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-?/VEGF pathway in endometrial cancer.
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences.
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.
PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
PIK3R1 (p85-alpha/p85{alpha}) is Somatically Mutated at High Frequency in Primary Endometrial Cancer.
Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations.
Progestin-associated shift of meningioma mutational landscape.
Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives.
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Rare Mutations in the PIK3CA Gene Contribute to Aggressive Endometrial Cancer.
Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer.
Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late.
The combination of everolimus and terameprocol exerts synergistic antiproliferative effects in endometrial cancer: molecular role of insulin-like growth factor binding protein 2.
Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer.
Use of mutation profiles to refine the classification of endometrial carcinomas.
Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.
Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
[Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
Endometriosis
(Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes.
17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway.
A case report of bladder and intestinal endometriosis, and the relationship between sex hormone receptor expression and PIK3CA mutation analysis.
A mouse model of endometriosis mimicking the natural spread of invasive endometrium.
Cancer Implications for Patients with Endometriosis.
Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010.
Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.
Distinguishing the progression of an endometrioma: Benign or malignant?
Epithelial Mutations in Endometriosis: Link to Ovarian Cancer.
Establishment of a Novel In Vitro Model of Endometriosis with Oncogenic KRAS and PIK3CA Mutations for Understanding the Underlying Biology and Molecular Pathogenesis.
Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma.
Molecular characterization of uterine and ovarian tumors with mixed epithelial and germ cell features confirms frequent somatic derivation.
Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.
Ovarian cancer in endometriosis: an update on the clinical and molecular aspects.
Ovarian clear cell carcinoma--bad endometriosis or bad endometrium?
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping.
The presence of KRAS, PPP2R1A and ARID1A mutations in 101 Chinese samples with ovarian endometriosis.
Endotoxemia
Disassociation of muscle insulin signaling and insulin-stimulated glucose uptake during endotoxemia.
L-selectin: an emerging player in chemokine function.
PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice.
Enterocolitis
Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of PIK3CD-encoded phosphoinositide 3-kinase ?.
Eosinophilia
The effect of pharmacological PI3K? inhibitor on eotaxin-induced human eosinophil functions.
Ependymoma
Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy.
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Pediatric Ependymoma: A Proteomics Perspective.
Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases.
Epilepsies, Partial
Precise detection of low-level somatic mutation in resected epilepsy brain tissue.
Epilepsy
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.
CB2R induces a protective response for epileptic seizure via the PI3K 110?-AKT signaling pathway.
Effect of PIK3CA variants on glioma-related epilepsy and response to treatment.
Geniposide attenuates epilepsy symptoms in a mouse model through the PI3K/Akt/GSK-3? signaling pathway.
Interaction Between Akt1-Positive Neurons and Age at Surgery Is Associated With Surgical Outcome in Children With Isolated Focal Cortical Dysplasia.
mTOR mutations in Smith-Kingsmore syndrome: four additional patients and a review.
Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders.
Precise detection of low-level somatic mutation in resected epilepsy brain tissue.
Epstein-Barr Virus Infections
Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.
Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.
Erdheim-Chester Disease
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.
Esophageal Achalasia
PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome.
Esophageal Neoplasms
Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients.
Genetic analysis of rapidly progressing esophageal squamous cell carcinoma: A case report.
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients.
PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome.
Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing.
Esophageal Squamous Cell Carcinoma
Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.
Copy number loss of variation_91720 in PIK3CA predicts risk of esophageal squamous cell carcinoma.
Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
Genotypic analysis of esophageal squamous cell carcinoma by molecular cytogenetics and real-time quantitative polymerase chain reaction.
MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib.
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
No significant association between PIK3CA mutation and survival of esophageal squamous cell carcinoma: A meta-analysis.
Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling.
Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma.
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
PIK3CA and TFRC Located in 3q Are New Prognostic Factors in Esophageal Squamous Cell Carcinoma.
PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma.
PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.
PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma.
PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome.
PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma.
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Exanthema
High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors.
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ? 2 line cetuximab-based therapy of colorectal cancer patients.
Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
Familial Mediterranean Fever
MicroRNA-204-3p inhibits lipopolysaccharide-induced cytokines in familial Mediterranean fever via the phosphoinositide 3-kinase ? pathway.
Fanconi Anemia
FANCM-FAAP24 and HCLK2: roles in ATR signalling and the Fanconi anemia pathway.
Fasciculation
The small GTPase Rac is involved in clustering of hippocampal neurons and fasciculation of their neurites.
Fatty Liver
Ablation of PI3K p110-{alpha} Prevents High-Fat Diet-Induced Liver Steatosis.
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity and dyslipidaemia by increased energy expenditure.
Fetal Growth Retardation
A novel PIK3R1 mutation of SHORT syndrome in a Chinese female with diffuse thyroid disease: a case report and review of literature.
Maternal protein restriction induces alterations in insulin signaling and ATP sensitive potassium channel protein in hypothalami of intrauterine growth restriction fetal rats.
[Perturbed hepatic phosphoinositol 3-kinase signaling pathway in the rat with intrauterine growth restriction.]
Fibroadenoma
PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.
Fibromyalgia
Electroacupuncture attenuates chronic fibromyalgia pain through the phosphorylated phosphoinositide 3-kinase signaling pathway in the mouse brain.
Fibrosarcoma
5-Azacytidine regulates matrix metalloproteinase-9 expression, and the migration and invasion of human fibrosarcoma HT1080 cells via PI3-kinase and ERK1/2 pathways.
miR-574-3p inhibits proliferation and invasion in esophageal cancer by targeting FAM3C and MAPK1.
Resveratrol induces MMP-9 and cell migration via the p38 kinase and PI-3K pathways in HT1080 human fibrosarcoma cells.
Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells.
Salinomycin causes migration and invasion of human fibrosarcoma cells by inducing MMP-2 expression via PI3-kinase, ERK-1/2 and p38 kinase pathways.
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Tumour necrosis factor-alpha activation of protein kinase B in WEHI-164 cells is accompanied by increased phosphorylation of Ser473, but not Thr308.
Fragile X Syndrome
Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome.
Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders.
Gallbladder Neoplasms
Identification of LIFR, PIK3R1, and MMP12 as Novel Prognostic Signatures in Gallbladder Cancer Using Network-Based Module Analysis.
Molecular characteristics of biliary tract cancer.
Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients.
Gastroesophageal Reflux
Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk.
Gastrointestinal Neoplasms
KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.
Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice.
Gastrointestinal Stromal Tumors
Cross regulation of signaling pathways in gastrointestinal stromal tumor.
Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.
Genetic Diseases, Inborn
Early activating somatic PIK3CA mutations promote ectopic muscle development and upper limb overgrowth.
Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro.
Integration of Liquid Biopsies into Clinical Laboratory Applications via NGS in Cancer Diagnostics.
NODAL/TGF? signalling mediates the self-sustained stemness induced by PIK3CA H1047R homozygosity in pluripotent stem cells.
Targeted therapy in patients with PIK3CA-related overgrowth syndrome.
Gingival Overgrowth
Comprehensive Mutation Analysis of PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1 Genes is Suggestive of a Non- Neoplastic Nature of Phenytoin Induced Gingival Overgrowth.
Glioblastoma
5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.
A PI3K- and GTPase-independent Rac1-mTOR mechanism mediates MET-driven anchorage-independent cell growth but not migration.
Aberrant Rac pathway signalling in glioblastoma.
Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells.
Activation of Polyamine Catabolism by N1, N11-Diethylnorspermine Alters the Cellular Localization of mTOR and Downregulates mTOR Protein Level in Glioblastoma Cells.
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression.
Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Cross-platform Q-TOF validation of global exo-metabolomic analysis: application to human glioblastoma cells treated with the standard PI 3-Kinase inhibitor LY294002.
CXCL12-induced glioblastoma cell migration requires intermediate-conductance Ca2+-activated K+ channel activity.
Differential involvement of p38 mitogen-activated protein kinase and phosphatidyl inositol 3-kinase in the IL-1-mediated NF-kappa B and AP-1 activation.
Differential SKIP expression in PTEN-deficient glioblastoma regulates cellular proliferation and migration.
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.
Downregulation of microRNA-431 by human interferon-? inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6.
Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo.
Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma.
Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis.
EGFR signals to mTOR through PKC and independently of Akt in glioma.
Enhanced cell killing by overexpression of dominant-negative phosphatidylinositol 3-kinase subunit, Deltap85, following genotoxic stresses.
Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia.
From epidemiology and neurodevelopment to antineoplasticity. Medroxyprogesterone reduces human glial tumor growth in vitro and C6 glioma in rat brain in vivo.
Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas.
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.
High frequency of mutations in the PIK3CA gene helical and kinase coding regions in a group of Iranian patients with high-grade glioblastomas: five novel mutations.
Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.
Hypoxia Induced by Cobalt Chloride Triggers Autophagic Apoptosis of Human and Mouse Drug-Resistant Glioblastoma Cells through Targeting the PI3K-AKT-mTOR Signaling Pathway.
Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme.
Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.
Influence of Pi3-K and PKC activity on 99mTc-(V)-DMSA uptake: correlation with tumour aggressiveness in an in vitro malignant glioblastoma cell line model.
Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs).
Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma.
MicroRNA-542-3p Suppresses Tumor Cell Invasion via Targeting AKT Pathway in Human Astrocytoma.
Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.
MiR-422a acts as a tumor suppressor in glioblastoma by targeting PIK3CA.
Molecular Characterization of "True" Low-Grade IDH-Wildtype Astrocytomas.
Molecular targeted therapy of glioblastoma.
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications.
Mutations of the PIK3CA gene are rare in human glioblastoma.
Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis.
Phosphorylation-independent stabilization of p27kip1 by the phosphoinositide 3-kinase pathway in glioblastoma cells.
PI3K signaling in glioma--animal models and therapeutic challenges.
PI3K/AKT/Afadin signaling pathway contributes to pathological vascularization in glioblastomas.
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma.
PIK3CA alterations in primary (de novo) and secondary glioblastomas.
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.
PIK3CA mutations in glioblastoma multiforme.
PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis.
PIKE-A promotes glioblastoma growth by driving PPP flux through increasing G6PD expression mediated by phosphorylation of STAT3.
PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
PREX1 integrates G protein-coupled receptor and phosphoinositide 3-kinase signaling to promote glioblastoma invasion.
Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.
PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1.
PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.
Regulation of glioblastoma cell invasion by PKC iota and RhoB.
Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation.
Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers.
Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation.
Somatic mutations of PIK3R1 promote gliomagenesis.
Stoichiometric quantification of Akt phosphorylation using LC-MS/MS.
Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2.
Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models.
Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma.
The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma.
Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors.
V-ATPase controls tumor growth and autophagy in a Drosophila model of gliomagenesis.
Glioma
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells.
Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12)?V-Ha-Ras transgenic mouse glioma model.
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor.
Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas.
CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway.
Circ_0000020 elevates the expression of PIK3CA and facilitates the malignant phenotypes of glioma cells via targeting miR-142-5p.
Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways.
Cytosolic and calcium-independent phospholipase A(2) mediate glioma-enhanced proangiogenic activity of brain endothelial cells.
Deregulated human glioma cell motility: inhibitory effect of somatostatin.
Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo.
Effect of PIK3CA variants on glioma-related epilepsy and response to treatment.
From epidemiology and neurodevelopment to antineoplasticity. Medroxyprogesterone reduces human glial tumor growth in vitro and C6 glioma in rat brain in vivo.
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Genomic Profiling Identified Novel Prognostic Biomarkers in Chinese Midline Glioma Patients.
Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor.
IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/?-catenin pathway.
Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Induced expression of MMP-9 in C6 glioma cells is inhibited by PDGF via a PI 3-kinase-dependent pathway.
Inhibitory effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Isoform specific inhibitors of PI3 kinase in glioma.
LINC01198 facilitates gliomagenesis through activating PI3K/AKT pathway.
Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis.
Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin.
Mutant IDH1 inhibits PI3K/Akt signaling in human glioma.
Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling.
Next-generation whole exome sequencing of glioblastoma with a primitive neuronal component.
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Phosphoinositide 3-kinase is required for bombesin-induced enhancement of fear memory consolidation in the hippocampus.
Phosphoinositide-3-kinase inhibition elevates ferritin level resulting depletion of labile iron pool and blocking of glioma cell proliferation.
PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.
PI3K? inhibitor AZD6482 exerts antiproliferative activity and induces apoptosis in human glioblastoma cells.
PIK3CA alterations in primary (de novo) and secondary glioblastomas.
PIK3CA Mutations Induce Neuronal Hyperactivity during Glioma Formation.
PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
Protein tyrosine kinase-dependent regulation of adenylate cyclase and phosphatidylinositol 3-kinase activates the expression of glial fibrillary acidic protein upon induction of differentiation in rat c6 glioma.
PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway.
Radiation-induced upregulation of telomerase activity escapes PI3-kinase inhibition in two malignant glioma cell lines.
Regulation of glioma cell invasion by 3q26 gene products PIK3CA, SOX2 and OPA1.
Signal transduction molecules in gliomas of all grades.
Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma.
Spatiotemporal genomic architecture informs precision oncology in glioblastoma.
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
Targeting the RTK-PI3K-mTOR Axis in Malignant Glioma: Overcoming Resistance.
The catalytic phosphoinositol 3-kinase isoform p110? is required for glioma cell migration and invasion.
The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.
Using isoform-specific inhibitors to target lipid kinases.
Variable expression of CXCR4 in molecular subtypes of infiltrating gliomas.
Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells.
Glomerulonephritis
Advances in development of phosphatidylinositol 3-kinase inhibitors.
PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus.
Glucagonoma
Glucagon release is regulated by tyrosine phosphatase and PI3-kinase activity.
Glucose Intolerance
Class IA phosphatidylinositol 3-kinase in pancreatic ? cells controls insulin secretion by multiple mechanisms.
Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver.
Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation.
Goiter
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
Granulomatous Disease, Chronic
Advances and highlights in primary immunodeficiencies in 2017.
Hamartoma
Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells.
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases.
Hamartoma Syndrome, Multiple
Cowden's syndrome with immunodeficiency.
[Germline mutations in PIK3CA and AKT1 in Cowden syndrome and related diseases].
Head and Neck Neoplasms
A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer.
Carcinogenesis of PIK3CA.
Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers.
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration.
Lessons learned from next-generation sequencing in head and neck cancer.
mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer.
PI3-kinase pathway biomarkers in oral cancer and tumor immune cells.
PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors.
Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer.
Role of microRNA-296-3p in the malignant transformation of sinonasal inverted papilloma.
Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures.
The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.
Translational Genomics and Recent Advances in Oral Squamous Cell Carcinoma.
Hearing Loss
Effects of epigallocatechin-3-gallate on proliferation and differentiation of mouse cochlear neural stem cells: Involvement of PI3K/Akt signaling pathway.
Heart Diseases
Genetic ablation of Cullin-RING E3 ubiquitin ligase 7 restrains pressure overload-induced myocardial fibrosis.
Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure.
Phosphoinositide 3-kinase inhibitor LY294002 ameliorates the severity of myosin-induced myocarditis in mice.
Role of insulin-like growth factor 1 and phosphoinositide 3-kinase in a setting of heart disease.
Role of phosphoinositide 3-kinases in regulating cardiac function.
Role of PI3 kinase gamma in excitation-contraction coupling and heart disease.
Heart Failure
Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase ? activity in pressure overload-induced cardiac failure.
Dynamic regulation of phosphoinositide 3-kinase-gamma activity and beta-adrenergic receptor trafficking in end-stage human heart failure.
FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K.
Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.
Leukocyte and cardiac phosphoinositide 3-kinase ? activity in pressure overload-induced cardiac failure.
Ouabain prevents pathological cardiac hypertrophy and heart failure through activation of phosphoinositide 3-kinase ? in mouse.
Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure.
Phosphoinositide 3-kinase gamma: kinase-dependent and -independent activities in cardiovascular function and disease.
Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure.
PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA.
Protein Kinases as Drug Development Targets for Heart Disease Therapy.
Regulation of heart rate and the pacemaker current by phosphoinositide 3-kinase signaling.
Role of phosphoinositide 3-kinase in cardiac function and heart failure.
Scaffolding Function of PI3Kgamma Emerges from Enzyme's Shadow.
Selective activation of PI3Kalpha/Akt/GSK-3beta signalling and cardiac compensatory hypertrophy during recovery from heart failure.
Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression.
Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize beta-adrenergic receptor function in heart failure.
The role of PI3-K/Akt signal pathway in the antagonist effect of CEPO on CHF rats.
[Effects of neuregulin on cardiac myocyte apoptosis and PI-3K signal transduction pathway in rapid pacing-induced heart failure in rhesus monkeys]
Hemangioma
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Hemangioma, Cavernous, Central Nervous System
Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations.
Hemangiosarcoma
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Active TGF-? signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart.
Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions.
Lgr5-positive endothelial progenitor cells occupy a tumor and injury prone niche in the kidney vasa recta.
PIK3CA mutations matter for cancer in dogs.
Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
Hematologic Neoplasms
2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3K? Selective Inhibitors.
Current and Investigational Agents Targeting the Phosphoinositide 3-Kinase Pathway.
Discovery of Orally Efficacious Phosphoinositide 3-Kinase ? Inhibitors with Improved Metabolic Stability.
Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors.
Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Phosphoinositide 3-kinase inhibitors in lymphoma.
Structural, Biochemical and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-kinase Delta.
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
The phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL/SLL.
Hemimegalencephaly
PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia.
The Fetus with Ganglionic Eminence Abnormality: Head Size and Extracranial Sonographic Findings Predict Genetic Diagnoses and Postnatal Outcomes.
Hepatitis
Phosphoinositide 3-kinase gamma inhibitor ameliorates concanavalin A-induced hepatic injury in mice.
Hepatitis B
Clinicopathological characteristics of PIK3CA and HBx mutations in Korean patients with hepatocellular carcinomas.
Expressions of MiR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus-related hepatocellular carcinoma.
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor alpha-mediated apoptosis by activation of phosphoinositol 3-kinase and beta-catenin.
The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor {alpha}-mediated apoptosis by activation of phosphoinositol 3-kinase and {beta}-catenin.
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Hepatitis C
Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription.
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network.
Hepatoblastoma
Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
Hepatomegaly
[Clinical and immunological characteristics of a case with activated phosphoinositide 3-kinase ? syndrome 2].
Herpes Simplex
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.
PI3-Kinase signaling may affect multiple steps during herpes simplex virus-1 entry.
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
Herpes Zoster
Phosphoinositide 3-kinase is involved in the induction of the human sperm acrosome reaction downstream of tyrosine phosphorylation.
Herpesviridae Infections
Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase ? Syndrome from the USIDNET Cohort.
Histiocytosis
Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis.
Histiocytosis, Langerhans-Cell
Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis.
HIV Infections
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).
Hodgkin Disease
A Rare Case of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Presenting With Hemophagocytosis Complicated With Hodgkin Lymphoma.
Huntington Disease
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.
Hydrocephalus
The Fetus with Ganglionic Eminence Abnormality: Head Size and Extracranial Sonographic Findings Predict Genetic Diagnoses and Postnatal Outcomes.
Hyper-IgM Immunodeficiency Syndrome
Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature.
Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence.
PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
Hyperalgesia
Inflammatory cytokines in midbrain periaqueductal gray contribute to diabetic induced pain hypersensitivity through phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway.
Mechanisms Mediating High-Molecular-Weight Hyaluronan-Induced Antihyperalgesia.
PI3K?/AKT signaling in high molecular weight hyaluronan (HMWH)-induced anti-hyperalgesia and reversal of nociceptor sensitization.
Hyperglycemia
Hyperglycemia activates glucose transport in rat skeletal muscle via a Ca(2+)-dependent mechanism.
Hyperglycemia enhances adipogenic induction of lipid accumulation: involvement of extracellular signal-regulated protein kinase 1/2, phosphoinositide 3-kinase/Akt, and peroxisome proliferator-activated receptor gamma signaling.
Hyperglycemia impairs the insulin signaling step between PI 3-kinase and Akt/PKB activations in ZDF rat liver.
Inhibitory effect of hyperglycemia on insulin-induced Akt/protein kinase B activation in skeletal muscle.
Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report.
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Hyperinsulinism
ANG II enhances contractile responses via PI3-kinase p110 delta pathway in aortas from diabetic rats with systemic hyperinsulinemia.
Defect in long-term activation of phosphatidylinositol 3-kinase by insulin in vivo: studies in insulin-resistant hHTg rats.
Early growth response gene-1 expression in vascular smooth muscle cells effects of insulin and oxidant stress.
Effects of chronic undernutrition on glucose uptake and glucose transporter proteins in rat heart.
Effects of exercise and insulin on insulin signaling proteins in human skeletal muscle.
Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells in vitro.
Elevated fasting insulin concentrations associate with impaired insulin signaling in skeletal muscle of healthy subjects independent of obesity.
Hyperinsulinemia impairs functions of circulating endothelial progenitor cells.
Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver.
Insulin and dexamethasone regulate insulin receptors, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in Fao hepatoma cells.
Insulin and exercise differentially regulate PI3-kinase and glycogen synthase in human skeletal muscle.
Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation.
Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH.
Insulin signaling in human skeletal muscle: time course and effect of exercise.
Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin-converting enzyme 2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats.
Regular exercise enhances insulin activation of IRS-1-associated PI3-kinase in human skeletal muscle.
Tissue-specific impairment of insulin signaling in vasculature and skeletal muscle of fructose-fed rats.
Hypersensitivity
Abdominal Massage Reduces Visceral Hypersensitivity via Regulating GDNF and PI3K/AKT Signal Pathway in a Rat Model of Irritable Bowel Syndrome.
Activation of protein kinase B/Akt signaling pathway contributes to mechanical hypersensitivity induced by capsaicin.
Essential role for the p110delta phosphoinositide 3-kinase in the allergic response.
Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance.
Inhibition of phosphoinositide 3-kinase ? attenuates inflammation, obesity, and cardiovascular risk factors.
Isoform-specific functions of phosphoinositide 3-kinases: p110delta but not p110gamma promotes optimal allergic responses in vivo.
Maternal food restriction enhances insulin-induced GLUT-4 translocation and insulin signaling pathway in skeletal muscle from suckling rats.
Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice.
PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.
Regulation of p110delta PI 3-kinase gene expression.
Regulation of phosphatidylinositol 3-kinase by insulin in rat skeletal muscle.
Resveratrol rescued the pain related hypersensitivity for Cntnap2-deficient mice.
Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing.
Targeting phosphoinositide 3-kinase: moving towards therapy.
Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy.
Unveiling novel 2-cyclopropyl-3-ethynyl-4-(4-fluorophenyl)quinolines as GPCR ligands via PI3-kinase/PAR-1 antagonism and platelet aggregation valuations; development of a new class of anticancer drugs with thrombolytic effects.
Hypersplenism
Knockdown of PIK3R1 by shRNA inhibits the activity of the splenic macrophages associated with hypersplenism due to portal hypertension.
Hypertension
Association analysis of the variant in the regulatory subunit of phosphoinositide 3-kinase (p85alpha) with Type 2 diabetes mellitus and hypertension in the Chinese Han population.
Increased PI3-kinase in presympathetic brain areas of the spontaneously hypertensive rat.
Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats.
Local angiotensin II aggravates cardiac remodeling in hypertension.
Phosphoinositide 3-kinase ? deficiency attenuates kidney injury and fibrosis in angiotensin II-induced hypertension.
Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of deoxycorticosterone acetate-salt hypertensive rats.
PI3-kinase upregulation and involvement in spontaneous tone in arteries from DOCA-salt rats: is p110delta the culprit?
Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma.
Redox-Sensitive Oxidation and Phosphorylation of PTEN Contribute to Enhanced Activation of PI3K/Akt Signaling in Rostral Ventrolateral Medulla and Neurogenic Hypertension in Spontaneously Hypertensive Rats.
Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension.
Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing.
Hypertension, Portal
Knockdown of PIK3R1 by shRNA inhibits the activity of the splenic macrophages associated with hypersplenism due to portal hypertension.
Hypertension, Pulmonary
NLRC3 inhibits MCT-induced pulmonary hypertension in rats via attenuating PI3K activation.
Hypertrophy, Right Ventricular
Ligustrazine Suppresses Platelet-Derived Growth Factor-BB-Induced Pulmonary Artery Smooth Muscle Cell Proliferation and Inflammation by Regulating the PI3K/AKT Signaling Pathway.
Hypoglycemia
Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway.
Polymicrogyria in association with hypoglycemia points to mutation in the mTOR pathway.
Role of the liver in glucose homeostasis in PI 3-kinase p85alpha-deficient mice.
Hypotension
Neuronal nitric oxide synthase-dependent elevation in adiponectin in the rostral ventrolateral medulla underlies g protein-coupled receptor 18-mediated hypotension in conscious rats.
Hypothyroidism
Roles of ERK1/2 and PI3K/AKT signaling pathways in mitochondria-mediated apoptosis in testes of hypothyroid rats.
Immune System Diseases
Class I phosphoinositide 3-kinases.
Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
Epstein-Barr Virus Susceptibility in Activated PI3K? Syndrome (APDS) Immunodeficiency.
Recent discovery of phosphoinositide 3-kinase ? inhibitors for the treatment of immune diseases and cancers.
Infections
A Peptide Derived from Phosphoinositide 3-kinase Inhibits Endocytosis and Influenza Virus Infection.
A Rare Case of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Presenting With Hemophagocytosis Complicated With Hodgkin Lymphoma.
A role for host phosphoinositide 3-kinase and cytoskeletal remodeling during Cryptosporidium parvum infection.
A role for phosphoinositide 3-kinase in bacterial invasion.
A sulfated glucuronorhamnan from the green seaweed Monostroma nitidum: Characteristics of its structure and antiviral activity.
Activation of cell signaling pathways is dependant on the biotype of bovine viral diarrhea viruses type 2.
Activation of host cell phosphatidylinositol 3-kinases by Trypanosoma cruzi infection.
Adenovirus Infection Results in Alterations of Insulin Signaling and Glucose Homeostasis.
Adjuvant-induced survival signaling in clonally expanded T cells is associated with transient increases in pAkt levels and sustained uptake of glucose.
Akt-dependent phosphorylation of serine 1179 and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase 1/2 cooperatively mediate activation of the endothelial nitric-oxide synthase by hydrogen peroxide.
Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis.
APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
Autophagy Benefits the Replication of Egg Drop Syndrome Virus in Duck Embryo Fibroblasts.
Avian reovirus triggers autophagy in primary chicken fibroblast cells and Vero cells to promote virus production.
Berberine inhibits Chlamydia pneumoniae infection-induced vascular smooth muscle cell migration through downregulating MMP3 and MMP9 via PI3K.
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
CIB1 synergizes with EphrinA2 to regulate Kaposi's sarcoma-associated herpesvirus macropinocytic entry in human microvascular dermal endothelial cells.
Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without Helicobacter pylori Infection.
Constitutively active phosphatidylinositol 3-kinase and AKT are sufficient to stimulate the epithelial Na+/H+ exchanger 3.
Corneal cell survival in adenovirus type 19 infection requires phosphoinositide 3-kinase/Akt activation.
Critical Roles of Phosphoinositide 3-Kinase ? in the Humoral Immune Response to Trypanosoma congolense Infection.
De novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly.
Diabetes and Infections-Hepatitis C: Is There Type 2 Diabetes Excess in Hepatitis C Infection?
Different expression of apoptotic proteins between HBV-infected and non-HBV-infected hepatocellular carcinoma.
Differential regulation of interleukin-12 and tumour necrosis factor-alpha by phosphatidylinositol 3-kinase and ERK 1/2 pathways during Mycobacterium tuberculosis infection.
Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase ? Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
EphrinA2 regulates clathrin mediated KSHV endocytosis in fibroblast cells by coordinating integrin-associated signaling and c-Cbl directed polyubiquitination.
ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection.
Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: involvement of insulin receptor substrate-related adapter proteins.
Exhaustion of the CD8
Functional analysis of host factors that mediate the intracellular lifestyle of Cryptococcus neoformans.
HACE1, an E3 ubiquitin-protein ligase, Mitigates Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Infection Induced Oxidative Stress by Promoting Nrf2 Activity.
Human adenovirus type 36 enhances glucose uptake in diabetic and nondiabetic human skeletal muscle cells independent of insulin signaling.
Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling.
Hydrogen sulfide-induced GAPDH sulfhydration disrupts the CCAR2-SIRT1 interaction to initiate autophagy.
Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes.
Induction of Central Host Signaling Kinases during Pneumococcal Infection of Human THP-1 Cells.
Induction of cyclin D2 in rat granulosa cells requires FSH-dependent relief from FOXO1 repression coupled with positive signals from Smad.
Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production.
Initiation of human astrovirus type 1 infection was blocked by inhibitors of phosphoinositide 3-kinase.
Interaction of c-Cbl with myosin IIA regulates Bleb associated macropinocytosis of Kaposi's sarcoma-associated herpesvirus.
Kaposi's sarcoma-associated herpesvirus induces the phosphatidylinositol 3-kinase-PKC-zeta-MEK-ERK signaling pathway in target cells early during infection: implications for infectivity.
KSHV Entry and Trafficking in Target Cells-Hijacking of Cell Signal Pathways, Actin and Membrane Dynamics.
Lipid rafts of primary endothelial cells are essential for Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8-induced phosphatidylinositol 3-kinase and RhoA-GTPases critical for microtubule dynamics and nuclear delivery of viral DNA but dispensable for binding and entry.
M. tuberculosis PknG manipulates host autophagy flux to promote pathogen intracellular survival.
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.
MTOR-Driven Metabolic Reprogramming Regulates Legionella pneumophila Intracellular Niche Homeostasis.
Novel Roles of Focal Adhesion Kinase in Cytoplasmic Entry and Replication of Influenza A Viruses.
Outer membrane protein A expression in Enterobacter sakazakii is required to induce microtubule condensation in human brain microvascular endothelial cells for invasion.
Overexpression of interferon-gamma-inducible GTPase inhibits coxsackievirus B3-induced apoptosis through the activation of the phosphatidylinositol 3-kinase/Akt pathway and inhibition of viral replication.
Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding.
PDPK1 regulates autophagosome biogenesis by binding to PIK3C3.
Phagocytic Entry of Legionella pneumophila into Macrophages through Phosphatidylinositol 3,4,5-Trisphosphate-Independent Pathway.
Phosphatidylinositol 3-kinase is required for rhinovirus-induced airway epithelial cell interleukin-8 expression.
Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages.
Phosphatidylinositol 3-kinase/Akt-dependent and -independent protection against apoptosis in normal human melanocytes.
Phosphoinositide 3-kinase ? gene mutation predisposes to respiratory infection and airway damage.
Phosphoinositide 3-Kinase ? Inhibition Improves Neutrophil Bacterial Killing in Critically Ill Patients at High Risk of Infection.
Phosphoinositide 3-kinase is required for insulin-induced but not for growth hormone- or hyperosmolarity-induced glucose uptake in 3T3-L1 adipocytes.
PI3K signaling in chronic obstructive pulmonary disease: mechanisms, targets, and therapy.
Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.
Protein phosphatase 2A and phosphatidylinositol 3-kinase regulate the activity of Sp1-responsive promoters.
Respiratory syncytial virus inhibits apoptosis and induces NF-kappa B activity through a phosphatidylinositol 3-kinase-dependent pathway.
Rhinovirus activates interleukin-8 expression via a Src/p110beta phosphatidylinositol 3-kinase/Akt pathway in human airway epithelial cells.
RhoA-GTPase facilitates entry of Kaposi's sarcoma-associated herpesvirus into adherent target cells in a Src-dependent manner.
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
Role of phosphatidylinositol 3-kinase in the binding of Bordetella pertussis to human monocytes.
Shiga toxin type-2 (Stx2) induces glutamate release via phosphoinositide 3-kinase (PI3K) pathway in murine neurons.
Single cell mass cytometry reveals remodeling of human T cell phenotypes by varicella zoster virus.
Somatic mutation in PIK3CA is a late event in cervical carcinogenesis.
The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-? (PI3K?) Syndrome (APDS).
The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network.
The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.
Toxoplasma gondii triggers Gi-dependent PI 3-kinase signaling required for inhibition of host cell apoptosis.
Infertility, Male
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Inflammatory Bowel Diseases
How autophagy controls the intestinal epithelial barrier.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer.
Phosphoinositide 3-Kinase P110?-Signaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
The roles of microbial products in the development of colorectal cancer: a review.
Inflammatory Breast Neoplasms
Identification of frequent somatic mutations in inflammatory breast cancer.
Influenza, Human
A Peptide Derived from Phosphoinositide 3-kinase Inhibits Endocytosis and Influenza Virus Infection.
Binding of influenza A virus NS1 protein to the inter-SH2 domain of p85 suggests a novel mechanism for phosphoinositide 3-kinase activation.
Effect of influenza A virus non-structural protein 1(NS1) on a mouse model of diabetes mellitus induced by Streptozotocin.
Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production.
Novel Roles of Focal Adhesion Kinase in Cytoplasmic Entry and Replication of Influenza A Viruses.
Reorganization of the host cell Crk(L)-PI3 kinase signaling complex by the influenza A virus NS1 protein.
Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein.
Infratentorial Neoplasms
Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas.
Insulin Resistance
A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies.
A High-sugar High-fat Diet Induced Metabolic Syndrome Shows some Symptoms of Alzheimer's Disease in Rats.
A single-nucleotide polymorphism in the p110beta gene promoter is associated with partial protection from insulin resistance in severely obese adolescents.
Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes.
Adipose tissue insulin sensitivity and macrophage recruitment: Does PI3K pick the pathway?
Alterations in insulin-induced postreceptor signaling in adipocytes of the Otsuka Long-Evans Tokushima fatty rat strain.
Anaesthesia generates neuronal insulin resistance by inducing hypothermia.
Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling.
Association analysis indicates that a variant GATA-binding site in the PIK3CB promoter is a Cis-acting expression quantitative trait locus for this gene and attenuates insulin resistance in obese children.
Association of impaired phosphatidylinositol 3-kinase activity in GLUT1-containing vesicles with malinsertion of glucose transporters into the plasma membrane of fibroblasts from a patient with severe insulin resistance and clinical features of Werner syndrome.
Association of SH2-containing inositol phosphatase 2 with the insulin resistance of diabetic db/db mice.
Association of the polymorphisms in the 5'-untranslated region of PTEN gene with type 2 diabetes in a Japanese population.
Attenuated Pik3r1 Expression Prevents Insulin Resistance and Adipose Tissue Macrophage Accumulation in Diet-Induced Obese Mice.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Beneficial effects of Aronia melanocarpa berry extract on hepatic insulin resistance in type 2 diabetes mellitus rats.
Calorie restriction increases the ratio of phosphatidylinositol 3-kinase catalytic to regulatory subunits in rat skeletal muscle.
Calorie Restriction-Induced Increase in Skeletal Muscle Insulin Sensitivity Is Not Prevented by Overexpression of the p55? Subunit of Phosphoinositide 3-Kinase.
Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver.
Chronic 17beta-estradiol treatment improves skeletal muscle insulin signaling pathway components in insulin resistance associated with aging.
Chronic hyperinsulinism induced down-regulation of insulin post-receptor signaling transduction in Hep G2 cells.
Commentary on Essential roles of PI(3)K-p110beta in cell growth, metabolism, and tumorigenesis Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ, Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Comparison of insulin signaling gene expression in insulin sensitive tissues between cats and dogs.
Decreased gene expression of insulin signaling genes in insulin sensitive tissues of obese cats.
Defect in long-term activation of phosphatidylinositol 3-kinase by insulin in vivo: studies in insulin-resistant hHTg rats.
Deficiency of phosphoinositide 3-kinase enhancer protects mice from diet-induced obesity and insulin resistance.
Diet-induced obesity alters signalling pathways and induces atrophy and apoptosis in skeletal muscle in a prediabetic rat model.
Dietary chokeberry and dried jujube fruit attenuates high-fat and high-fructose diet-induced dyslipidemia and insulin resistance via activation of the IRS-1/PI3K/Akt pathway in C57BL/6?J mice.
Different subcellular distribution and regulation of expression of insulin receptor substrate (IRS)-3 from those of IRS-1 and IRS-2.
Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.
Diversification of cardiac insulin signaling involves the p85 alpha/beta subunits of phosphatidylinositol 3-kinase.
Early growth response gene-1 expression in vascular smooth muscle cells effects of insulin and oxidant stress.
Effect of sidt2 Gene on Cell Insulin Resistance and Its Molecular Mechanism.
Effects of Aerobic Exercise Combined with Panaxatriol Derived from Ginseng on Insulin Resistance and Skeletal Muscle Mass in Type 2 Diabetic Mice.
Effects of contractile activity on tyrosine phosphoproteins and PI 3-kinase activity in rat skeletal muscle.
Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity.
Effects of Insulin on the Vasculature.
Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior.
Elevated basal PI 3-kinase activity and reduced insulin signaling in sucrose-induced hepatic insulin resistance.
Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets.
Energy balancing by fat Pik3ca.
Enhanced insulin-stimulated activation of phosphatidylinositol 3-kinase in the liver of high-fat-fed rats.
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.
Ethanol feeding induces insulin resistance with enhanced PI 3-kinase activation.
Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion.
Exercise training prevents maturation-induced decreases in insulin receptor substrate-1 and phosphatidylinositol 3-kinase in rat skeletal muscle.
Exposure to maternal obesity during suckling outweighs in utero exposure in programming for post-weaning adiposity and insulin resistance in rats.
Fatty acid induced insulin resistance in rat-1 fibroblasts overexpressing human insulin receptors: impaired insulin-stimulated mitogen-activated protein kinase activity.
Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C lambda /zeta but not on glycogen synthase kinase-3.
Gene expression of insulin signal-transduction pathway intermediates is lower in rats fed a beef tallow diet than in rats fed a safflower oil diet.
Glucosamine infusion in rats rapidly impairs insulin stimulation of phosphoinositide 3-kinase but does not alter activation of Akt/protein kinase B in skeletal muscle.
Glucose Transporters in Diabetic Kidney Disease-Friends or Foes?
Glucose-induced insulin resistance of phosphatidylinositol 3'-OH kinase and AKT/PKB is mediated by the hexosamine biosynthesis pathway.
Green tea polyphenol extract regulates the expression of genes involved in glucose uptake and insulin signaling in rats fed a high fructose diet.
Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its downstream signals in 3T3-L1 adipocytes.
Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance.
High-fat diet and leptin treatment alter skeletal muscle insulin-stimulated phosphatidylinositol 3-kinase activity and glucose transport.
Human target validation of phosphoinositide 3-kinase (PI3K)?; effects on platelets and insulin sensitivity, using AZD6482 a novel PI3K? inhibitor.
Hyperglycemia impairs the insulin signaling step between PI 3-kinase and Akt/PKB activations in ZDF rat liver.
Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index.
Impact of rs361072 in the phosphoinositide 3-kinase p110beta gene on whole-body glucose metabolism and subunit protein expression in skeletal muscle.
Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly. A disorder characterized by selective postreceptor insulin resistance.
Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients.
Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes.
Improvement of insulin sensitivity in obese Zucker rats by myricetin extracted from Abelmoschus moschatus.
In obese and non-obese adults, the cis-regulatory rs361072 promoter variant of PIK3CB is associated with insulin resistance not with type 2 diabetes.
In vitro and in vivo studies of a naturally occurring variant of the human p85alpha regulatory subunit of the phosphoinositide 3-kinase: inhibition of protein kinase B and relationships with type 2 diabetes, insulin secretion, glucose disappearance constant, and insulin sensitivity.
In vivo administration of glucosamine inhibited phosphatidylinositol 3-kinase activity without affecting tyrosine phosphorylation of the insulin receptor or insulin receptor substrate in rat adipocytes.
In vivo insulin signaling through PI3-kinase is impaired in skeletal muscle of adult rat offspring exposed to ethanol in utero.
In vivo knockdown of p85alpha with an antisense oligonucleotide improves insulin sensitivity in Lep(ob/ob) and diet-induced obese mice.
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase.
Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase.
Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle.
Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess.
Influence and related mechanism of Retn gene expression on glucose uptake in 3T3-L1 cells.
Inhibition of endogenous SHIP2 ameliorates insulin resistance caused by chronic insulin treatment in 3T3-L1 adipocytes.
Inhibitory effect of hyperglycemia on insulin-induced Akt/protein kinase B activation in skeletal muscle.
Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways.
Insulin and dexamethasone regulate insulin receptors, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in Fao hepatoma cells.
Insulin attenuates vascular smooth muscle calcification but increases vascular smooth muscle cell phosphate transport.
Insulin regulation of sterol regulatory element-binding protein-1 expression in L-6 muscle cells and 3T3 L1 adipocytes.
Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway.
Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle.
Insulin resistance in fat cells from obese Zucker rats--evidence for an impaired activation and translocation of protein kinase B and glucose transporter 4.
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats.
Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH.
Insulin Resistance: Pathophysiology and Rationale for Treatment.
Insulin signal transduction and glucose transport in human adipocytes: effects of obesity and low calorie diet.
Insulin signal transduction by a mutant human insulin receptor lacking the NPEY sequence. Evidence for an alternate mitogenic signaling pathway that is independent of Shc phosphorylation.
Insulin signaling and life span.
Insulin signaling stimulates insulin transport by bovine aortic endothelial cells.
Insulin-mediated phosphorylation of the proline-rich Akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats.
Latent Inflammation and Insulin Resistance in Adipose Tissue.
LBP-4a improves insulin resistance via translocation and activation of GLUT4 in OLETF rats.
Lipid phosphatases as drug discovery targets for type 2 diabetes.
Lipopolysaccharide impairs insulin sensitivity via activation of phosphoinositide 3-kinase in adipocytes.
Long-term denervation impairs insulin receptor substrate-1-mediated insulin signaling in skeletal muscle.
Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin-converting enzyme 2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats.
Maternal protein restriction affects postnatal growth and the expression of key proteins involved in lifespan regulation in mice.
Mediation of beta-endorphin in exercise-induced improvement in insulin resistance in obese Zucker rats.
Meta-analysis approach identifies candidate genes and associated molecular networks for type-2 diabetes mellitus.
Modulation of human insulin receptor substrate-1 tyrosine phosphorylation by protein kinase Cdelta.
Molecular mechanisms of insulin action in normal and insulin-resistant states.
Myricetin, a naturally occurring flavonol, ameliorates insulin resistance induced by a high-fructose diet in rats.
Natural variants of human p85 alpha phosphoinositide 3-kinase in severe insulin resistance: a novel variant with impaired insulin-stimulated lipid kinase activity.
Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta.
New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: Influence of insulin resistance and oxidative stress.
NO-Dependent Akt Inactivation by S-Nitrosylation as a Possible Mechanism of STZ-Induced Neuronal Insulin Resistance.
Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR.
Novel PIK3R1 mutation of SHORT syndrome: A case report with a 6-month follow up.
Nutrient sensing in the mTOR/S6K1 signalling pathway.
Nutritional upregulation of p85alpha expression is an early molecular manifestation of insulin resistance.
Obesity, insulin resistance and hepatic perfusion.
Oleate protects against palmitate-induced insulin resistance in L6 myotubes.
Opioid ?-receptors as new target for insulin resistance.
Overfeeding During Lactation in Rats is Associated with Cardiovascular Insulin Resistance in the Short-Term.
Oxidative stress impairs insulin but not platelet-derived growth factor signalling in 3T3-L1 adipocytes.
Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase.
p50alpha/p55alpha phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity.
Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice.
Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene PIK3R1 haplotype is associated with body fat and serum leptin in a female twin population.
Phosphatidylinositol 3-kinase redistribution is associated with skeletal muscle insulin resistance in gestational diabetes mellitus.
Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice.
Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles.
PI3-kinase activity modulates apo B available for hepatic VLDL production in apobec-1-/- mice.
PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy.
Polymorphism in postinsulin receptor signaling pathway is not associated with polycystic ovary syndrome.
Post-receptoral adipocyte insulin resistance induced by nelfinavir is caused by insensitivity of PKB/Akt to phosphatidylinositol-3,4,5-trisphosphate.
Postreceptor crosstalk on PI3K/Akt between GH and insulin in non-catch-up growth rats born small for gestational age.
Preoperative feeding does not reverse postoperative insulin resistance in skeletal muscle in the rat.
Progesterone inhibits glucose uptake by affecting diverse steps of insulin signaling in 3T3-L1 adipocytes.
Programming of central and peripheral insulin resistance by low birthweight and postnatal catch-up growth in male mice.
Promoter polymorphisms -359T/C and -303A/G of the catalytic subunit p110beta gene of human phosphatidylinositol 3-kinase are not associated with insulin secretion or insulin sensitivity in finnish subjects.
Propranolol Improves Impaired Hepatic PI3K/Akt Signaling Post Burn Injury.
Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes.
Reduction of PTP1B induces differential expression of PI3-kinase (p85alpha) isoforms.
Regulation of insulin receptor substrate-2 tyrosine phosphorylation in animal models of insulin resistance.
Regulation of IRS-2 tyrosine phosphorylation in fasting and diabetes.
Regulation of phosphatidylinositol 3-kinase by insulin in rat skeletal muscle.
Rescuing 3T3-L1 adipocytes from insulin resistance induced by stimulation of Akt-mammalian target of rapamycin/p70 S6 kinase (S6K1) pathway and serine phosphorylation of insulin receptor substrate-1: effect of reduced expression of p85alpha subunit of phosphatidylinositol 3-kinase and S6K1 kinase.
Role of the liver in glucose homeostasis in PI 3-kinase p85alpha-deficient mice.
Skeletal muscle insulin resistance after trauma: insulin signaling and glucose transport.
Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation.
Spinal cord injury causes insulin resistance associated with PI3K signaling pathway in hypothalamus.
Studies of variability in the PTEN gene among Danish caucasian patients with Type II diabetes mellitus.
The beneficial effects of N-acetyl cysteine (NAC) against obesity associated complications: A systematic review of pre-clinical studies.
The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage.
The mechanism of insulin-induced signal transduction mediated by the insulin receptor substrate family.
The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex.
The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance.
The Redox Regulation of PI 3-Kinase-Dependent Signaling.
The silent PPARgamma exon 6 CAC(His) --> CAT(His) polymorphism does not affect the plasma leptin levels in a collective of first degree relatives of type 2 diabetes patients from South West Germany.
Tissue-specific impairment of insulin signaling in vasculature and skeletal muscle of fructose-fed rats.
TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells.
Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitor.
Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity and dyslipidaemia by increased energy expenditure.
Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism.
[Effect of chronic ethanol intake on insulin receptor, insulin receptor subsrate-1 and phosphoinositide 3-kinase mRNA expression in skeletal muscle of rats]
[Induction of insulin resistance induced by PI-3K inhibitor in porcine granulosa cells]
Insulinoma
Essential role of phosphoinositide 3-kinase in leptin-induced K(ATP) channel activation in the rat CRI-G1 insulinoma cell line.
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
Intellectual Disability
Germline pathogenic variant in PIK3CA leading to symmetrical overgrowth with marked macrocephaly and mild global developmental delay.
Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Intestinal Neoplasms
Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice.
PIK3CA and APC mutations are synergistic in the development of intestinal cancers.
Intracranial Aneurysm
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Intracranial Hemorrhages
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Ischemic Stroke
Neuroprotective mechanisms of miR-124 activating PI3K/Akt signaling pathway in ischemic stroke.
Keratoconus
Modeling Keratoconus Using Induced Pluripotent Stem Cells.
Keratosis
FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra.
FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.
Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.
Somatic FGFR3 and PIK3CA mutations are present in familial seborrhoeic keratoses.
Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next?
Keratosis, Actinic
Review of the European Society for Photodynamic Therapy (Euro-PDT) Annual Congress 2020.
Keratosis, Seborrheic
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
Two cases of seborrheic keratosis of the external ear canal: involvement of PIK3CA and FGFR3 genes.
Ketosis
Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report.
Kidney Neoplasms
Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.
Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro.
Effects of miR-455 on PIK3R1 gene expression regulation and kidney cancer cell functions.
Genetic Analysis and Targeted Therapy Using Buparlisib and MK2206 in a Patient with Triple Metachronous Cancers of the Kidney, Prostate, and Squamous Cell Carcinoma of the Lung: A Case Report.
miR-490-5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA.
Molecular imaging of phosphorylation events for drug development.
PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3?/CTNNB1 signaling pathway.
Regulation of PI 3-K, PTEN, p53, and mTOR in Malignant and Benign Tumors Deficient in Tuberin.
The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.
Unilateral synchronous papillary renal neoplasm with reverse polarity and clear cell renal cell carcinoma: a case report with KRAS and PIK3CA mutations.
Klippel-Trenaunay-Weber Syndrome
A pilot study of next generation sequencing-liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel-Trenaunay syndrome.
Klippel-Trenaunay Syndrome.
Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation.
Ophthalmic Alterations in the Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome, and the Phakomatosis Pigmentovascularis: An Independent Group of Conditions?
PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum.
[PIK3CA-related overgrowth syndrome (PROS)].
Laryngeal Neoplasms
New miRNA expression abnormalities in laryngeal squamous cell carcinoma.
Over-expression of MEOX2 promotes apoptosis through inhibiting the PI3K/Akt pathway in laryngeal cancer cells.
Leiomyoma
Targeting leiomyomas with all-trans-retinoic acid at phosphoinositide 3-kinase pathway suppression: Effective roles of ?-catenin and of signaling interactions.
Leiomyosarcoma
Differential Expression of IRS-1 and IRS-2 in Uterine Leiomyosarcomas with Distinct Oncogenic Phenotypes: Lack of Correlation with Downstream Signaling Events.
The Phosphatidylinositol 3' Kinase-Akt-mammalian Target of Rapamycin Pathway in Smooth Muscle Tumors of the Uterus: Selected Protein Expression Patterns and Their Clinicopathologic Implications.
Lentigo
FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo.
FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
The absence of BRAF, FGFR3, and PIK3CA mutations differentiates lentigo simplex from melanocytic nevus and solar lentigo.
Leukemia
A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma.
A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.
Association of the Src homology 2 domain-containing leukocyte phosphoprotein of 76 kD (SLP-76) with the p85 subunit of phosphoinositide 3-kinase.
BCR/ABL regulation of PI-3 kinase activity.
Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine,wortmannin and UCN-01.
Calming down T cell acute leukemia.
Codelivery of Genistein and miRNA-29b to A549 Cells Using Aptamer-Hybrid Nanoparticle Bioconjugates.
Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells.
DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo.
H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells.
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway.
Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120.
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
Leukemia inhibitory factor promotes olfactory sensory neuronal survival via phosphoinositide 3-kinase pathway activation and Bcl-2.
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance.
PI 3-K signaling pathway suppresses PMA-induced expression of p21WAF1/Cip1 in human leukemia cells.
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Rac and phosphatidylinositol 3-kinase regulate the protein kinase B in Fc epsilon RI signaling in RBL 2H3 mast cells.
Rac is required for v-Abl tyrosine kinase to activate mitogenesis.
Reprogramming of the Epigenome by MLL1 Links Early-Life Environmental Exposures to Prostate Cancer Risk.
Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
RKTG overexpression inhibits proliferation and induces apoptosis of human leukemia cells via suppression of the ERK and PI3K/AKT signaling pathways.
Side-chain modified vitamin D analogs require activation of both PI 3-K and erk1,2 signal transduction pathways to induce differentiation of human promyelocytic leukemia cells.
Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.
Silencing the PIK3CA Gene Enhances the Sensitivity of Childhood Leukemia Cells to Chemotherapy Drugs by Suppressing the Phosphorylation of Akt.
TAPP2 links phosphoinositide 3-kinase signaling to B cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B cell leukemia.
Targeting phosphatidylinositol 3-kinase gamma (PI3K?): Discovery and development of its selective inhibitors.
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
The Phosphoinositide 3-Kinase p110? Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma.
The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-differentiated HL-60 cells.
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.
Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.
Leukemia, B-Cell
Silencing the PIK3CA Gene Enhances the Sensitivity of Childhood Leukemia Cells to Chemotherapy Drugs by Suppressing the Phosphorylation of Akt.
TAPP2 links phosphoinositide 3-kinase signaling to B cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B cell leukemia.
Leukemia, Erythroblastic, Acute
Protein kinase C delta specifically associates with phosphatidylinositol 3-kinase following cytokine stimulation.
Role of phosphatidylinositol 3-kinase in friend spleen focus-forming virus-induced erythroid disease.
The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis.
Leukemia, Lymphocytic, Chronic, B-Cell
Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway.
Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia.
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
How I Manage CLL with Venetoclax-Based Treatments.
Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia.
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia.
Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia.
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
PI3-kinase inhibitors in chronic lymphocytic leukemia.
PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation.
Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.
The phosphoinositide 3-kinase pathway in chronic lymphocytic leukemia: evidence for phosphatase and tensin homolog deletion on chromosome 10 deregulation.
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101).
Leukemia, Lymphoid
Dynamics of the Phosphoinositide 3-Kinase p110? Interaction with p85? and Membranes Reveals Aspects of Regulation Distinct from p110?.
The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance.
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
Leukemia, Myeloid
Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias.
Leukemia, Myeloid, Acute
Arsenic Disulfide Synergizes with the Phosphoinositide 3-Kinase Inhibitor PI-103 to Eradicate Acute Myeloid Leukemia Stem Cells by Inducing Differentiation.
Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3K? inhibitor: Design, synthesis and biological evaluation.
Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations.
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia.
Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells.
Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Nuclear inositol lipid metabolism: more than just second messenger generation?
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring.
Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry.
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.
Leukemia, Promyelocytic, Acute
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120.
Leukemia, T-Cell
H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells.
Leukemia-Lymphoma, Adult T-Cell
Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL).
HTLV-I Tax regulates the cellular proliferation through the down-regulation of PIP3-phosphatase expressions via the NF-?B pathway.
Human T-cell leukemia virus type I tax down-regulates the expression of phosphatidylinositol 3,4,5-trisphosphate inositol phosphatases via the NF-kappaB pathway.
Leukocytosis
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
Leukoencephalopathies
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Lichen Planus
FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
Lichen Planus, Oral
LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma.
Lipoblastoma
Lipoblastoma phenotype contains a somatic PIK3CA mutation.
Lipodystrophy
SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling.
Skeletal Muscle Insulin Signaling Defects Downstream of Phosphatidylinositol 3-Kinase at the Level of Akt Are Associated With Impaired Nonoxidative Glucose Disposal in HIV Lipodystrophy.
Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity and dyslipidaemia by increased energy expenditure.
Lipoma
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
PIK3CA mutations in lipomatosis of nerve with or without nerve territory overgrowth.
PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma.
Lipomatosis
Clinical and Molecular Investigation of Familial Multiple Lipomatosis: Variants in the HMGA2 Gene.
Congenital infiltrating lipomatosis of the face with lingual mucosal neuromas associated with a PIK3CA mutation.
Facial Infiltrating Lipomatosis Contains Somatic PIK3CA Mutations in Multiple Tissues.
PIK3CA activating mutations in facial infiltrating lipomatosis.
PIK3CA mutations in lipomatosis of nerve with or without nerve territory overgrowth.
PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Somatic mosaicism for the p.His1047Arg mutation in PIK3CA in a girl with mesenteric lipomatosis.
Somatic PIK3CA mutations are present in multiple tissues of facial infiltrating lipomatosis.
[PIK3CA-related overgrowth syndrome (PROS)].
Liposarcoma
Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA.
Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.
Prognostic implications of PIK3CA amplification in curatively resected liposarcoma.
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma.
Liposarcoma, Myxoid
Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.
Molecular profiling of soft-tissue sarcomas with FoundationOne® Heme identifies potential targets for sarcoma therapy: a single-centre experience.
Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma.
Liver Cirrhosis
Astragaloside IV combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway.
Phosphoinositide 3-kinase gamma inhibitor ameliorates concanavalin A-induced hepatic injury in mice.
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Liver Diseases
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Liver Neoplasms
Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget's disease.
Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
Hematopoietic-substrate-1 associated protein X-1 (HAX-1) regulates liver cancer cells growth, metastasis, and angiogenesis through Akt.
Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid.
MicroRNA-203 suppresses proliferation in liver cancer associated with PIK3CA, p38 MAPK, c-Jun, and GSK3 signaling.
Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin.
Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3?/?-catenin signalling.
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
The Orphan Nuclear Receptor Gene NR0B2 Is a Favorite Prognosis Factor Modulated by Multiple Cellular Signal Pathways in Human Liver Cancers.
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Long QT Syndrome
Acquired long QT syndrome and phosphoinositide 3-kinase.
Increased Late Sodium Current Contributes to the Electrophysiological Effects of Chronic, but Not Acute, Dofetilide Administration.
Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome.
Lung Diseases
Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
Oxidative Imbalance as a Crucial Factor in Inflammatory Lung Diseases: Could Antioxidant Treatment Constitute a New Therapeutic Strategy?
Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
Lung Injury
Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcgamma receptor activation and immune complex-induced inflammation.
Phosphoinositide-3 kinase {gamma} required for LPS-induced transepithelial neutrophil trafficking in the lung.
Lung Neoplasms
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.
A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.
Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer.
Activation of Akt involves resistance to NF-?B inhibition and abrogation of both triggers synergistic apoptosis in lung adenocarcinoma cells.
Analysis of EGFR, KRAS, and PIK3CA gene mutation rates and clinical distribution in patients with different types of lung cancer.
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
Anticancer activity of 2'-hydroxyflavanone towards lung cancer.
Apigenin inhibits cell proliferation, migration, and invasion by targeting Akt in the A549 human lung cancer cell line.
Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
Asymmetric real-time PCR and multiplex melting curve analysis with TaqMan probes for detecting PIK3CA mutations.
Bauerane Induces S-Phase Cell Cycle Arrest, Apoptosis, and Inhibition of Proliferation of A549 Human Lung Cancer Cells Through the Phosphoinositide 3-Kinase (PI3K)/AKT and Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway.
Bcl-X(L) and STAT3 mediate malignant actions of gamma-irradiation in lung cancer cells.
BYL719, a selective inhibitor of phosphoinositide 3-Kinase ?, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Cancer genes in lung cancer: racial disparities: are there any?
Catalog of Lung Cancer Gene Mutations Among Chinese Patients.
Chromosomal and genomic changes in lung cancer.
Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer.
Clinical perspective of afatinib in non-small cell lung cancer.
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma.
Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers.
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Clinicopathological and Survival Analysis of Japanese Patients with Resected Non-Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification.
Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI 3-kinase in KRAS mutant lung cancer.
Correlation between the expression levels of miR-1 and PIK3CA in non-small-cell lung cancer and their relationship with clinical characteristics and prognosis.
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling.
Design and development of Tetrahydro-Quinoline derivatives as dual mTOR-C1/C2 inhibitors for the treatment of lung cancer.
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer.
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase.
Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report.
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Effects of Collagen IV on Cisplatin-Induced Apoptosis of Non-Small Cell Lung Cancer Cells.
EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.
EMT twists the road to PI3K.
Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation.
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma.
Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer.
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Genetic Analysis and Targeted Therapy Using Buparlisib and MK2206 in a Patient with Triple Metachronous Cancers of the Kidney, Prostate, and Squamous Cell Carcinoma of the Lung: A Case Report.
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC).
Identification of lung cancer oncogenes based on the mRNA expression and single nucleotide polymorphism profile data.
Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.
Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas.
Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies.
Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
Inhibition of PI-3K restores nuclear p27(Kip1) expression in a mouse model of Kras-driven lung cancer.
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Integration of Liquid Biopsies into Clinical Laboratory Applications via NGS in Cancer Diagnostics.
Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer.
Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth.
Interferon-? signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells.
Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients.
Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer.
LY294002, an inhibitor of PI-3K, enhances heat sensitivity independently of p53 status in human lung cancer cells.
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases.
Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer.
MiR-142-5p Suppresses Tumorigenesis by Targeting PIK3CA in Non-Small Cell Lung Cancer.
miR-183-5p functions as a tumor suppressor in lung cancer through PIK3CA inhibition.
MiR-486-5p Serves as a Good Biomarker in Nonsmall Cell Lung Cancer and Suppresses Cell Growth With the Involvement of a Target PIK3R1.
miR?10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Molecular profiling of non-small cell lung cancer.
Molecular spectrum of PIK3CA gene mutations in patients with nonsmall-cell lung cancer in Turkey.
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer.
Morphological and genetic heterogeneity of synchronous multifocal lung adenocarcinoma in a Chinese cohort.
Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
Multiplexed assays for detection of mutations in PIK3CA.
Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.
Mutationally Activated PIK3CAH1047R Cooperates With BRAFV600E In Lung Cancer Progression.
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Next?generation sequencing?based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her?2 and TP53 mutations in patients with non?small cell lung cancer.
NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.
No impact of passive smoke on the somatic profile of lung cancers in never-smokers.
Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.
Oncogenic mutation of PIK3CA in small cell lung carcinoma: A potential therapeutic target pathway for chemotherapy-resistant lung cancer.
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
Overexpression of Aiolos promotes epithelial-mesenchymal transition and cancer stem cell-like properties in lung cancer cells.
Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Peroxiredoxin 6 promotes lung cancer cell invasion by inducing urokinase-type plasminogen activator via p38 kinase, phosphoinositide 3-kinase, and Akt.
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
PI3K expression predicts overall survival in lung adenocarcinoma.
PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[?]indene Derivative in Lung Cancer Cells.
PIK3CA gene amplification in Japanese non-small cell lung cancer.
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
PIK3CA mutation and amplification in human lung cancer.
PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
PIK3CA mutation status in Japanese lung cancer patients.
PIK3CA mutations and copy number gains in human lung cancers.
PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.
PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies.
PIK3CA Mutations in Resected Small Cell Lung Cancer.
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Predictive and Prognostic Biomarkers for Patients Treated with Anti-EGFR Agents in Lung Cancer: A Systemic Review and Meta-Analysis.
Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis.
Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing.
Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
Prognostic significance of phosphoinositide 3-kinase p110? and p110? isoforms in non-small cell lung cancer.
Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer.
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy.
Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR.
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells.
Sensitive genotyping of somatic mutations in the EGFR, KRAS, PIK3CA, BRAF genes from NSCLC patients using hydrogel biochips.
Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer.
Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Targeted therapies in development for non-small cell lung cancer.
Targeting mTOR signaling in lung cancer.
Targeting phosphoinositide 3-kinase signalling in lung cancer.
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Targeting the phosphoinositide 3-kinase p110-? isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells.
The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA.
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
The fibronectin EDA splicing variant induces epithelial-mesenchymal transition in lung cancer cells through integrin {alpha}9{beta}1-mediated activation of PI3-K and Erk.
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer.
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway.
The Proto-oncogene PKC? regulates the alternative splicing of Bcl-x pre-mRNA.
The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.
Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer.
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.
Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer.
Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review.
Tripchlorolide induces autophagy in lung cancer cells by inhibiting the PI3K/AKT/mTOR pathway and improves cisplatin sensitivity in A549/DDP cells.
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
[Correlation between expression of TUBB3/STMN1 and EGFR signaling pathway in non-small cell lung cancer].
[Research Advances of Pan-negative Type of Non-small Cell Lung Cancer].
[Scanning for KRAS, NRAS, BRAF, and PIK3CA mutations by DNA melting analysis with TaqMan probes].
Lupus Erythematosus, Systemic
Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion.
Enhanced Phosphoinositide 3-Kinase {delta} Activity Is a Frequent Event in Systemic Lupus Erythematosus That Confers Resistance to Activation-Induced T Cell Death.
Inhibition of Phosphoinositide 3-Kinase Ameliorates Dextran Sodium Sulfate-Induced Colitis in Mice.
Lymphadenopathy
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase ? syndrome 2: A cohort study.
Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase ? Syndrome from the USIDNET Cohort.
Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature.
Effective "activated PI3K? syndrome"-targeted therapy with the PI3K? inhibitor leniolisib.
Exhaustion of the CD8
Genetic Defects in Phosphoinositide 3-Kinase ? Influence CD8+ T Cell Survival, Differentiation, and Function.
Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: An intriguing challenge.
PI3K? and primary immunodeficiencies.
Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
The Treatment of Activated PI3K? Syndrome.
Lymphangioma
A Child With Lymphangioma Due to Somatic Mutation in PIK3CA Successfully Treated With Everolimus.
Enlarging cystic lymphangioma of the mediastinum in an adult: is this a neoplastic lesion related to the recently discovered PIK3CA mutation?
Lymphangioma, Cystic
Enlarging cystic lymphangioma of the mediastinum in an adult: is this a neoplastic lesion related to the recently discovered PIK3CA mutation?
Lymphatic Metastasis
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma.
Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Correlation of breast cancer axillary lymph node metastases with stem cell mutations.
Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases.
Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features.
Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
Immunophenotypic and genomic characterization of papillary carcinomas of the breast.
Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis.
MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib.
Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
Mutations of key driver genes in gastric cancer metastasis risk: a systematic review and meta-analysis.
Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma.
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.
PIK3CA and TFRC Located in 3q Are New Prognostic Factors in Esophageal Squamous Cell Carcinoma.
PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma.
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma.
Up-regulation of PIK3CA promotes metastasis in gastric carcinoma.
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
Lymphocytosis
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
Lymphoma
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R.
A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity).
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Calming down T cell acute leukemia.
Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-? Syndrome 2 in an Adult Patient.
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.
Genetic alterations in lung adenocarcinoma with a micropapillary component.
Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo.
High co-expression of PD-L1 and HIF-1? correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
Hyaluronan oligosaccharides induce cell death through PI3-K/Akt pathway independently of NF-kappaB transcription factor.
Identification of Top-ranked Proteins within a Directional Protein Interaction Network using the PageRank Algorithm: Applications in Humans and Plants.
Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Methodology, criteria and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts.
MicroRNA library screening identifies growth-suppressive microRNAs that regulate genes involved in cell cycle progression and apoptosis.
Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.
Mutations of the PIK3CA gene in diffuse large B cell lymphoma.
Novel Therapeutic Targets in Non-small Cell Lung Cancer.
Nucleophosmin/B23, a multifunctional protein that can regulate apoptosis.
p110delta is required for innate immunity to transplantable lymphomas.
Pharmacotherapeutic Management of Pediatric Lymphoma.
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma.
Phosphoinositide 3-kinase inhibitors in lymphoma.
PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro.
Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K ?/? in relapsed refractory B cell lymphoma.
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Prolactin induced tyrosine phosphorylation of p59fyn may mediate phosphatidylinositol 3-kinase activation in Nb2 cells.
Propofol mediates signal transducer and activator of transcription 3 activation and crosstalk with phosphoinositide 3-kinase/AKT.
Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line.
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Regulation of phosphoinositide 3-kinase signaling by oxidants: hydrogen peroxide selectively enhances immunoreceptor-induced recruitment of phosphatidylinositol (3,4) bisphosphate-binding PH domain proteins.
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
SHC014748M, a novel selective inhi-bitor of PI3K?, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
Targeting leiomyomas with all-trans-retinoic acid at phosphoinositide 3-kinase pathway suppression: Effective roles of ?-catenin and of signaling interactions.
Targeting phosphatidylinositol 3-kinase gamma (PI3K?): Discovery and development of its selective inhibitors.
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.
The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-? (PI3K?) Syndrome (APDS).
The genetic landscape of mutations in Burkitt lymphoma.
The role of microRNA-150 as a tumor suppressor in malignant lymphoma.
The Role of PI3K Inhibition in Lymphoid Malignancies.
Variant PIK3R1 Hypermorphic Mutation and Clinical Phenotypes in a Family with Short Statures, Mild Immunodeficiency and Lymphoma.
Lymphoma, B-Cell
8-Cetylcoptisine, a new coptisine derivative, induces mitochondria-dependent apoptosis and G0/G1 cell cycle arrest in human A549?cells.
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel.
Characterization of Apoptosis in a Breast Cancer Cell Line after IL-10 Silencing
Cinobufagin Induces Cell Cycle Arrest at the G2/M Phase and Promotes Apoptosis in Malignant Melanoma Cells.
Dexmedetomidine pretreatment protects the heart against apoptosis in ischemia/reperfusion injury in diabetic rats by activating PI3K/Akt signaling in vivo and in vitro.
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.
Effect of apigenin on apoptosis induced by renal ischemia/reperfusion injury in vivo and in vitro.
Germacrone protects against oxygen-glucose deprivation/reperfusion injury by inhibiting autophagy processes in PC12 cells.
Ginkgetin aglycone attenuates neuroinflammation and neuronal injury in the rats with ischemic stroke by modulating STAT3/JAK2/SIRT1.
Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway.
MicroRNA library screening identifies growth-suppressive microRNAs that regulate genes involved in cell cycle progression and apoptosis.
MicroRNA-10a suppresses breast cancer progression via PI3K/Akt/mTOR pathway.
MicroRNA-146b induces the PI3K/Akt/NF-?B signaling pathway to reduce vascular inflammation and apoptosis in myocardial infarction by targeting PTEN.
miR-30d inhibits cell biological progression of Ewing's sarcoma by suppressing the MEK/ERK and PI3K/Akt pathways
Mutations of the PIK3CA gene in diffuse large B cell lymphoma.
New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase ? syndrome.
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
PIK3CA amplification and PTEN loss in diffused large B-cell lymphoma.
PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro.
PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma.
Predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers.
Propofol mediates signal transducer and activator of transcription 3 activation and crosstalk with phosphoinositide 3-kinase/AKT.
PVT1 Mediates Cell Proliferation, Apoptosis and Radioresistance in Nasopharyngeal Carcinoma Through Regulating miR-515-5p/PIK3CA Axis.
Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line.
Rapid Eye Movement Sleep Deprivation Combined With Fluoxetine Protects Against Depression-Induced Damage and Apoptosis in Rat Hippocampi via A1 Adenosine Receptor.
Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
Synergistic killing of lung cancer cells by cisplatin and radiation via autophagy and apoptosis.
Triptolide induces DNA breaks, activates caspase-3-dependent apoptosis and sensitizes B-cell lymphoma to poly(ADP-ribose) polymerase 1 and phosphoinositide 3-kinase inhibitors.
Lymphoma, B-Cell, Marginal Zone
Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type.
Lymphoma, Follicular
APRIL mediates follicular lymphoma B cell proliferation and cyclin D1 expression through PI3-kinase regulated mTOR activation.
Lymphoma, Large B-Cell, Diffuse
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
Mutations of the PIK3CA gene in diffuse large B cell lymphoma.
PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro.
PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma.
Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
Lymphoma, Large-Cell, Anaplastic
Nucleophosmin/B23, a multifunctional protein that can regulate apoptosis.
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
Lymphoma, Mantle-Cell
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma.
Lymphoma, Non-Hodgkin
Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type.
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
Pan-class I  PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Lymphoma, Primary Effusion
Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.
Lymphoma, T-Cell
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.
Lymphoma, T-Cell, Cutaneous
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K ?/? Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
Lymphopenia
A novel monoallelic gain of function mutation in p110? causing atypical activated phosphoinositide 3-kinase ? syndrome (APDS-1).
Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase ? Syndrome from the USIDNET Cohort.
Lymphoproliferative Disorders
Association of the X-linked lymphoproliferative disease gene product SAP/SH2D1A with 2B4, a natural killer cell-activating molecule, is dependent on phosphoinositide 3-kinase.
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: An intriguing challenge.
Malformations of Cortical Development
PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia.
Mammary Neoplasms, Animal
Multiplex Gene Expression Profiling of 16 Target Genes in Neoplastic and Non-Neoplastic Canine Mammary Tissues Using Branched-DNA Assay.
Mania
Manic episode occurring during investigational treatment with pan-class I phosphoinositide 3-kinase inhibitor in a patient with breast cancer.
Measles
Measles virus induces expression of SIP110, a constitutively membrane clustered lipid phosphatase, which inhibits T cell proliferation.
Medulloblastoma
A compartmentalized phosphoinositide signaling axis at cilia is regulated by INPP5E to maintain cilia and promote Sonic Hedgehog medulloblastoma.
A Sensitized RNA Interference Screen Identifies a Novel Role for the PI3K p110{gamma} Isoform in Medulloblastoma Cell Proliferation and Chemoresistance.
Childhood tumors of the nervous system as disorders of normal development.
Downregulation of microRNA-431 by human interferon-? inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6.
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN.
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Pik3ca mutations significantly enhance the growth of SHH medulloblastoma and lead to metastatic tumour growth in a novel mouse model.
Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines.
Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
The Phosphoinositide 3-Kinase p110? Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma.
Megalencephaly
Caught in the AKT: identification of a de novo pathway in MCAP and MPPH and its therapeutic implications.
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes.
Detection of a mosaic PIK3CA mutation in dental DNA from a child with megalencephaly capillary malformation syndrome.
Germline pathogenic variant in PIK3CA leading to symmetrical overgrowth with marked macrocephaly and mild global developmental delay.
Identification and Characterization of a Novel Constitutional PIK3CA Mutation in a Child Lacking the Typical Segmental Overgrowth of "PIK3CA-Related Overgrowth Spectrum".
Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway.
Megalencephaly syndromes associated with mutations of core components of the PI3K-AKT-MTOR pathway: PIK3CA, PIK3R2, AKT3, and MTOR.
Megalencephaly syndromes: exome pipeline strategies for detecting low-level mosaic mutations.
Novel features of PIK3CA-Related Overgrowth Spectrum: Lesson from an aborted fetus presenting a de novo constitutional PIK3CA mutation.
PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia.
PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Polymicrogyria in association with hypoglycemia points to mutation in the mTOR pathway.
The Fetus with Ganglionic Eminence Abnormality: Head Size and Extracranial Sonographic Findings Predict Genetic Diagnoses and Postnatal Outcomes.
[PIK3CA-related overgrowth syndrome (PROS)].
Melanoma
A Potent Inhibitor of Phosphoinositide 3-Kinase (PI3K) and Mitogen Activated Protein (MAP) Kinase Signalling, Quercetin (3, 3', 4', 5, 7-Pentahydroxyflavone) Promotes Cell Death in Ultraviolet (UV)-B-Irradiated B16F10 Melanoma Cells.
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
Activation of p21-activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells.
Anticancer effects of combinational treatment with BRAFV600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAFV600E.
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
Basic fibroblast growth factor-mediated overexpression of vascular endothelial growth factor in 1F6 human melanoma cells is regulated by activation of PI-3K and p38 MAPK.
Beyond BRAF in Melanoma.
BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation.
C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
Chondroitin Sulfate Proteoglycan-4 Does Not Protect Melanoma Cells During Inhibition of PI3K and mTOR Pathways.
Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.
Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner.
Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.
Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.
Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure.
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma.
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors.
Embryonic Stem Cells Modulate the Cancer-Permissive Microenvironment of Human Uveal Melanoma.
Enhanced cell killing by overexpression of dominant-negative phosphatidylinositol 3-kinase subunit, Deltap85, following genotoxic stresses.
Erratum: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation.
Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy.
Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review.
Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family.
Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.
Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt.
Identification of the interaction network of hub genes for melanoma treated with vemurafenib based on microarray data.
Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
Insulin-like growth factor I-stimulated melanoma cell migration requires phosphoinositide 3-kinase but not extracellular-regulated kinase activation.
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.
Isoangustone A, a novel licorice compound, inhibits cell proliferation by targeting PI3-K, MKK4 and MKK7 in human melanoma.
KIT pathway alterations in mucosal melanomas of the vulva and other sites.
Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer.
MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma.
Molecular Profiling of Merkel Cell Polyomavirus-Associated Merkel Cell Carcinoma and Cutaneous Melanoma.
Multiplexed assays for detection of mutations in PIK3CA.
Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.
Mutations of PIK3CA are rare in cutaneous melanoma.
Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma.
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.
Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors.
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.
Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry.
PI3-kinase is involved in mitogenic signaling by the oncogenic receptor tyrosine kinase Xiphophorus melanoma receptor kinase in fish melanoma.
PI3-kinase subunits are infrequent somatic targets in melanoma.
PI3Kgamma activation by CXCL12 regulates tumor cell adhesion and invasion.
PIK3CA-Mutated Melanoma Cells Rely on Cooperative Signaling through mTORC1/2 for Sustained Proliferation.
Prognostic genes of melanoma identified by weighted gene co-expression network analysis and drug repositioning using a network-based method.
RAB7 counteracts PI3K-driven macropinocytosis activated at early stages of melanoma development.
Rational targeting of BRAF and PI3-Kinase signaling for melanoma therapy.
ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis.
Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors.
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.
The Genetic Germline Background of Single and Multiple Primary Melanomas.
The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma.
The P110 subunit of PI3-K is a therapeutic target of acacetin in skin cancer.
The Phosphoinositide 3-Kinase? Selective Inhibitor, BYL719, Enhances the Effect of the Protein Kinase C Inhibitor, AEB071, in GNAQ/GNA11 Mutant Uveal Melanoma Cells.
The role of phosphoinositide 3-kinase in the sorting and transport of newly synthesized tyrosinase-related protein-1 (TRP-1).
Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation.
Timp1 Promotes Cell Survival by Activating the PDK1 Signaling Pathway in Melanoma.
Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice.
Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy.
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.
[Scanning for KRAS, NRAS, BRAF, and PIK3CA mutations by DNA melting analysis with TaqMan probes].
Memory Disorders
Bis(propyl)-cognitin Prevents ?-amyloid-induced Memory Deficits as Well as Synaptic Formation and Plasticity Impairments via the Activation of PI3-K Pathway.
Caffeic acid phenethyl ester rescued streptozotocin-induced memory loss through PI3-kinase dependent pathway.
Fasudil hydrochloride ameliorates memory deficits in rat model of streptozotocin-induced Alzheimer's disease: Involvement of PI3-kinase, eNOS and NF?B.
Meningioma
A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
Calcifying pseudoneoplasm of neuroaxis (CAPNON): a comprehensive immunohistochemical and morphological characterization of five cases.
Clinical potential of meningioma genomic insights: a practical review for neurosurgeons.
Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.
Curcumin Inhibits HGF-Induced EMT by Regulating c-MET-Dependent PI3K/Akt/mTOR Signaling Pathways in Meningioma.
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas.
Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas.
High-grade meningiomas: biology and implications.
Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment.
Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma.
Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications.
New molecular targets in meningiomas: the present and the future.
Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
PIK3CA mutations in meningioma.
Progestin-associated shift of meningioma mutational landscape.
Rare mutation of PIK3CA in meningiomas.
Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.
Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations.
SWI/SNF chromatin remodeling complex alterations in meningioma.
Meningitis, Pneumococcal
Diosmetin Suppresses Neuronal Apoptosis and Inflammation by Modulating the Phosphoinositide 3-Kinase (PI3K)/AKT/Nuclear Factor-?B (NF-?B) Signaling Pathway in a Rat Model of Pneumococcal Meningitis.
Mesothelioma
Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Mesothelioma, Malignant
Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase.
Metabolic Diseases
Inhibition of phosphoinositide 3-kinase ? attenuates inflammation, obesity, and cardiovascular risk factors.
Metabolic Syndrome
Cracking the context-specific PI3K signaling code.
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
Neuroprotective effects of estrogens: cross-talk between estrogen and intracellular insulin signalling.
[Insulin resistance - its causes and therapy possibilities].
Microcephaly
De novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly.
Mouth Neoplasms
Absence of the frequently reported PIK3CA, CASP8, and NOTCH1 mutations in South Indian oral cancers.
Clinical significance of TC21 overexpression in oral cancer.
Detection of two novel mutations and relatively high incidence of H-RAS mutations in Vietnamese oral cancer.
Genetic deregulation of the PIK3CA oncogene in oral cancer.
Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells.
PI3-kinase pathway biomarkers in oral cancer and tumor immune cells.
Surfactin from Bacillus subtilis attenuates ambient air particulate matter-promoted human oral cancer cells metastatic potential.
Mucositis
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Multiple Endocrine Neoplasia
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Multiple Endocrine Neoplasia Type 2b
Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
Multiple Myeloma
A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.
Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination.
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk.
PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Multiple Sclerosis
Absence of PI3Kgamma leads to increased leukocyte apoptosis and diminished severity of experimental autoimmune encephalomyelitis.
Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis.
Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase ? (PI3K?) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS).
PI3K? drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation.
Multiple System Atrophy
Immunohistochemical localization of phosphoinositide 3-kinase in brains with multiple system atrophy.
Muscular Atrophy, Spinal
Fine mapping of human PI 3-kinase associated p85 alpha transcripts in the YAC contig surrounding the spinal muscular atrophy gene.
Muscular Dystrophy, Emery-Dreifuss
Differentiation of C2C12 myoblasts expressing lamin A mutated at a site responsible for Emery-Dreifuss muscular dystrophy is improved by inhibition of the MEK-ERK pathway and stimulation of the PI3-kinase pathway.
Mycosis Fungoides
Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas.
Myelitis, Transverse
Transverse myelitis in a patient with activated phosphoinositide 3-kinase ? syndrome type 1.
Myelodysplastic Syndromes
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Myocardial Infarction
Antidiabetic drug pioglitazone protects the heart via activation of PPAR-{gamma} receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction.
Effects of PI3Kgamma inhibition using AS-605240 in acute myocardial infarction.
Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice.
Protein Kinases as Drug Development Targets for Heart Disease Therapy.
[Cardiovascular effects of incretin-based therapies].
Myocardial Ischemia
Cardiovascular effects of incretin-based therapies.
Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning.
PI3Kgamma protects from myocardial ischemia and reperfusion injury through a kinase-independent pathway.
Myocarditis
Phosphoinositide 3-kinase inhibitor LY294002 ameliorates the severity of myosin-induced myocarditis in mice.
[Intervention effect of PI3Kgamma inhibitor AS605240 on autoimmune myocarditis in mice]
Nasopharyngeal Carcinoma
Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase.
Clinicopathological significance of ROCK1 and PIK3CA expression in nasopharyngeal carcinoma.
Correction to: Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase.
Effect of DNAzymes targeting Akt1 on cell proliferation and apoptosis in nasopharyngeal carcinoma.
Increased Expression of Phosphatidylinositol 3-Kinase p110? and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.
LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85.
MiR-122 exerts anti-proliferative and apoptotic effects on nasopharyngeal carcinoma cells via the PI3K/AKT signaling pathway.
miR-144-3p facilitates nasopharyngeal carcinoma via crosstalk with PTEN.
miR-331-3p Inhibits Proliferation and Promotes Apoptosis of Nasopharyngeal Carcinoma Cells by Targeting elf4B-PI3K-AKT Pathway.
PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma.
PIK3CA gene mutations in breast carcinoma in Malaysian patients.
PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival.
PIK3CA mutations in nasopharyngeal carcinoma.
Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC).
Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.
Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.
Prognostic significance of the EGFR pathway in nasopharyngeal carcinoma: a systematic review and meta-analysis.
[Effects of basic fibroblast growth factor on protein kinase B activity and c-fos expression in CNE- I nasopharyngeal carcinoma cell line]
[Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma]
[The expression of PIK3CA in nasopharyngeal carcinoma].
Neoplasm Metastasis
(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.
?-Fetoprotein-Producing Hepatoid Gastric Adenocarcinoma With Osteoclast-Like Giant Cells and Neuroendocrine Differentiation: A Case Study With Molecular Profiling.
?Np63? is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-? signaling axes.
Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.
Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells.
Anti-metastasis effect of fucoidan from Undaria pinnatifida sporophylls in mouse hepatocarcinoma Hca-F cells.
APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.
Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer.
Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.
circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer.
Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma.
Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.
Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.
Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer.
Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis.
Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
Correlation between metastatic potential and variants from colorectal tumor cell line HT-29.
Correlation of breast cancer axillary lymph node metastases with stem cell mutations.
Deep sequencing of KIT, MET, PIK3CA, and PTEN hotspots in papillary thyroid carcinomas with distant metastases.
Detection of PIK3CA Mutations in Breast Cancer Bone Metastases.
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
Dihydroartemisinin selectively inhibits PDGFR?-positive ovarian cancer growth and metastasis through inducing degradation of PDGFR? protein.
Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses.
Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.
Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.
Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases.
Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
Gene heterogeneity in metastasis of colorectal cancer to the lung.
Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression.
Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours.
Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells.
Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative.
Genomic profiling of endometrial cancer and relationship with volume of endometrial cancer disease spread.
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer.
High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features.
Histologic features and genomic alterations of primary colorectal adenocarcinoma predict growth patterns of liver metastasis.
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.
Identification and Validation of PIK3CA as a Marker Associated with Prognosis and Immune Infiltration in Renal Clear Cell Carcinoma.
Identification of differentially expressed genes in salivary adenoid cystic carcinoma cells associated with metastasis.
Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease.
Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
Immunophenotypic and genomic characterization of papillary carcinomas of the breast.
Impact of KRAS, BRAF, PIK3CA, TP53 status and intra-individual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway.
Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis.
Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer.
Interactions of multiple gene alterations in colorectal liver metastases.
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Knockdown of thrombospondin 2 inhibits metastasis through modulation of PI3K signaling pathway in uveal melanoma cell line M23.
KRAS mutation in lung metastases from colorectal cancer: prognostic implications.
KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer.
KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer.
KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications.
Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer.
LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway.
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.
Long non-coding RNA THOR promotes cell proliferation and metastasis in hepatocellular carcinoma.
Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis.
LOXL1-AS1 Drives The Progression Of Gastric Cancer Via Regulating miR-142-5p/PIK3CA Axis.
LRRC4 Suppresses E-Cadherin-Dependent Collective Cell Invasion and Metastasis in Epithelial Ovarian Cancer.
MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing Rhabdomyosarcoma.
MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib.
MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells.
miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA.
miR-34a and miR-125a-5p inhibit proliferation and metastasis but induce apoptosis in hepatocellular carcinoma cells via repressing the MACC1-mediated PI3K/AKT/mTOR pathway.
miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma.
Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
Molecular prognosticators in clinically and pathologically distinct cohorts of head and neck squamous cell carcinoma-A meta-analysis approach.
Molecular Targets of Genistein and Its Related Flavonoids to Exert Anticancer Effects.
Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman.
Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients.
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Mutations of key driver genes in colorectal cancer progression and metastasis.
Mutations of key driver genes in gastric cancer metastasis risk: a systematic review and meta-analysis.
Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer.
Mutations of PIK3CA are rare in cutaneous melanoma.
Mutations of the PIK3CA gene in hereditary colorectal cancers.
Neurotensin promotes cholangiocarcinoma metastasis via the EGFR/AKT pathway.
NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction.
Oncogene mutational profile in nasopharyngeal carcinoma.
Oncogenic PI3K and its role in cancer.
Oncogenic PIK3CA mutations in lobular breast cancer progression.
Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.
Overexpression of Hypoxia Inducible Factor-1 Alpha is an Independent Risk Factor for Recurrence After Curative Resection of Colorectal Liver Metastases.
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma.
p120-Catenin Downregulation and PIK3CA Mutations Cooperate to Induce Invasion through MMP1 in HNSCC.
Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer.
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo.
Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases.
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma.
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.
PIK3CA and TFRC Located in 3q Are New Prognostic Factors in Esophageal Squamous Cell Carcinoma.
PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma.
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
PIK3CA Is Regulated by CUX1, Promotes Cell Growth and Metastasis in Bladder Cancer via Activating Epithelial-Mesenchymal Transition.
PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer.
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
PIK3CA mutations may be discordant between primary and corresponding metastatic disease in Breast Cancer.
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma.
PIK3CG Is a Potential Therapeutic Target in Androgen Receptor-Indifferent Metastatic Prostate Cancer.
PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3?/CTNNB1 signaling pathway.
Precision cell-free DNA extraction for liquid biopsy by integrated microfluidics.
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
Predictive genetic profiles for regional lymph node metastasis in primary cutaneous melanoma: a case-matched pilot study.
Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer.
Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone.
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.
RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression.
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
Role of Cadherins in Cancer-A Review.
Role of Forkhead Box Class O proteins in cancer progression and metastasis.
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.
Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications.
Silencing TAK1 alters gene expression signatures in bladder cancer cells.
Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma.
Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis.
Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer.
Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Stanniocalcin-1 promotes metastasis in a human breast cancer cell line through activation of PI3K.
Target-Enriched Next-Generation Sequencing Reveals Differences between Primary and Secondary Ovarian Tumors in Formalin-Fixed, Paraffin-Embedded Tissue.
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma: A single institution's experience.
The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.
The Prognostic Influence of BRAF Mutation and other Molecular, Clinical and Laboratory Parameters in Stage IV Colorectal Cancer.
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
Type I to Type II Ovarian Carcinoma Progression: Mutant Trp53 or Pik3ca Confers a More Aggressive Tumor Phenotype in a Mouse Model of Ovarian Cancer.
Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
Up-regulation of PIK3CA promotes metastasis in gastric carcinoma.
Upregulation of microRNA-31 targeting integrin ?5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells.
WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear ?-Catenin depend on active PI3K signaling.
[18F]-FLT Positron Emission Tomography can be used to image the response of sensitive tumors to PI3-Kinase inhibition with the novel agent GDC-0941.
[A study of the relationship between the mutation of PIK3CA, PTEN and the occurrence of liver metastasis of colorectal cancer: survival analysis].
[Aspirin and colorectal cancer].
[Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
Neoplasm Micrometastasis
Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
Neoplasm, Residual
Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
Neoplasms
(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.
14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation site(s).
3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth.
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
3D modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
3q26 Amplifications in Cervical Squamous Carcinomas.
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.
5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
5-fluorouracil enhances the anti-tumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers.
?Np63? is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies.
A case report of tongue metastasis from lung squamous cell carcinoma and literature review.
A Cell-Cell Communication Marker for Identifying Targeted Tumor Therapies.
A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma.
A cohort study of p27 localization in colon cancer, body mass index, and patient survival.
A combination of molecular markers and clinical features improve the classification of pancreatic cysts.
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
A compartmentalized phosphoinositide signaling axis at cilia is regulated by INPP5E to maintain cilia and promote Sonic Hedgehog medulloblastoma.
A comprehensive in vivo and mathematic modeling-based kinetic characterization for aspirin-induced chemoprevention in colorectal cancer.
A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
A drug targeting only p110? can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.
A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients.
A Genomic and Clinicopathologic Study of Non-Small Cell Lung Cancers with Discordant ROS1 Gene Status by Fluorescent In Situ Hybridization and Immunohistochemical Analysis.
A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response.
A high-throughput liposome substrate assay with automated lipid extraction process for PI 3-kinase.
A High-Throughput Screen with Isogenic PTEN+/+ and PTEN-/- Cells Identifies CID1340132 as a Novel Compound That Induces Apoptosis in PTEN and PIK3CA Mutant Human Cancer Cells.
A kinase-independent function of AKT promotes cancer cell survival.
A microscopic landscape of the invasive breast cancer genome.
A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.
A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report.
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).
A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
A new evaluation method for quantifying PI3K activity by HTRF assay.
A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy Resistance.
A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type.
A novel approach to rescue immune escape in oral squamous cell carcinoma: Combined use of interferon-? and LY294002.
A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells.
A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.
A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation.
A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.
A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.
A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival.
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death.
A novel variant in GPAA1, encoding a GPI transamidase complex protein, causes inherited vascular anomalies with various phenotypes.
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer.
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor Positive Metastatic Breast Cancer.
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
A Phase Ib Study of Alpelisib (BYL719), a PI3K?-specific Inhibitor, with Letrozole in ER+/HER2-Negative Metastatic Breast Cancer.
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer.
A phosphatidylinositol 3-kinase inhibitor wortmannin induces radioresistant DNA synthesis and sensitizes cells to bleomycin and ionizing radiation.
A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.
A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.
A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy.
A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
A primary splenic angiosarcoma hepatic metastasis after splenectomy and its genomic alteration profile.
A Prospective Cohort Study Shows Unique Epigenetic, Genetic, and Prognostic Features of Synchronous Colorectal Cancers.
A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
A robust screen for inhibitors and enhancers of phosphoinositide-3 kinase (PI3K) activities by ratiometric fluorescence superquenching.
A simple and robust real-time qPCR method for the detection of PIK3CA mutations.
A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene.
A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.
A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction.
A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells.
A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases.
A synthetic peptide hijacks the catalytic subunit of class I PI3K to suppress the growth of cancer cells.
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.
A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.
A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity).
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.
A unified nomenclature and amino acid numbering for human PTEN.
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer.
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Aberrant Rac pathway signalling in glioblastoma.
Abnormal expression of PTEN and PIK3CA in pemetrexed-resistant human pancreatic cancer cell line Patu8988.
Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells.
Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients.
Absence of the frequently reported PIK3CA, CASP8, and NOTCH1 mutations in South Indian oral cancers.
Absolute quantification of four isoforms of the class I phosphoinositide-3-kinase catalytic subunit by real-time RT-PCR.
Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells.
Accumulated promoter methylation as a potential biomarker for esophageal cancer.
ACLY is the novel signaling target of PIP2/PIP3 and Lyn in acute myeloid leukemia.
Actionable mutations in canine hemangiosarcoma.
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells.
Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumor formation in mice via AKT2/mTORC1 cascade.
Activated Mutant p110? Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion.
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes.
Activating Mutations in PIK3CA Lead to Widespread Modulation of the Tyrosine Phosphoproteome.
Activating PIK3CA mutation promotes osteogenesis of bone marrow mesenchymal stem cells in macrodactyly.
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia.
Activation of Akt predicts poor outcome in neuroblastoma.
Activation of diverse signalling pathways by oncogenic PIK3CA mutations.
Activation of endothelial ras signaling bypasses senescence and causes abnormal vascular morphogenesis.
Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
Activation of IGF1R/p110?/AKT/mTOR confers resistance to ?-specific PI3K inhibition.
Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth.
Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells.
Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.
Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85? regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.
Activation of PI3K? by physiological effectors and by oncogenic mutations: structural and dynamic effects.
Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.
Activation of the phosphatidylinositol 3'-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1.
Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.
Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Activation of tumor suppressor protein PTEN and induction of apoptosis are involved in cAMP-mediated inhibition of cell number in B92 glial cells.
Activation of WNT/?-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Activity of any class IA PI3K isoform can sustain cell proliferation and survival.
Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's lymphoma.
Adamantinomatous Craniopharyngioma in an Adult: A Case Report with NGS Analysis.
Adaptation of an amplicon-based human cancer next-generation sequencing panel assay for murine tumors.
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.
Adenosquamous gallbladder carcinoma: Multigene hotspot mutational profiling reveals a monoclonal origin of the two components.
Adhesion-linked kinases in cancer; emphasis on src, focal adhesion kinase and PI 3-kinase.
Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease.
Advanced glycation end products in diabetes, cancer and phytochemical therapy.
Advances in development of phosphatidylinositol 3-kinase inhibitors.
Advances in subunits of PI3K class I in cancer.
Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors.
Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT.
AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation.
AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.
Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin.
Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus.
AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma.
AKT-independent PI3-K signaling in cancer - emerging role for SGK3.
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
Akt/PKB signaling in cancer: a function in cell motility and invasion.
Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway.
AKT1 E17K in Colorectal Carcinoma is Associated with BRAF V600E but not MSI-H status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.
AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.
AKT3 is a key regulator of head and neck squamous cell carcinoma.
Akt: a potential target for thyroid cancer therapy.
ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients.
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Alpelisib to treat breast cancer.
Alpelisib-Induced Diabetic Ketoacidosis.
Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer.
Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL).
Alteration of tumor associated neutrophils by PIK3CA expression in endometrial carcinoma from TCGA data.
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors.
Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors.
Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.
Altered Composition of Fatty Acids Exacerbates Hepatotumorigenesis during Activation of the Phosphatidylinositol 3-kinase Pathway.
Altered gene expression in glycolysis-cholesterol synthesis axis correlates with outcome of triple-negative breast cancer.
Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
Alternative AKT2 splicing produces protein lacking the hydrophobic motif regulatory region.
Amplicon profiles in ovarian serous carcinomas.
An ?-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin.
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
An essential role for protein synthesis in oncogenic cellular transformation.
An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial-mesenchymal transition and cancer stem cell expansion in human breast cancer cells.
An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma.
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
An insight into the molecular genetics of a uveal melanoma patient cohort.
An insulin-like growth factor-mediated, phosphatidylinositol 3' kinase-independent survival signaling pathway in beta tumor cells.
An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer.
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
An inverted CAV1 (caveolin 1) topology defines novel autophagy-dependent exosome secretion from prostate cancer cells.
An oncogenic, somatic mutation of PIK3CA identified in 2 primary malignancies: clear cell renal cell carcinoma and prostate adenocarcinoma in the same patient.
Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays.
Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy.
Analysis of K-ras, BRAF, and PIK3CA mutations in laterally-spreading tumors of the colorectum.
Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.
Analysis of PI3K pathway components in human cancers.
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.
Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Analysis of PIK3CA mutations in breast cancer subtypes.
Analysis of signaling pathways in 90 cancer cell lines by protein lysate array.
Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: Implications for cancer therapy.
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature.
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.
Anthricin Isolated from Anthriscus sylvestris (L.) Hoffm. Inhibits the Growth of Breast Cancer Cells by Inhibiting Akt/mTOR Signaling, and Its Apoptotic Effects Are Enhanced by Autophagy Inhibition.
Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.
Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/protein kinase B.
Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor.
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
Any Role of PIK3CA and PTEN Biomarkers in the Prognosis in Oral Squamous Cell Carcinoma?
Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice.
APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development.
APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma.
Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.
Apoptosis and inactivation of the PI3-kinase pathway by tetrocarcin A in breast cancers.
Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts.
Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma.
APRIL mediates follicular lymphoma B cell proliferation and cyclin D1 expression through PI3-kinase regulated mTOR activation.
Aquaporin 9 is down-regulated in hepatocellular carcinoma and its over-expression suppresses hepatoma cell invasion through inhibiting epithelial-to-mesenchymal transition.
ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion.
ARID1A gene mutation in ovarian and endometrial cancers (Review).
ARID2, p110?, p53, and ?-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications.
Aspirin acts in esophageal cancer: a brief review.
Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone?
Aspirin and colorectal cancer: back to the future.
Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.
Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.
Association between genomic alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic hybridization.
Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk.
Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.
Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer.
Association of autophagy status with amount of Fusobacterium nucleatum in colorectal cancer.
Association of epidermal growth factor receptor and mitogen-activated protein kinase with cystic neoplasms of the pancreas.
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
Association of PIK3CA gene mutations with head and neck squamous cell carcinomas.
Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma.
Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer.
Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer.
Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
Associations of PI3KR1 and mTOR Polymorphisms with Esophageal Squamous Cell Carcinoma Risk and Gene-Environment Interactions in Eastern Chinese Populations.
Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer.
Asymmetric real-time PCR and multiplex melting curve analysis with TaqMan probes for detecting PIK3CA mutations.
AT-rich interactive domain 2, p110?, p53, and ?-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications.
ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.
Aurora-A expression is independently associated with chromosomal instability in colorectal cancer.
Autophagy in the physiological endometrium and cancer.
Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells.
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
B cell receptor signaling in chronic lymphocytic leukemia.
B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells.
Baculovirus production of fully-active phosphoinositide 3-kinase alpha as a p85alpha-p110alpha fusion for X-ray crystallographic analysis with ATP competitive enzyme inhibitors.
Basic helix-loop-helix transcription factor DEC1 negatively regulates cyclin D1.
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110? and p110? activities in tumor cell lines and xenograft models.
BEAMing up personalized medicine: mutation detection in blood.
Beta-testing of PI3-kinase inhibitors: is beta better?
Better Understanding of Phosphoinositide 3-Kinase (PI3K) Pathways in Vasculature: Towards Precision Therapy Targeting Angiogenesis and Tumor Blood Supply.
Beyond BRAF in Melanoma.
Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
BIM expression in treatment naïve cancers predicts responsiveness to kinase inhibitors.
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Biological activities of sinularin: A literature-based review.
Biological significance of c-erbB family oncogenes in head and neck cancer.
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.
Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma.
Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer.
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma.
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy.
BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-?B/MGMT signaling pathway.
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737.
BRAF and KRAS Mutations in Sporadic Glomus Tumors.
BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.
BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.
Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice.
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
C-terminal domain of p42 Ebp1 is essential for down regulation of p85 subunit of PI3K, inhibiting tumor growth.
Caffeic acid phenethyl ester suppresses melanoma tumor growth by inhibiting PI3K/AKT/XIAP pathway.
Caloric restriction augments radiation efficacy in breast cancer.
Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study.
Cancer cell-derived clusterin modulates the phosphatidylinositol 3'-kinase-Akt pathway through attenuation of insulin-like growth factor 1 during serum deprivation.
Cancer-Associated Mutations in Endometriosis without Cancer.
Cancer-associated mutations in the p85? N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases.
Cancer-Associated PIK3CA Mutations in Overgrowth Disorders.
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Cancer-specific mutations in PIK3CA are oncogenic in vivo.
Cancers of the Upper Gastro-intestinal Tract: A Review of Somatic Mutation Distributions.
Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds.
Cannabinoid pharmacology in cancer research: A new hope for cancer patients?
Carcinogenesis of PIK3CA.
CarcSeq Measurement of Rat Mammary Cancer Driver Mutations and Relation to Spontaneous Mammary Neoplasia.
Caspase-activated phosphoinositide binding by CNT-1 promotes apoptosis by inhibiting the AKT pathway.
Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using Systems Genetics Network Analysis.
Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA-related overgrowth spectrum.
CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors.
Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast.
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
Cell activation-induced phosphoinositide 3-kinase alpha/beta dimerization regulates PTEN activity.
Cellular and Genetic Determinants of the Sensitivity of Cancer to ?-Particle Irradiation.
Cellular and molecular mechanisms of PIK3CA-related vascular anomalies.
Cellular energy stress induces AMPK-mediated regulation of glioblastoma cell proliferation by PIKE-A phosphorylation.
Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase 2 trial of FOLFOX plus cetuximab versus FOLFOX.
Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
Characterization and radiosensitivity of HPV-related oropharyngeal squamous cell carcinoma patient-derived xenografts.
Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics.
Characterization of a tumor-associated activating mutation of the p110? PI 3-kinase.
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.
Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer.
Characterization of in vitro 3D cultures.
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Characterization of PI3K class IA isoforms with regulatory subunit p55alpha using a scintillation proximity assay.
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma.
Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab.
Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence.
Characterizing the Sources of Pharmacokinetic Variability for TAK-117 (Serabelisib), an Investigational Phosphoinositide 3-Kinase Alpha Inhibitor: A Clinical Biopharmaceutics Study to Inform Development Strategy.
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases.
Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.
Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K.
Childhood tumors of the nervous system as disorders of normal development.
Chromosomal and genomic changes in lung cancer.
Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer.
Circulating HPV DNA as a marker for early detection of relapse in patients with cervical cancer.
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
Circulating tumor cells and breast cancer-specific mutations in primary breast cancer.
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.
CISK attenuates degradation of the chemokine receptor CXCR4 via the ubiquitin ligase AIP4.
Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor.
Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-?B-TNF?-PIK3CA loop.
Class I Phosphoinositide 3-Kinase PIK3CA/p110? and PIK3CB/p110? Isoforms in Endometrial Cancer.
Class I phosphoinositide 3-kinases.
Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1.
Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.
Class I PI3K in oncogenic cellular transformation.
Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery.
Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
Class III PI3K Vps34: essential roles in autophagy, endocytosis, and heart and liver function.
Classes of phosphoinositide 3-kinases at a glance.
Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis.
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER project.
Clinical Features and Genomic Characterization of Post-Colonoscopy Colorectal Cancer.
Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.
Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer.
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.
Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?
Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients.
Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.
Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.
Clinical relevance of oncogenic driver mutations identified in endometrial carcinoma.
Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia.
Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Clinical significance of YAP1 activation in head and neck squamous cell carcinoma.
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Clinical value of CagA, c-Met, PI3K and Beclin-1 expressed in gastric cancer and their association with prognosis.
Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer.
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.
Clinical-Pathologic Analysis of Breast Cancer With PIK3CA Mutations in Chinese Women.
Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer.
Clinico-pathological Features of PIK3CA Mutation in HER2-Positive Breast Cancer of Indian Population.
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Clinicopathologic Significance of HNF-1?, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.
Clinicopathological and molecular characteristics of endometrial neuroendocrine carcinomas reveal preexisting endometrial carcinoma origin.
Clinicopathological characteristics of PIK3CA and HBx mutations in Korean patients with hepatocellular carcinomas.
Clinicopathological Characteristics of PIK3CA Mutation and Amplification in Korean Patients with Breast Cancers.
Clinicopathological Correlates of ?? T Cell Infiltration in Triple-Negative Breast Cancer.
Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer.
Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?
Clinicopathological significance of ROCK1 and PIK3CA expression in nasopharyngeal carcinoma.
Clonal analyses of refractory testicular germ cell tumors.
Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit.
CNTN-1 promotes docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer.
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence.
Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo.
Colorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing?
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.
Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice.
Commentary on Essential roles of PI(3)K-p110beta in cell growth, metabolism, and tumorigenesis Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ, Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Common and distinct features of mammary tumors driven by Pten-deletion or activating Pik3ca mutation.
Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.
Comparative genomic analysis of primary and synchronous metastatic colorectal cancers.
Comparative genomic analysis of primary versus metastatic colorectal carcinomas.
Comparative genomics of high grade neuroendocrine carcinoma of the cervix.
Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.
Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas.
Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.
Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer.
Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients.
Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA.
Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer.
Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors.
Complementary DNA arrays identify CD63 tetraspanin and alpha3 integrin chain as differentially expressed in low and high metastatic human colon carcinoma cells.
Complete genomic landscape of a recurring sporadic parathyroid carcinoma.
Compound HRAS/PIK3CA Mutations in Chinese Patients with Alveolar Rhabdomyosarcomas.
Comprehensive analysis of PTEN status in breast carcinomas.
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
Comprehensive characteristics of somatic mutations in the normal tissues of patients with cancer and existence of somatic mutant clones linked to cancer development.
Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer.
Comprehensive genomic characterization of head and neck squamous cell carcinomas.
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers.
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Comprehensive genomic profile of cholangiocarcinomas in China.
Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418).
Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal.
Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.
Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA.
Comprehensive molecular characterization of gastric adenocarcinoma.
Comprehensive molecular portraits of human breast tumours.
Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
Comprehensive Mutation Analysis of PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1 Genes is Suggestive of a Non- Neoplastic Nature of Phenytoin Induced Gingival Overgrowth.
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Concordance of Mutation Detection in Circulating Tumor DNA in Early Clinical Trials Using Different Blood Collection Protocols.
Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Connecting the dots between different networks: miRNAs associated with bladder cancer risk and progression.
Connecting with an old partner in a new way.
Constitutive activation of p70S6k in cancer cells.
Constitutive cellular expression of PI 3-kinase is distinct from transient expression.
Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer.
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.
Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels.
Convergent loss of PTEN leads to clinical resistance to a PI(3)K? inhibitor.
Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.
Cooperation between Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation.
Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.
Coordinated regulation of serum- and glucocorticoid-inducible kinase 3 by a C-terminal hydrophobic motif and Hsp90-Cdc37 chaperone complex.
Copanlisib: First Global Approval.
Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
Copy number loss of variation_91720 in PIK3CA predicts risk of esophageal squamous cell carcinoma.
Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer.
Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
Correlation between metastatic potential and variants from colorectal tumor cell line HT-29.
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(-) advanced breast cancer: results from BOLERO-2.
Correlation of breast cancer axillary lymph node metastases with stem cell mutations.
Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget's disease.
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.
Cowden Syndrome: Case Report, Update and Proposed Diagnostic and Surveillance Routines.
Cracking the context-specific PI3K signaling code.
Cribriform-morular variant of papillary thyroid carcinoma: a study of 3 cases featuring the PIK3CA mutation.
Critical role for PI3-kinase in regulating the use of proteins as an amino acid source.
Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation.
Cross regulation of signaling pathways in gastrointestinal stromal tumor.
Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
Cross-species oncogenic signatures of breast cancer in canine mammary tumors.
Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.
Crosstalk between PKC? and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium.
CTNNB1 mutations in basal cell adenoma of the salivary gland.
Current and future strategies for treatment of ovarian clear cell carcinoma.
Current and Investigational Agents Targeting the Phosphoinositide 3-Kinase Pathway.
Custom Glycosylation of Cells and Proteins Using Cyclic Carbamate-Derivatized Oligosaccharides.
Custom Pediatric Oncology Next-Generation Sequencing Panel Identifies Somatic Mosaicism in Archival Tissue and Enhances Targeted Clinical Care.
Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer.
Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics.
Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients.
Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.
Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells.
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.
Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice.
Deficiency of phosphoinositide 3-kinase enhancer protects mice from diet-induced obesity and insulin resistance.
Defining the blueprint of the cancer genome.
Deguelin targets multiple oncogenic signaling pathways to combat human malignancies.
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Deletion of p53 and Hyper-Activation of PIK3CA in Keratin-15+ Stem Cells Lead to the Development of Spontaneous Squamous Cell Carcinoma.
Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines.
Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer.
Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer.
Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment.
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women.
Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3K?/mTOR inhibitors.
Design, synthesis and evaluation of some 1,6-disubstituted-1H-benzo[d]imidazoles derivatives targeted PI3K as anticancer agents.
Design, synthesis, and anticancer properties of novel benzophenone-conjugated coumarin analogs.
Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3K? inhibitors.
Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.
Detection of oncogenic mutations in cervical carcinoma using method High Resolution Melting (HRM).
Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
Detection of PIK3CA E545A mutation in circulating tumor DNA of a patient affected by uterine carcinosarcoma.
Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Detection of PIK3CA Mutations in Breast Cancer Bone Metastases.
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis.
Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Detection of tumor PIK3CA status in Metastatic Breast Cancer using Peripheral Blood.
Development of a tandem affinity phosphoproteomic method with motif selectivity and its application in analysis of signal transduction networks.
Development of a UPLC-MS/MS Method for the Quantification of VS-5584 and Its Application in Pharmacokinetic Studies in Rats.
Development of Multi-Target Chemometric Models for the Inhibition of Class I PI3K Enzyme Isoforms: A Case Study Using QSAR-Co Tool.
Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
Diet and colorectal cancer: analysis of a candidate pathway using SNPS, haplotypes, and multi-gene assessment.
Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers.
Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature.
Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma.
Differences in the molecular profile of endometrial cancers from British White and British South Asian women.
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
Different correlations between tumor size and cancer-related gene profiles according to histologic type of salivary gland tumor.
Different expression of apoptotic proteins between HBV-infected and non-HBV-infected hepatocellular carcinoma.
Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location.
Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells.
Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
Differential Expression of IRS-1 and IRS-2 in Uterine Leiomyosarcomas with Distinct Oncogenic Phenotypes: Lack of Correlation with Downstream Signaling Events.
Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model.
Differential involvement of RalA and RalB in colorectal cancer.
Differential modulation of signaling pathways and apoptosis of ras-transformed 10T1/2 cells by the depsipeptide FR901228.
Differential SKIP expression in PTEN-deficient glioblastoma regulates cellular proliferation and migration.
Discovery and Features of an Alkylating Signature in Colorectal Cancer.
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).
Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3K? inhibitors.
Discovery of 2-(5-(quinolin-6-yl)-1,3,4-oxadiazol-2-yl)acetamide derivatives as novel PI3K? inhibitors via docking-based virtual screening.
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a ?-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.
Discovery of a novel class of AKT pleckstrin homology domain inhibitors.
Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.
Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.
Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors.
Discovery of a Phosphoinositide 3-Kinase (PI3K) ?/? Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3K? Potency in a PI3K?-Selective Template by Targeting Nonconserved Asp856.
Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues.
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.
Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy.
Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3K? Inhibitors.
Discovery of Potent and Selective PI3K? Inhibitors.
Disease evolution and heterogeneity in bilateral breast cancer.
Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110?/PIK3CA but not by HER2 or mutant AKT1.
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model.
Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer.
Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes.
Distinct epithelial-to-mesenchymal transitions induced by PIK3CA H1047R and PIK3CB.
Distinct genomic profile in h. pylori-associated gastric cancer.
Distinct molecular features of different macroscopic subtypes of colorectal neoplasms.
Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas.
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.
Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B.
Distinguishing the progression of an endometrioma: Benign or malignant?
DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations.
DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
DNA Methylation and Genetic Aberrations in Gastric Cancer.
DNA-dependent protein kinase regulates lysosomal AMP-dependent protein kinase activation and autophagy.
Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Dolastatin, along with Celecoxib, stimulates apoptosis by a mechanism involving oxidative stress, membrane potential change and PI3-K/AKT pathway down regulation.
Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers.
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K? inhibitors.
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
Down Regulation of FOXO1 Promotes Cell Proliferation in Cervical Cancer.
Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation.
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Downregulation of MACC1 inhibits the viability, invasion and migration and induces apoptosis in esophageal carcinoma cells through the phosphatase and tensin homolog/phosphoinositide 3-kinase/protein kinase B signaling pathway.
Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth.
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
Dual HER2\PIK3CA targeting overcomes single-agent acquired resistance in HER2 amplified uterine serous carcinoma cell lines in vitro and in vivo.
Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma.
Dual Inhibition of PI3K/Akt/mTOR Pathway and Role of Autophagy in Non-Small Cell Lung Cancer Cells.
Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation.
Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma.
Dual PI-3 kinase/mTOR inhibition impairs autophagy flux and induces cell death independent of apoptosis and necroptosis.
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses.
Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR.
Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells.
Dynamic changes of driver genes' mutations across clinical stages in nine cancer types.
Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer.
Dysregulation of PI3K/Akt/PTEN Pathway in Canine Mammary Tumor.
Early-onset colorectal cancer: A distinct entity with unique genetic features.
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Effects of BENC-511, a novel PI3K inhibitor, on the proliferation and apoptosis of A549 human lung adenocarcinoma cells.
Effects of dietary tryptophan levels on antioxidant status and immunity for juvenile blunt snout bream (Megalobrama amblycephala) involved in Nrf2 and TOR signaling pathway.
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.
Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
Effects of PTEN inhibition on regulation of tau phosphorylation in an okadaic acid-induced neurodegeneration model.
Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma.
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma.
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features.
EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours.
EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas.
EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy.
Elevated expression of SHIP2 correlates with poor prognosis in non-small cell lung cancer.
Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer.
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer.
Emerging role of PTEN loss in evasion of the immune response to tumours.
Emerging Roles for AKT Isoform Preference in Cancer Progression Pathways.
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity.
Emerging roles of microRNAs in regulating the mTOR signaling pathway during tumorigenesis.
Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.
Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action.
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Endometrial cancer and somatic G>T KRAS transversion in patients with constitutional MUTYH biallelic mutations.
Endometrial cancer cells exhibit high expression of p110? and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.
Endometrioid carcinoma of the endometrium: pathologic and molecular features.
Enhanced cell killing by overexpression of dominant-negative phosphatidylinositol 3-kinase subunit, Deltap85, following genotoxic stresses.
Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer.
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Environmental and sex-specific molecular signatures of glioma causation.
EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation.
Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Epigallocatechin-3-gallate inhibits proliferation and triggers apoptosis in colon cancer via the hedgehog/phosphoinositide 3-kinase pathways.
Epigenetic and genetic burden measures are associated with tumor characteristics in invasive breast carcinoma.
Epigenetic and genetic features of 24 colon cancer cell lines.
Epigenetic regulation in macrophage migration inhibitory factor (MIF)-mediated signaling in cancer and inflammation.
Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.
Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation.
Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.
Essential role of PI3-kinase pathway in p53-mediated transcription: Implications in cancer chemotherapy.
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.
Establishing a patient-derived xenograft model of human myxoid and round-cell liposarcoma.
Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.
Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.
Establishment and preclinical application of a patient-derived xenograft model for uterine cancer.
Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.
ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.
ETV5 overexpression contributes to tumor growth and progression of thyroid cancer through PIK3CA.
Evaluation of a novel approach to circulating tumor cell isolation for cancer gene panel analysis in patients with breast cancer.
Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.
Evaluation of PTEN expression in cervical adenocarcinoma by tissue microarray.
Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study.
Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer.
Evolutionary pathways in BRCA1-associated breast tumors.
Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant.
Exome sequencing identifies predisposing and fusion gene in ganglioneuroma, ganglioneuroblastoma and neuroblastoma.
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.
Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes.
Exome sequencing of oral squamous cell carcinoma in users of Arabian snuff reveals novel candidates for driver genes.
Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.
Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer.
Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication.
Experimental verification of a predicted novel microRNA located in human PIK3CA gene with a potential oncogenic function in colorectal cancer.
Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.
Exploring Flavonoids for Potential Inhibitors of a Cancer Signaling Protein PI3K? Kinase Using Computational Methods.
Exploring phenotype patterns of breast cancer within somatic mutations: a modicum in the intrinsic code.
Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma.
Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.
Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation.
Expression of HLA Class I Antigen, Aspirin Use, and Survival After a Diagnosis of Colon Cancer.
Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis.
Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type.
Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R.
Expression of PTEN and Akt phosphorylation in lipopolysaccharide-treated NIH3T3 cells.
Expression of TGF?3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement of PI3-kinase/AKT signaling pathway.
Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.
Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML.
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis.
Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features.
First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center.
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.
First-in-human trial of the PI3K?-selective inhibitor SAR260301 in patients with advanced solid tumors.
First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.
Fluoride Exposure Induces Inhibition of Sodium/Iodide Symporter (NIS) Contributing to Impaired Iodine Absorption and Iodine Deficiency: Molecular Mechanisms of Inhibition and Implications for Public Health.
For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors.
Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.
FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients.
FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K-AKT Pathway.
Foxo3a drives proliferation in anaplastic thyroid carcinoma via transcriptional regulation of cyclin A1: A paradigm shift that impacts current therapeutic strategies.
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis.
FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis.
Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.
Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.
Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
Frequent activating PIK3CA mutations in sporadic angiolipoma.
Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer.
Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression.
Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
Frequent FOXA1-Activating Mutations in Extramammary Paget's Disease.
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.
Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma.
Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors.
Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
Frequent PIK3CA activating mutations in nipple adenomas.
Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.
Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.
Frequent PIK3CA mutations in radial scars.
Frequent PIK3CA-activating mutations in hidradenoma papilliferums.
Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration.
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer.
Function of G-Protein-Coupled Estrogen Receptor-1 in Reproductive System Tumors.
Function of MiR-152 As a Tumor Suppressor in Human Breast Cancer By Targeting PIK3CA.
Function of PTEN during the formation and maintenance of neuronal circuits in the brain.
Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine.
Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Functional characterization of a novel somatic oncogenic mutation of
Functional differences between two classes of oncogenic mutation in the PIK3CA gene.
Functional differentiation of three phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) in response to Vibrio anguillarum infection in turbot (Scophthalmus maximus).
Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.
Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.
Functional integrity of nuclear factor kappaB, phosphatidylinositol 3'-kinase, and mitogen-activated protein kinase signaling allows tumor necrosis factor alpha-evoked Bcl-2 expression to provoke internal ribosome entry site-dependent translation of hypoxia-inducible factor 1alpha.
Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Functional role of phosphatidylinositol 3-kinase in direct tumor lysis by human natural killer cells.
Functional role of SGK3 in PI3K/Pten driven liver tumor development.
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA.
Fusobacterium nucleatum and T Cells in Colorectal Carcinoma.
Gain of interaction with IRS1 by p110?-helical domain mutants is crucial for their oncogenic functions.
Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion.
Ganoderma lucidum targeting lung cancer signaling: A review.
Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features.
GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy.
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
GDNF family receptor alpha 2 promotes neuroblastoma cell proliferation by interacting with PTEN.
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.
Gene amplifications associated with the development of hormone-resistant prostate cancer.
Gene expression profiling analysis contributes to understanding the association between non-syndromic cleft lip and palate, and cancer.
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Gene mutation characteristics of nonsmall-cell lung carcinoma patients with wild-type epidermal growth factor receptor and sensitivity to Tarceva therapy.
Gene of the month: PIK3CA.
Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas.
Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas.
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer.
Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
Genetic Alterations in Benign Breast Biopsies of Subsequent Breast Cancer Patients.
Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection.
Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II.
Genetic alterations in endometrial cancer by targeted next-generation sequencing.
Genetic alterations in Japanese extrahepatic biliary tract cancer.
Genetic Alterations in the PI3K Pathway in Prostate Cancer.
Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.
Genetic alterations of the PIK3CA oncogene in human oral squamous cell carcinoma in an Indian population.
Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology.
Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers.
Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
Genetic association between PIK3CA gene and oral squamous cell carcinoma: a case control study conducted in Chongqing, China.
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.
Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.
Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Genetic Profiling of Breast Cancer with and Without Preexisting Metabolic Disease.
Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
Genetically engineered mouse models of PI3K signaling in breast cancer.
Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.
Genome-derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care.
Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors.
Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma.
Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway.
Genome-wide somatic copy number alteration analysis and database construction for cervical cancer.
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.
Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications.
Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget's Disease of the Vulva.
Genomic Alterations in Gastrointestinal Stromal Tumors as Revealed by Conventional and Array-based Comparative Genomic Hybridization.
Genomic alterations in neuroendocrine cancers of the ovary.
Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients.
Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma.
Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma.
Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
Genomic analysis for the prediction of prognosis in small-bowel cancer.
Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas.
Genomic analysis of recurrences and high-grade forms of polymorphous adenocarcinoma.
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma.
Genomic Characterization of de novo Metastatic Breast Cancer.
Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population.
Genomic characterization of high-risk non-muscle invasive bladder cancer.
Genomic Characterization of Primary Invasive Lobular Breast Cancer.
Genomic characterization of vulvar squamous cell carcinoma.
Genomic Database Analysis for Head and Neck Cancer Prevention Targets: MTOR Signal Transduction Pathway.
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.
Genomic Dissection of Hurthle Cell Carcinoma Reveals a Unique Class of Thyroid Malignancy.
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.
Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart.
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer.
Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer.
Genomic landscape of adenoid cystic carcinoma of the breast.
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.
Genomic profile of advanced breast cancer in circulating tumour DNA.
Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours.
Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.
Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer.
Genomic profiling of endometrial cancer and relationship with volume of endometrial cancer disease spread.
Genomic profiling of large-cell neuroendocrine carcinoma of the lung.
Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival.
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.
Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions.
Genomics and splicing events of type II endometrial cancers in the black population: racial disparity, socioeconomic and geographical differences.
Genotypic analysis of esophageal squamous cell carcinoma by molecular cytogenetics and real-time quantitative polymerase chain reaction.
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors.
Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.
Germline and Somatic mutations in postmenopausal breast cancer patients.
Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations, and immune activation.
Glucose Metabolism Measured by [F]Fluorodeoxyglucose Positron Emission Tomography Is Independent of PTEN/AKT Status in Human Colon Carcinoma Cells.
GSK-3?-mediated fatty acid synthesis enhances epithelial to mesenchymal transition of TLR4-activated colorectal cancer cells through regulation of TAp63.
GSTO1*CC Genotype (rs4925) Predicts Shorter Survival in Clear Cell Renal Cell Carcinoma Male Patients.
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.
Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line.
Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress.
Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer.
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.
Hepatic small vessel neoplasm, a rare infiltrative vascular neoplasm of uncertain malignant potential.
Hepatoid adenocarcinoma of the stomach with PIK3Ca mutation during pregnancy: A case report with molecular profile.
Hesperidin inhibits insulin-induced phosphoinositide 3-kinase/Akt activation in human pre-B cell line NALM-6.
Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody.
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
Heterogeneous mutational profile and prognosis conferred by TP53 mutations in Appendiceal mucinous neoplasms.
Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects.
Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones.
High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.
High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer.
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
High frequency of mutations in the PIK3CA gene helical and kinase coding regions in a group of Iranian patients with high-grade glioblastomas: five novel mutations.
High frequency of mutations of the PIK3CA gene in human cancers.
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability.
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
High Resolution Melting Analysis for Rapid Detection of PIK3CA Gene Mutations in Bladder Cancer: A Mutated Target for Cancer Therapy.
High selectivity of PI3K? inhibitors in SETD2-mutated renal clear cell carcinoma.
High-grade fetal adenocarcinoma of the lung is a tumour with a fetal phenotype that shows diverse differentiation, including high-grade neuroendocrine carcinoma: a clinicopathological, immunohistochemical and mutational study of 20 cases.
High-resolution genomic and expression analyses of copy number alterations in breast tumors.
High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing.
High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.
Highlights from the 38th SABCS annual meeting, 8th - 12th December 2015, San Antonio, USA.
Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission.
Highly sensitive detection of sentinel lymph node metastasis of breast cancer by digital PCR for RASSF1A methylation.
Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.
Hippo Pathway and YAP Signaling Alterations in Squamous Cancer of the Head and Neck.
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Hotspot mutations in polyomavirus positive and negative Merkel cell carcinomas.
Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
How autophagy controls the intestinal epithelial barrier.
How moderate changes in Akt T-loop phosphorylation impact on tumorigenesis and insulin resistance.
How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
HPV: Molecular pathways and targets.
HTLV-I Tax regulates the cellular proliferation through the down-regulation of PIP3-phosphatase expressions via the NF-?B pathway.
Human mucosal CD4(+) T cells but not blood CD4(+) T cells respond vigorously towards CD28 engagement.
Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells.
Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.
Human Papillomavirus-Associated Adenocarcinoma of the Base of Tongue: Potentially Actionable Genetic Changes.
Human tumor mutants in the p110alpha subunit of PI3K.
Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway.
Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression.
Hyperoside exerts potent anticancer activity in skin cancer.
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Identification and Validation of PIK3CA as a Marker Associated with Prognosis and Immune Infiltration in Renal Clear Cell Carcinoma.
Identification of a Potent Phosphoinositide 3-Kinase Pan Inhibitor Displaying a Strategic Carboxylic Acid Group and Development of Its Prodrugs.
Identification of allosteric binding sites for PI3K? oncogenic mutant specific inhibitor design.
Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments.
Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing.
Identification of differentially expressed genes in salivary adenoid cystic carcinoma cells associated with metastasis.
Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease.
Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis.
Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors.
Identification of novel effectors of invasive cell growth downstream of phosphoinositide 3-kinase.
Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA.
Identification of Novel Piperazinylquinoxaline Derivatives as Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors.
Identification of novel potential PI3K? inhibitors for cancer therapy.
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.
Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma.
Identification of PI3K-AKT signaling as the dominant altered pathway in intestinal type ampullary cancers through whole-exome sequencing.
Identification of PIK3CA multigene mutation patterns associated with superior prognosis in stomach cancer.
Identification of potentially druggable molecular alterations in skin adnexal malignancies.
Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations.
Identification of somatic gene mutations in penile squamous cell carcinoma.
Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.
Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.
Identification of ZASC1 encoding a Krüppel-like zinc finger protein as a novel target for 3q26 amplification in esophageal squamous cell carcinomas.
IGF-1 induces expression of zinc-finger protein 143 in colon cancer cells through phosphatidylinositide 3-kinase and reactive oxygen species.
IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions.
IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.
Imidazoquinolines: Recent Developments in Anticancer Activity.
Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells.
Immunocytochemical detection of phosphatidylinositol 3 kinase in Burkitt lymphoma cells.
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.
Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples.
Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-?+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Impact of E6-associated protein on the proliferation and invasion of prostate cancer cells in bone metastasis.
Impact of genetic alterations on mTOR-targeted cancer therapy.
Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Impact of the obesity epidemic on cancer.
Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.
Improving the genetic signature of prostate cancer, the somatic mutations.
Improving the performance of somatic mutation identification by recovering circulating tumor DNA mutations.
In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis.
In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa.
In Vitro and in Vivo antitumor activity and the mechanism of siphonodictyal B in human colon cancer cells.
In vitro antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines.
In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN.
In-silico & In-vitro Identification of Structure-Activity Relationship Pattern of Serpentine & Gallic Acid Targeting PI3K? as Potential Anticancer Target.
Inactivating CUX1 mutations promote tumorigenesis.
Inactivation of endothelial cell phosphoinositide 3-kinase ? inhibits tumor angiogenesis and tumor growth.
Inactivation of Pten in osteo-chondroprogenitor cells leads to epiphyseal growth plate abnormalities and skeletal overgrowth.
Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin.
Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
Increased Expression of Phosphatidylinositol 3-Kinase p110? and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.
Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors.
Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis.
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Increased Rac activity is required for the progression of T-lymphomas induced by Pten-deficiency.
Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.
Inflammation and prostate cancer: the role of interleukin-6.
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
Influence of Pi3-K and PKC activity on 99mTc-(V)-DMSA uptake: correlation with tumour aggressiveness in an in vitro malignant glioblastoma cell line model.
Infrequent loss of SMARCA4, SMARCA2, and SMARCB1 expression in uterine mesenchymal tumors.
Inherited PTEN mutations and the prediction of phenotype.
Inhibiting PI3K as a therapeutic strategy against cancer.
Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment.
Inhibition by platelet-activating factor of Src- and hepatocyte growth factor-dependent invasiveness of intestinal and kidney epithelial cells. Phosphatidylinositol 3'-kinase is a critical mediator of tumor invasion.
Inhibition of AKT-Signaling Sensitizes Soft Tissue Sarcomas (STS) and Gastrointestinal Stromal Tumors (GIST) to Doxorubicin via Targeting of Homology-Mediated DNA Repair.
Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells.
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.
Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells.
Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit.
Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival.
Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction.
Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest.
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Inhibition of PI3K/AKT/mTOR Pathway Enhances Temozolomide-Induced Cytotoxicity in Pituitary Adenoma Cell Lines in Vitro and Xenografted Pituitary Adenoma in Female Nude Mice.
Inhibition of the ?-subunit of phosphoinositide 3-kinase (PI3K) in heart increases late sodium current and is arrhythmogenic.
Inhibition of the p110? isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis.
Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo.
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Inhibition of the PI3K Pathway: Hope We Can Believe in?
Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45.
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance.
Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN.
Inhibitors of STAT3, ?-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Inhibitory activity of flavonoids against class I phosphatidylinositol 3-kinase isoforms.
Inhibitory effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Initiation of a formalized precision medicine program in gynecologic oncology.
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway.
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling.
INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival.
Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations.
Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
Insulin-Like Growth Factor-1 Increases the Expression of Inflammatory Biomarkers and Sebum Production in Cultured Sebocytes.
Integrated analysis of oral tongue squamous cell carcinoma identifies key variants and pathways linked to risk habits, HPV, clinical parameters and tumor recurrence.
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.
Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.
Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
Integrated genomic characterization of endometrial carcinoma.
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Integration of Liquid Biopsies into Clinical Laboratory Applications via NGS in Cancer Diagnostics.
Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Integrative clinical genomics of metastatic cancer.
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Interaction with PI3-kinase contributes to the cytotoxic activity of apoptin.
Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth.
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
Intermittent high dose scheduling of AZD8835, a novel selective inhibitor of PI3K? and PI3K?, demonstrates treatment strategies for PIK3CA-dependent breast cancers.
Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
Intraductal tubulopapillary neoplasm of the pancreas with somatic BRAF mutation.
Intraductal Tubulopapillary Neoplasm of the Pancreas: An Overview.
Intratumor heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification (MLPA). A DESCRIPTIVE STUDY.
Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial.
Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3K?) inhibitors.
Invasive ductal carcinoma arising in borderline phyllode tumor: A potential role of PIK3CA mutation.
Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach.
Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant.
Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells.
Investigation of the expression levels of CPEB4, APC, TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and CTNNB1 genes in different stage colorectal tumors
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Involvement of autophagy in the response of tumor cells to PtdIns3K inhibitors: Therapeutic implications.
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.
Involvement of phosphoinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairments induced by beta-amyloid 1-40 peptide in mice.
Involvement of PTEN/Akt signaling in capsular invasive carcinomas developed in a rat two-stage thyroid carcinogenesis model after promotion with sulfadimethoxine.
Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.
Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine.
Is the PIK3CA gene expression level in FNAB washouts equivalent to that in postoperative tissue specimens of papillary thyroid carcinoma?
Ischaemic Preconditioning Protects Cardiomyocytes from Anthracycline-Induced Toxicity via the PI3K Pathway.
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
JAK/STAT pathway interacts with intercellular cell adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) while prostate cancer stem cells form tumor spheroids.
Jiedu Sangen decoction inhibits chemoresistance to 5-fluorouracil of colorectal cancer cells by suppressing glycolysis via PI3K/AKT/HIF-1? signaling pathway.
KEAP1-Dependent Synthetic Lethality Induced by AKT and TXNRD1 Inhibitors in Lung Cancer.
Key autophagic targets and relevant small-molecule compounds in cancer therapy.
Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.
Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the ?GBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo.
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.
Knockin of mutant PIK3CA activates multiple oncogenic pathways.
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.
KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages.
KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment.
KRAS Mutation Status and Clinical Outcome of Preoperative Chemoradiation With Cetuximab in Locally Advanced Rectal Cancer: A Pooled Analysis of 2 Phase II Trials.
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer.
KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC).
Kras-driven heterotopic tumor development from hepatobiliary organoids.
Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management.
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma.
Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.
Letter re: uncommon mutation but common amplifications of the PIK3CA gene in thyroid tumors.
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance.
Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells.
Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer.
LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers.
Lipid accumulation in macrophages confers protumorigenic polarization and immunity in gastric cancer.
Lipid-dependent Akt-ivity: where, when, and how.
Liquid biopsies for bladder cancer.
Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer.
Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.
Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women.
LncRNA TSLC1-AS1 is a novel tumor suppressor in glioma.
Lobular breast cancer: Clinical, molecular and morphological characteristics.
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.
Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer.
Long noncoding RNA NEAT1 promotes the growth of gastric cancer cells by regulating miR-497-5p/PIK3R1 axis.
Long-term p110? PI3K inactivation exerts a beneficial effect on metabolism.
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports.
Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.
Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis.
Loss of PI3K blocks cell-cycle progression in a Drosophila tumor model.
Loss of PTEN expression does not contribute to PDK-1 activity and PKC activation-loop phosphorylation in Jurkat leukaemic T cells.
Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas.
Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women.
Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin.
Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling.
Low Frequency of PIK3CA Gene Mutations in Hepatocellular Carcinoma in Chinese Population.
Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients.
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology.
LOXL1-AS1 Drives The Progression Of Gastric Cancer Via Regulating miR-142-5p/PIK3CA Axis.
LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.
LRIG2 is a growth suppressor of Hec-1A and Ishikawa endometrial adenocarcinoma cells by regulating PI3K/AKT- and EGFR-mediated apoptosis and cell-cycle.
LRRC4 Suppresses E-Cadherin-Dependent Collective Cell Invasion and Metastasis in Epithelial Ovarian Cancer.
Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
Lung cancer in never smokers from the Princess Margaret Cancer Centre.
Lung Metastasis in Pediatric Thyroid Cancer: Radiological Pattern, Molecular Genetics, Response to Therapy and Outcome.
Luteolin, a flavonoid with potential for cancer prevention and therapy.
LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway.
LY294002, an inhibitor of PI-3K, enhances heat sensitivity independently of p53 status in human lung cancer cells.
m6A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer.
Macroscopic morphologic subtypes of laterally spreading colorectal tumors showing distinct molecular alterations.
Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes.
Management of toxicity to isoform ?-specific PI3K inhibitors.
MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling.
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing Rhabdomyosarcoma.
Measurement of PIP3 levels reveals an unexpected role for p110? in early adaptive responses to p110?-specific inhibitors in luminal breast cancer.
Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.
Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model.
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.
MEK, P38 AND PI-3K MEDIATE CROSS TALK BETWEEN EGFR AND TNFR IN ENHANCING HEPATOCYTE GROWTH FACTOR PRODUCTION FROM HUMAN MESENCHYMAL STEM CELLS.
Melatonin alleviates liver steatosis induced by prenatal dexamethasone exposure and postnatal high-fat diet.
Membrane-binding and activation mechanism of PTEN.
MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases.
MET in gastric cancer - discarding a 10% cutoff rule.
MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation.
Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line.
Metaplastic Breast Cancer: Molecular Typing and Identification of Potential Targeted Therapies at a Single Institution.
Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.
Metastasis suppressor protein 1 regulated by PTEN suppresses invasion, migration, and EMT of gastric carcinoma by inactivating PI3K/AKT signaling.
Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.
MEX3A promotes development and progression of breast cancer through regulation of PIK3CA.
Mgat5 and Pten interact to regulate cell growth and polarity.
Mice expressing activated PI3K rapidly develop advanced colon cancer.
Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer.
MicroRNA MIR21 and T Cells in Colorectal Cancer.
MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by targeting PIK3CA.
MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA.
MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.
MicroRNA?363?3p inhibits cell proliferation and induces apoptosis in retinoblastoma cells via the Akt/mTOR signaling pathway by targeting PIK3CA.
Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
MiR-125b inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting phosphoinositide 3-kinase catalytic subunit delta.
MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells.
miR-183-5p functions as a tumor suppressor in lung cancer through PIK3CA inhibition.
miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA.
miR-203 inhibits cell proliferation and promotes cisplatin induced cell death in tongue squamous cancer.
miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1.
MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB.
MiR-422a acts as a tumor suppressor in glioblastoma by targeting PIK3CA.
MiR-486-5p Serves as a Good Biomarker in Nonsmall Cell Lung Cancer and Suppresses Cell Growth With the Involvement of a Target PIK3R1.
miR-490-5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA.
miR-495 promotes apoptosis and inhibits proliferation in endometrial cells via targeting PIK3R1.
miR-502 inhibits cell proliferation and tumor growth in hepatocellular carcinoma through suppressing phosphoinositide 3-kinase catalytic subunit gamma.
miR?10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
miR?142?5p inhibits pancreatic cancer cell migration and invasion by targeting PIK3CA.
miRNA expression can classify pediatric thyroid lesions and increases the diagnostic yield of mutation testing.
miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma.
miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling.
Mislocalization of the cell polarity protein Scribble promotes mammary tumorigenesis and is associated with basal breast cancer.
Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: Implications for Anabolic Metabolism, Stemness, and Metastasis.
Mixed Adenoma Well-differentiated Neuroendocrine Tumor (MANET) of the Digestive System: An Indolent Subtype of Mixed Neuroendocrine-NonNeuroendocrine Neoplasm (MiNEN).
Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids.
Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability.
Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells.
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.
Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXR?.
Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection.
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
Molecular alterations in uterine serous carcinoma.
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Molecular analysis of encapsulated papillary carcinoma of the breast with and without invasion.
Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas.
Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation.
Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report.
Molecular association of functioning stroma with carcinoma cells in the ovary: A preliminary study.
Molecular biomarkers predicting early development of endometrial carcinoma: A pilot study.
Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.
Molecular characteristics and biological behaviours of the oncocytic and pancreatobiliary subtypes of intraductal papillary mucinous neoplasms.
Molecular Characterization of an Endometrial Endometrioid Adenocarcinoma Metastatic to a Thyroid Hürthle Cell Adenoma Showing Cancerization of Follicles.
Molecular characterization of colorectal cancer using whole-exome sequencing in a Taiwanese population.
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases.
Molecular characterization of uterine and ovarian tumors with mixed epithelial and germ cell features confirms frequent somatic derivation.
Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts.
Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications.
Molecular diagnostics helps to identify distinct subgroups of spinal astrocytomas.
Molecular Dissection of AKT Activation in Lung Cancer Cell Lines.
Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence.
Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Molecular Heterogeneity of High Grade Colorectal Adenocarcinoma.
Molecular imaging of Akt kinase activity.
Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes.
Molecular pathological classification of colorectal cancer.
Molecular pathways in head and neck cancer.
Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia.
Molecular patterns in salivary duct carcinoma identify prognostic subgroups.
Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers.
Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.
Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin.
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
Molecular Profiling Reveals a Clonal Relationship Between Ovarian Mucinous Tumors and Corresponding Mural Carcinomatous Nodules.
Molecular prognosticators in clinically and pathologically distinct cohorts of head and neck squamous cell carcinoma-A meta-analysis approach.
Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
Molecular spectrum of PIK3CA gene mutations in patients with nonsmall-cell lung cancer in Turkey.
Molecular testing of NSCLC using a platform for rapid detection of multiple oncogenetic mutations.
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer.
Molecules in medicine mini-review: isoforms of PI3K in biology and disease.
More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
Morin protects against acrylamide-induced neurotoxicity in rats: an investigation into different signal pathways.
Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman.
Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications.
Mouse Models as a Tool for Understanding Progression in BrafV600E-Driven Thyroid Cancers.
Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy.
Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.
Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.
mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
mTOR Signalling in Head and Neck Cancer: Heads Up.
MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.
mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients.
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis.
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.
Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study.
Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source.
Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.
Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform.
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.
Multiplexed assays for detection of mutations in PIK3CA.
Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.
Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin.
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
Mutant PIK3CA Induces EMT in a Cell Type Specific Manner.
Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation.
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.
Mutant SF3B1 promotes AKT- and NF-?B-driven mammary tumorigenesis.
Mutated PI 3-kinases: cancer targets on a silver platter.
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas.
Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.
Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma (HNSCC).
Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women.
Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer.
Mutation of the PIK3CA gene in ovarian and breast cancer.
Mutation of the PIK3CA oncogene in human cancers.
Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA).
Mutation profile of non-small cell lung cancer revealed by next generation sequencing.
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions.
Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis.
Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components.
Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.
Mutational analysis of beta-catenin and the RAS-RAF signalling pathway in early flat-type colorectal tumours.
Mutational analysis of PI3K/AKT and RAS/RAF pathway activation in malignant salivary gland tumours with a new mutation of PIK3CA.
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas.
Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy.
Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.
Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy.
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.
Mutational Hotspot in Exon 20 of PIK3CA in Breast Cancer Among Singapore Chinese.
Mutational Landscape of Esophageal Squamous Cell Carcinoma in an Indian Cohort.
Mutational landscape of penile squamous cell carcinoma in a Chinese population.
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA.
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas.
Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.
Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance.
Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.
Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women.
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Mutations in long-lived epithelial stem cells and their clonal progeny in pre-malignant lesions and in oral squamous cell carcinoma.
Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.
Mutations in PIK3CA are infrequent in neuroblastoma.
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.
Mutations in renal cell carcinoma.
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer.
Mutations of PIK3CA are rare in cutaneous melanoma.
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Mutations of PIK3CA in gastric adenocarcinoma.
Mutations of the human PTEN gene.
Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications.
Mutations of the PIK3CA gene in hereditary colorectal cancers.
MYC acts via the PTEN tumor suppressor to elicit autoregulation and genome-wide gene repression by activation of the Ezh2 methyltransferase.
MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.
MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
Myosin 1b Regulates Nuclear AKT Activation by Preventing Localization of PTEN in the Nucleus.
Myristoylated p110? Causes Embryonic Death Due to Developmental and Vascular Defects.
NAD(P)H Quinone Dehydrogenase 1 Ablation Inhibits Activation of the Phosphoinositide 3-Kinase/Akt Serine/Threonine Kinase and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathways and Blocks Metabolic Adaptation in Hepatocellular Carcinoma.
Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy.
Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.
Near-Comprehensive Resequencing of Cancer-Associated Genes in Surgically Resected Metastatic Liver Tumors of Gastric Cancer.
NEDD4L Protein Catalyzes Ubiquitination of PIK3CA Protein and Regulates PI3K-AKT Signaling.
Negative regulatory role of PI3-kinase in TNF-induced tumor necrosis.
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges.
Neoadjuvant treatment of breast cancer--Clinical and research perspective.
Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation.
Network Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome.
Network Pharmacology Analysis of ZiShenWan for Diabetic Nephropathy and Experimental Verification of Its Anti-Inflammatory Mechanism.
Network pharmacology-based strategy to investigate pharmacological mechanisms of Tinospora sinensis for treatment of Alzheimer's disease.
Neuroblast niche position is controlled by Phosphoinositide 3-kinase-dependent DE-Cadherin adhesion.
Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites.
New agents in follicular lymphoma.
New and emerging factors in tumorigenesis: an overview.
New connections between old pathways: PDK1 signaling promotes cellular transformation through PLK1-dependent MYC stabilization.
New generation breast cancer cell lines developed from patient-derived xenografts.
New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients.
New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs).
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.
New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.
New miRNA expression abnormalities in laryngeal squamous cell carcinoma.
New molecular prognostic factors of adult diffuse lower-grade gliomas in post-2016 molecular era: a retrospective analysis from single center.
New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway--The Devil Is in the Details.
Next generation sequencing of cervical high grade dysplasia and invasive squamous cell carcinoma: A case study.
Next-generation sequencing identified somatic alterations that may underlie the etiology of Chinese papillary thyroid carcinoma.
Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Next-Generation Sequencing in the Diagnosis of Metastatic Lesions: Reclassification of a Glioblastoma as an Endometrial Cancer Metastasis to the Brain.
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction.
No somatic genetic change in the paxillin gene in nonsmall-cell lung cancer.
NODAL/TGF? signalling mediates the self-sustained stemness induced by PIK3CA H1047R homozygosity in pluripotent stem cells.
Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models.
Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
Normal vitreous promotes angiogenesis via activation of Axl.
Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway.
Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3K? inhibition.
Novel approaches to inhibitor design for the p110? phosphoinositide 3-kinase.
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
Novel molecular insights from routine genotyping of colorectal carcinomas.
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Novel Mutations in Neuroendocrine Carcinoma of the Breast: Possible Therapeutic Targets.
Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets.
Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells.
NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer.
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
Nuclear upregulation of class I phosphoinositide 3-kinase p110? correlates with high 47S rRNA levels in cancer cells.
NVP-BEZ235 Attenuated Cell Proliferation and Migration in the Squamous Cell Carcinoma of Oral Cavities and p70S6K Inhibition Mimics its Effect.
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer.
Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects.
Oligonucleotide PIK3CA/Chromosome 3 Dual in Situ Hybridization Automated Assay with Improved Signals, One-Hour Hybridization, and No Use of Blocking DNA.
Oncogene alterations in endometrial carcinosarcomas.
Oncogene and therapeutic target analyses in Atypical fibroxanthomas and pleomorphic dermal sarcomas.
Oncogene mutational profile in nasopharyngeal carcinoma.
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.
Oncogenic ?-catenin and PIK3CA instruct network states and cancer phenotypes in intestinal organoids.
Oncogenic activation of the PI3-kinase p110? isoform via the tumor-derived PIK3C?(D1067V) kinase domain mutation.
Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.
Oncogenic mutation of PIK3CA in small cell lung carcinoma: A potential therapeutic target pathway for chemotherapy-resistant lung cancer.
Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients.
Oncogenic mutations of p110? isoform of PI 3-kinase upregulate its protein kinase activity.
Oncogenic mutations of PIK3CA in human cancers.
Oncogenic Mutations of PIK3CA in Human Cancers.
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Oncogenic PI3K and its role in cancer.
Oncogenic PI3K mutations lead to NF-?B-dependent cytokine expression following growth factor deprivation.
Oncogenic PI3K? promotes multipotency in breast epithelial cells.
Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling.
Oncogenic PIK3CA mutations in colorectal cancers and polyps.
Oncogenic PIK3CA mutations in lobular breast cancer progression.
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner.
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
Oncogenic signaling of class I PI3K isoforms.
Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway.
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.
OncomiRs: the discovery and progress of microRNAs in cancers.
Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents.
Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
Origin of mutations in genes associated with human glioblastoma multiform cancer: random polymerase errors versus deamination.
Osthole shows the potential to overcome P-glycoprotein?mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway.
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids.
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
Oxidative Cyclization-Induced Activation of a Phosphoinositide 3-Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics.
p-AKT overexpression in primary renal cell carcinomas and their metastases.
P-REX2a driving tumorigenesis by PTEN inhibition.
P-selectin activates integrin-mediated colon carcinoma cell adhesion to fibronectin.
p110? Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110? Kinase Activity.
p110? PI 3-kinase inhibition perturbs APP and TNF? trafficking, reduces plaque burden, dampens neuroinflammation and prevents cognitive decline in an Alzheimer's disease mouse model.
p110? PI3K as a therapeutic target of solid tumours.
p110delta is required for innate immunity to transplantable lymphomas.
p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease.
p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities.
P53 and PIK3CA Mutations in KRAS/HER2 Negative Ovarian Intestinal-Type Mucinous Carcinoma Associated with Mature Teratoma.
p53 Loses grip on PIK3CA expression leading to enhanced cell survival during platinum resistance.
p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
p55PIK Transcriptionally Activated by MZF1 Promotes Colorectal Cancer Cell Proliferation.
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
p85 Associates with unphosphorylated PTEN and the PTEN-associated complex.
p85? increases phosphoinositide 3-kinase activity and accelerates tumor progression.
p85? neomorphic mutants: splitting away from the canonical path.
p85? phosphoinositide 3-kinase subunit regulates tumor progression.
Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis.
PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas.
pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation.
Pan-class I  PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.
Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs.
Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110?.
Papillary thyroid cancer in a struma ovarii: a report of a rare case.
Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B.
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase ? Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy.
Particular molecular and ultrastructural aspects in invasive mammary carcinoma.
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis.
Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer.
Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients.
Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma.
PD-1/PD-L1-associated immunoarchitectural patterns stratify pancreatic cancer patients into prognostic/predictive subgroups.
PDGF regulated migration of mesenchymal stem cells towards malignancy acts via the PI3K signaling pathway.
Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models.
Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers.
Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors.
Perspective: Potential Impact and Therapeutic Implications of Oncogenic PI3K Activation on Chromosomal Instability.
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer.
Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer cells.
Pharmacologically targeting the myristoylation of the scaffold protein FRS2? inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma.
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies.
Phase I Study of the Anti-Angiogenic Antibody Bevacizumab and the mTOR / Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin.
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer.
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.
Phase II trial of temsirolimus in patients with metastatic breast cancer.
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
PHLPP2 gene L1016S (rs61733127) and PIK3R1 gene Met326Ile (rs3730089) polymorphisms are associated with the risk of colon and breast cancers.
Phospatidylinositol 3-kinase expression in human breast cancer.
Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B-containing lipoproteins.
Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
Phosphatidylinositol 3'-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells.
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.
Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer.
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages.
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells.
Phosphatidylinositol 3-kinase translocates to the nucleus of osteoblast-like MC3T3-E1 cells in response to insulin-like growth factor I and platelet-derived growth factor but not to the proapoptotic cytokine tumor necrosis factor alpha.
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
Phosphatidylinositol Phosphate 5-Kinase I? and Phosphoinositide 3-Kinase/Akt Signaling Couple to Promote Oncogenic Growth.
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation.
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients.
Phosphoinositide 3-kinase ? inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy.
Phosphoinositide 3-kinase beta controls replication factor C assembly and function.
Phosphoinositide 3-kinase inhibition in cancer treatment.
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.
Phosphoinositide 3-kinase inhibitors in lymphoma.
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development.
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Phosphoinositide 3-kinase signaling pathway mediated by p110? regulates invadopodia formation.
Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis.
Phosphoinositide 3-kinase-related overgrowth: cellular phenotype and future therapeutic options.
Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer.
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.
Phosphoinositide 3-kinases as drug targets in cancer.
Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate.
Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers.
Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex.
Phosphorylation of the PTEN tail regulates protein stability and function.
Phylogenetic analysis of combined lobular and ductal carcinoma of the breast.
Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ER?-positive tumors.
Phytochemicals and PI3K Inhibitors in Cancer-An Insight.
PI 3-kinase and cancer: changing accents.
PI 3-kinase, Akt and cell survival.
PI 3-kinase, mTOR, protein synthesis and cancer.
PI 3-kinases: hidden potentials revealed.
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?
PI3-kinase ? promotes Rap1a-mediated activation of myeloid cell integrin ?4?1, leading to tumor inflammation and growth.
PI3-kinase and the control of T cell growth and proliferation by FoxOs.
PI3-kinase pathway biomarkers in oral cancer and tumor immune cells.
PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.
PI3K and cancer: lessons, challenges and opportunities.
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies.
PI3K and RAC signalling in leukocyte and cancer cell migration.
PI3K as a Target for Therapy in Haematological Malignancies.
PI3K expression predicts overall survival in lung adenocarcinoma.
PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment.
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
PI3K inhibitors are finally coming of age.
PI3K inhibitors for cancer therapy: what has been achieved so far?
PI3K inhibitors: review and new strategies.
PI3K mutations in breast cancer: prognostic and therapeutic implications.
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers.
PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression free survival.
PI3K pathway alterations in cancer: variations on a theme.
PI3K Pathway in Gynecologic Malignancies.
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases.
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
PI3K regulatory subunits lose control in cancer.
PI3K signaling in cancer: beyond AKT.
PI3K signaling in glioma--animal models and therapeutic challenges.
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.
PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.
PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer.
PI3K/AKT/Afadin signaling pathway contributes to pathological vascularization in glioblastomas.
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations.
PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.
PI3K? Is a Therapeutic Target in Hepatocellular Carcinoma.
PI3K?? Inhibitor Combined With Radiation Enhances the Antitumor Immune Effect of Anti-PD1 in a Syngeneic Murine Triple-Negative Breast Cancer Model.
PI3KCA Mutations in Uterine Cervix Carcinoma.
PI3Kgamma activation by CXCL12 regulates tumor cell adhesion and invasion.
PI3K{gamma} regulates cartilage damage in chronic inflammatory arthritis.
PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor.
PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
PIK3CA alterations in Middle Eastern ovarian cancers.
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma.
PIK3CA and AKT1 mutations in hidradenoma papilliferum.
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
PIK3CA and p53 Mutations by Next Generation Sequencing in Lymphoepithelioma-Like Carcinoma of the Endometrium.
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.
PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma.
PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney.
PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia.
PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.
PIK3CA as an oncogene in cervical cancer.
PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-? inhibition.
PIK3CA cancer mutations display gender and tissue specificity patterns.
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer.
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
PIK3CA Double Mutations in Cis May Predict PI3K?-Inhibitor Response.
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro.
PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
PIK3CA gene aberrancy and role in targeted therapy of solid malignancies.
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
PIK3CA gene amplification and PI3K p110? protein expression in breast carcinoma.
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma.
PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences.
PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.
PIK3CA gene mutations in breast carcinoma in Malaysian patients.
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma.
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis.
PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies.
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.
PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
PIK3CA in cancer: The past 30 years.
PIK3CA in Colorectal Cancer.
PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells.
PIK3CA is implicated as an oncogene in ovarian cancer.
Pik3ca is required for mouse uterine gland development and pregnancy.
PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.
PIK3CA mutant tumors depend on oxoglutarate dehydrogenase.
PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer.
PIK3CA mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis.
PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
PIK3CA mutation associates with improved outcome in breast cancer.
PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.
PIK3CA mutation detected by liquid biopsy in patients with metastatic breast cancer.
PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.
PIK3CA mutation enrichment and quantitation from blood and tissue.
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups.
PIK3CA mutation in a mixed dysembryoplastic neuroepithelial tumor and rosette forming glioneuronal tumor, a case report and literature review.
PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene.
PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype.
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT).
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
PIK3CA mutation status in Japanese lung cancer patients.
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ER? serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive early breast cancer.
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
PIK3CA Mutational Analysis of Parathyroid Adenomas.
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT.
PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance.
PIK3CA mutations and copy number gains in human lung cancers.
PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis.
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.
PIK3CA Mutations and Their Impact on Survival Outcomes of Patients with Cervical Cancer: A Systematic Review.
PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity.
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
PIK3CA Mutations are Common in Many Tumor Types and are Often Associated With Other Driver Mutations.
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer.
PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer.
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers.
PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes.
PIK3CA mutations in advanced ovarian carcinomas.
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
PIK3CA mutations in breast cancer are associated with poor outcome.
PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.
PIK3CA mutations in hepatocellular carcinoma in Korea.
PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients
PIK3CA Mutations in Hormone Receptor-Positive Breast Cancers: PIKing Biomarkers to Inform Adjuvant Endocrine Therapy Decisions.
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
PIK3CA mutations in in situ and invasive breast carcinomas.
PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population.
PIK3CA mutations in mucinous cystic neoplasms of the pancreas.
PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies.
PIK3CA mutations in oligodendroglial tumours.
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors.
PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers.
PIK3CA Mutations in Resected Small Cell Lung Cancer.
PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
PIK3CA mutations in small bowel adenocarcinoma.
PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
PIK3CA mutations in vascular malformations.
PIK3CA mutations matter for cancer in dogs.
PIK3CA mutations may be discordant between primary and corresponding metastatic disease in Breast Cancer.
PIK3CA Mutations mostly Begin to Develop in Ductal Carcinoma of the Breast.
PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer.
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
Pik3ca mutations significantly enhance the growth of SHH medulloblastoma and lead to metastatic tumour growth in a novel mouse model.
PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma.
PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
PIK3CA somatic mutation in sinonasal teratocarcinosarcoma.
PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer.
PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations.
PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
PIK3CA, a hotspot for postzygotic mutations in nonhereditary overgrowth syndromes.
PIK3CA, HRAS and KRAS Gene Mutations in Human Penile Cancer.
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis.
PIK3CD induces cell growth and invasion by activating AKT/GSK-3?/?-catenin signaling in colorectal cancer.
PIK3CG Is a Potential Therapeutic Target in Androgen Receptor-Indifferent Metastatic Prostate Cancer.
PIK3R1 (p85-alpha/p85{alpha}) is Somatically Mutated at High Frequency in Primary Endometrial Cancer.
PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.
PIKE-A is required for prolactin-mediated STAT5a activation in mammary gland development.
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer.
Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.
PipeIT: A Singularity Container for Molecular Diagnostic Somatic Variant Calling on the Ion Torrent Next-Generation Sequencing Platform.
PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation.
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.
Plasma Circulating Tumor DNA Sequencing Predicts Minimal Residual Disease in Resectable Esophageal Squamous Cell Carcinoma.
Plasma Fibronectin Promotes Tumor Cell Survival and Invasion through Regulation of Tie2.
Plasma metabolomic changes following PI3K inhibition as pharmacodynamic biomarkers: preclinical discovery to Phase I trial evaluation.
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer.
Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells.
POLE somatic mutations in advanced colorectal cancer.
Polymorphic GT dinucleotide repeat in the PIK3CA gene and risk of colorectal cancer.
Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.
Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival.
Posttranscriptional Control of PD-L1 Expression by 17?-Estradiol via PI3K/Akt Signaling Pathway in ER?-Positive Cancer Cell Lines.
Potent anti-cancer activity of Alnus nitida against lung cancer cells; in vitro and in vivo studies.
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer.
Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
Power to see-Drivers of aerobic glycolysis in the mammalian retina: A review.
PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
Pre-clinical validation of a next generation sequencing testing panel.
Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome.
Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice.
Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin.
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Preclinical Pharmacology of AZD5363, an Orally Bioavailable Inhibitor of AKT: Pharmacodynamics, Antitumor Activity and Correlation of Monotherapy Activity with Genetic Background.
Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations.
Predicted Vitamin D Status and Colon Cancer Recurrence and Mortality in CALGB 89803 (Alliance).
Prediction of PIK3CA mutations from cancer gene expression data.
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
Predictors of Lymph Node Count in Colorectal Cancer Resections: Data From US Nationwide Prospective Cohort Studies.
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing.
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Prevalence and architecture of posttranscriptionally impaired synonymous mutations in 8,320 genomes across 22 cancer types.
Prevalence and characteristics of PIK3CA mutation in mismatch repair-deficient colorectal cancer.
Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients.
Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer.
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
Prevention of Tumor Growth Driven by PIK3CA and HPV Oncogenes by Targeting mTOR Signaling with Metformin in Oral Squamous Carcinomas Expressing OCT3.
PREX2 promotes the proliferation, invasion and migration of pancreatic cancer cells by modulating the PI3K signaling pathway.
Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer.
Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.
Pro-inflammatory type-1 and anti-inflammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma T24 cells.
Probable hereditary familial overlap syndrome with multiple synchronous lung tumors.
Probing of breast cancer using a combination of plasma and urinary circulating cell-free DNA.
Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids.
Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Progestin-associated shift of meningioma mutational landscape.
Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.
Prognostic and predictive parameters in breast pathology: a pathologist's primer.
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Prognostic impact of mutation profiling in patients with stage II and III colon cancer.
Prognostic implications of PIK3CA amplification in curatively resected liposarcoma.
Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers.
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review.
Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.
Prognostic Significance and Molecular Associations of Tumor Growth Pattern in Colorectal Cancer.
Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer.
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions.
Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma.
Proliferation of PTEN-deficient haematopoietic tumour cells is not affected by isoform-selective inhibition of p110 PI3-kinase and requires blockade of all class 1 PI3K activity.
Proliferative and antiapoptotic signaling stimulated by nuclear-localized PDK1 results in oncogenesis.
Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3?/?-catenin signalling.
Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab.
Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer.
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.
Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.
Prostate cancer, PI3K, PTEN and prognosis.
Prostate Power Play: Does Pik3ca Accelerate Pten-Deficient Cancer Progression?
Protein interactions of PTEN and its cancer-associated G20E mutant compared by stable isotope labeling by amino acids in cell culture -based parallel affinity purification.
Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival.
Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer.
Protein Kinase C-{alpha} Mediated Regulation of Low-Density Lipoprotein Receptor Related Protein and Urokinase Increases Astrocytoma Invasion.
Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting.
Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer.
Proximity ligation assay to detect and localize the interactions of ER? with PI3-K and Src in breast cancer cells and tumor samples.
PTEN and Other PtdIns(3,4,5)P3 Lipid Phosphatases in Breast Cancer.
PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment.
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy.
PTEN and the PI3-Kinase Pathway in Cancer.
PTEN deficiency contributes to the development and progression of head and neck cancer.
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression.
PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.
PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway.
PTEN is required for the migration and invasion of Ras-transformed MDCK cells.
PTEN loss correlates with T cell exclusion across human cancers.
PTEN M-CBR3, a versatile and selective regulator of inositol 1,3,4,5,6-pentakisphosphate (Ins(1,3,4,5,6)P5). Evidence for Ins(1,3,4,5,6)P5 as a proliferative signal.
PTEN mutations are common in sporadic microsatellite stable colorectal cancer.
PTEN regulate angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells.
PTEN regulates cilia through Dishevelled.
PTEN regulation of ERK1/2 signaling in cancer.
PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
PTEN, more than the AKT pathway.
PTEN-Associated Complexes: An Overview.
PTEN-deficient cancers depend on PIK3CB.
PTEN-mediated AKT activation contributes to the reduced apoptosis among Indian oral squamous cell carcinoma patients.
Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction.
PTHrP increases xenograft growth and promotes integrin alpha6beta4 expression and Akt activation in colon cancer.
Pulmonary adenocarcinoma with psammoma bodies is associated with a specific endobronchial ultrasound pattern and a high prevalence of actionable driver mutations.
Pulmonary Adenocarcinoma With Signet Ring Cell Features: A Comprehensive Study From 3 Distinct Patient Cohorts.
Putting the rap on Akt.
Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours.
R-Ras promotes tumor growth of cervical epithelial cells.
Racial Disparities in the Molecular Landscape of Cancer.
Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay.
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors.
Ramentaceone, a Naphthoquinone Derived from Drosera sp., Induces Apoptosis by Suppressing PI3K/Akt Signaling in Breast Cancer Cells.
Ran GTPase in Nuclear Envelope Formation and Cancer Metastasis.
Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing.
Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling.
Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
Rare genetic heterogeneity within single tumor discovered for the first time in colorectal liver metastases after liver resection.
Rare Mutations in the PIK3CA Gene Contribute to Aggressive Endometrial Cancer.
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression.
Rational design of phosphoinositide 3-kinase ? inhibitors that exhibit selectivity over the phosphoinositide 3-kinase ? isoform.
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.
Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology.
Recent discovery of phosphoinositide 3-kinase ? inhibitors for the treatment of immune diseases and cancers.
Recent Patents and Advances in Genomic Biomarker Discovery for Colorectal Cancers.
Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Recent progess in phosphoinositide 3-kinases: oncogenic properties and prognostic and therapeutic implications.
Recent therapeutic advances in the treatment of colorectal cancer.
Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3k?, a single convergent point promoting tumor inflammation and progression.
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.
Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.
Recurrent PIK3CA mutations in rosette-forming glioneuronal tumor.
Redox regulation of PI 3-kinase signalling via inactivation of PTEN.
Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations.
Regulation and repurposing of nutrient sensing and autophagy in innate immunity.
Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells.
Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression.
Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Regulation of dauer larva development in Caenorhabditis elegans by daf-18, a homologue of the tumour suppressor PTEN.
Regulation of heart rate and the pacemaker current by phosphoinositide 3-kinase signaling.
Regulation of human neutrophil-mediated cartilage proteoglycan degradation by phosphatidylinositol-3-kinase.
Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Regulation of mRNA Translation by Signaling Pathways.
Regulation of multidrug resistance in cancer cells by hyaluronan.
Regulation of phosphoinositide 3-kinase expression in health and disease.
Regulation of PI 3-K, PTEN, p53, and mTOR in Malignant and Benign Tumors Deficient in Tuberin.
Regulation of SCF(SKP2) ubiquitin E3 ligase assembly and p27(KIP1) proteolysis by the PTEN pathway and cyclin D1.
Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.
Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells.
Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.
Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations.
Relationship between mismatch repair protein, RAS, BRAF, PIK3CA gene expression and clinicopathological characteristics in elderly colorectal cancer patients.
Relationship Between PIK3CA Amplification and P110? and CD34 Tissue Expression as Angiogenesis Markers in Iranian Women with Sporadic Breast Cancer.
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
Requirement for interaction of PI3-kinase p110? with RAS in lung tumor maintenance.
Requirement of phosphatidylinositol 3-kinase activity for bradykinin stimulation of NF-kappaB activation in cultured human epithelial cells.
Research Strategies for Low-Survival Cancers.
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report.
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors.
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Revealing tumor heterogeneity of breast cancer by utilizing the linkage between somatic and germline mutations.
Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer.
Review of natural compounds for potential skin cancer treatment.
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Riedel's thyroiditis - a case report with genes' expression studies.
Risk factors for brain metastases in patients with metastatic colorectal cancer.
Rlip Depletion Suppresses Growth of Breast Cancer.
RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer.
RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives.
Role of c-Met in cancer: emphasis on lung cancer.
Role of Cadherins in Cancer-A Review.
Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Role of estrogen in lung cancer based on the estrogen receptor-epithelial mesenchymal transduction signaling pathways.
Role of Forkhead Box Class O proteins in cancer progression and metastasis.
Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.
Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737.
Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
Role of phosphoinositide 3-kinase in adhesion of platelets to fibrinogen stimulated by cancer procoagulant.
Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells.
Role of PTEN/PI3K pathway in endothelial cells.
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines.
Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications.
Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis.
Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis.
Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.
Rosette forming glioneuronal tumor in the optico-chiasmatic region-a novel entity in a new location.
Rosette-Forming Glioneuronal Tumor in the Pineal Region: A Series of 6 Cases and Literature Review.
Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1.
Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
RTK-dependent inducible degradation of mutant PI3K? drives GDC-0077 (Inavolisib) efficacy.
S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis.
SABCS 2016: systemic therapy for metastatic breast cancer.
Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway.
Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.
Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.
SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice.
Scaffolding Function of PI3Kgamma Emerges from Enzyme's Shadow.
Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current.
Screening for PIK3CA mutations among Saudi women with ovarian cancer.
Screening key genes and miRNAs in early-stage colon adenocarcinoma by RNA-sequencing.
Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro.
Search for mutations in signaling pathways in head and neck squamous cell carcinoma.
Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells.
Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation.
Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer.
Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.
Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.
Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas.
Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells.
Sequence Mutations and Amplification of PIK3CA and AKT2 Genes in Purified Ovarian Serous Neoplasms.
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils.
Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.
SGK2 promotes hepatocellular carcinoma progression and mediates GSK-3?/?-catenin signaling in HCC cells.
SGK3 (CISK) may induce tumor angiogenesis (Hypothesis).
SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.
Should individual PI3 kinase isoforms be targeted in cancer?
Sialadenoma Papilliferum of the Bronchus: An Unrecognized Bronchial Counterpart of the Salivary Gland Tumor With Frequent BRAF V600E Mutations.
Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin.
Signaling pathways in HPV-associated cancers and therapeutic implications.
Signalling specificity in the Akt pathway in breast cancer.
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers.
Silencing TAK1 alters gene expression signatures in bladder cancer cells.
Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing.
Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Single Cell RNA-Seq Analysis Identifies Differentially Expressed Genes of Treg Cell in Early Treatment-Naive Rheumatoid Arthritis By Arsenic Trioxide.
Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
Single nucleotide polymorphism of PIK3CA and its interaction with the environment are risk factors for Chinese Han ovarian cancer.
Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification.
Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Single-Dose Neoadjuvant AKT Pathway Inhibitor Reduces Growth of Hepatocellular Carcinoma after Laser Thermal Ablation in Small-Animal Model.
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.
Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27.
Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.
SMARCB1 (INI1)-negative Rhabdoid Carcinomas of the Gastrointestinal Tract: Clinicopathologic and Molecular Study of a Highly Aggressive Variant With Literature Review.
Smoking Status at Diagnosis and Colorectal Cancer Prognosis According to Tumor Lymphocytic Reaction.
SNP variants at the MAP3K1/SETD9 locus 5q11.2 associate with somatic PIK3CA variants in breast cancers.
Solid Papillary Breast Carcinomas Resembling the Tall Cell Variant of Papillary Thyroid Neoplasms (Solid Papillary Carcinomas with Reverse Polarity) Harbor Recurrent Mutations Affecting IDH2 and PIK3CA: A Validation Cohort.
Somatic alterations in the human cancer genome.
Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 were associated with chemosensitivity for breast cancers.
Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping.
Somatic Host Cell Alterations in HPV Carcinogenesis.
Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
Somatic Mutation of PIK3CA (H1047R) Is a Common Driver Mutation Hotspot in Canine Mammary Tumors as Well as Human Breast Cancers.
Somatic mutation of PIK3R1 gene is rare in common human cancers.
Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma.
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.
Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis.
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.
Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas.
Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.
Somatic mutations in the notch, NF-KB, PIK3CA, and hedgehog pathways in human breast cancers.
Somatic mutations of PIK3R1 promote gliomagenesis.
Somatic mutations of triple-negative breast cancer: a comparison between Black and White women.
Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next?
Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer.
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma.
Spatiotemporal genomic architecture informs precision oncology in glioblastoma.
Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST).
Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.
Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells.
Src Cooperates with Oncogenic Ras in Tumourigenesis via the JNK and PI3K Pathways in Drosophila epithelial Tissue.
Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism.
Starving PTEN-deficient prostate cancer cells thrive under nutrient stress by scavenging corpses for their supper.
Stimulation of PI 3-kinase signaling via inhibition of the tumor suppressor phosphatase, PTEN.
Stoichiometric quantification of Akt phosphorylation using LC-MS/MS.
Stopping ras in its tracks.
Stromal resistance of fibroblasts against oxidative damage: involvement of tumor cell-secreted platelet-derived growth factor (PDGF) and phosphoinositide 3-kinase (PI3K) activation.
Stromal signatures in endometrioid endometrial carcinomas.
Structural comparisons of class I phosphoinositide 3-kinases.
Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein.
Structure of the phosphoinositide 3-kinase (PI3K) p110?-p101 complex reveals molecular mechanism of GPCR activation.
Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.
Structure-Based Drug Design and Synthesis of PI3K?-Selective Inhibitor (PF-06843195).
Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
Structure-based virtual screening approach to the discovery of phosphoinositide 3-kinase alpha inhibitors.
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Subclonal diversification of primary breast cancer revealed by multiregion sequencing.
Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing: challenges and possible solutions.
Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy.
Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression.
Successful targeting of ErbB2 receptors-is PTEN the key?
Suppression of CD4+ T lymphocyte activation in vitro and experimental encephalomyelitis in vivo by the phosphatidyl inositol 3-kinase inhibitor PIK-75.
Suppression of epidermal growth factor receptor-mediated ?-catenin nuclear accumulation enhances the anti-tumor activity of phosphoinositide 3-kinase inhibitor in breast cancer.
Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
Surgical resection of breast cancers: Molecular analysis of cancer stem cells in residual disease.
Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.
Survival prediction model for non-small cell lung cancer based on somatic mutations.
Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer.
Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.
Synchronous rosette-forming glioneuronal tumor and diffuse astrocytoma with molecular characterization: a case report.
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
Synergistic interactions with PI3K inhibition that induce apoptosis.
Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors.
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.
Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.
Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy.
Systematic functional characterization of resistance to PI3K inhibition in breast cancer.
Systemic therapy for gallbladder cancer.
Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer.
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
T-Cell-Specific Loss of the PI-3-Kinase p110? Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response.
Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.
Target sequencing of cancer-related genes in early esophageal squamous neoplasia resected by endoscopic resection in Japanese patients.
Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations.
Target-Enriched Next-Generation Sequencing Reveals Differences between Primary and Secondary Ovarian Tumors in Formalin-Fixed, Paraffin-Embedded Tissue.
Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.
Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer.
Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models.
Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas.
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity.
Targeted Sequencing of Taiwanese Breast Cancer with Risk Stratification by the Concurrent Genes Signature: A Feasibility Study.
Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.
Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
Targeted treatment and new agents in follicular lymphoma.
Targeting ?-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations.
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant.
Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma.
Targeting disease through novel pathways of apoptosis and autophagy.
Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response.
Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition.
Targeting EGFR and PI3K pathways in ovarian cancer.
Targeting HER2 heterogeneity in early-stage breast cancer.
Targeting kinases with thymoquinone: a molecular approach to cancer therapeutics.
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Targeting mTOR signaling in lung cancer.
Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.
Targeting PDK1 in cancer.
Targeting phosphatidylinositol 3-kinase gamma (PI3K?): Discovery and development of its selective inhibitors.
Targeting phosphoinositide 3-kinase signalling in lung cancer.
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma.
Targeting PI3K in neuroblastoma.
Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy.
Targeting protein kinase inhibitors with Traditional Chinese Medicine.
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.
Targeting the genetic landscape of oral potentially malignant disorders has the potential as a preventative strategy in oral cancer.
Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application.
Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer.
Targeting the Phosphatidyl Inositol 3-Kinase Signaling Pathway in Breast Cancer.
Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.
Targeting the phosphoinositide 3-kinase p110-? isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
Targeting the phosphoinositide 3-kinase pathway in cancer.
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
Targeting the PI3K signaling pathway in cancer.
Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.
Targeting truncated retinoid X receptor-? by CF31 induces TNF-?-dependent apoptosis.
Targeting truncated RXR? for cancer therapy.
Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.
TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma.
Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer.
The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.
The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.
The anticancer activities of Vernonia amygdalina Delile. Leaves on 4T1 breast cancer cells through phosphoinositide 3-kinase (PI3K) pathway.
The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network.
The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia.
The cell biology behind the oncogenic PIP3 lipids.
The chromosome 3q26 OncCassette: A multigenic driver of human cancer.
The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer.
The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
The conundrum of the Epstein-Barr virus-associated gastric carcinoma in the Americas.
The CTLH Complex in Cancer Cell Plasticity.
The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase ?
The double life of p85.
The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression.
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas.
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.
The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.
The effect of reactive oxygen species on the synthesis of prostanoids from arachidonic acid.
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
The evolving genomic landscape of urothelial carcinoma.
The fate of BRCA1-related germline mutations in triple-negative breast tumors.
The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer.
The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
The FOXO1-miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma.
The frequent co-expression of the oncogenes PIK3CA and PAK1 in oral carcinomas.
The genetic landscape of 87 ovarian germ cell tumors.
The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
The Genomic Landscape of Lobular Breast Cancer.
The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.
The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients.
The genomics and epigenetics of olfactory neuroblastoma: A?systematic review.
The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor alpha-mediated apoptosis by activation of phosphoinositol 3-kinase and beta-catenin.
The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor {alpha}-mediated apoptosis by activation of phosphoinositol 3-kinase and {beta}-catenin.
The Hidden Conundrum of Phosphoinositide Signaling in Cancer.
The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients.
The Hippo signal transduction pathway in soft tissue sarcomas.
The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC).
The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation.
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells.
The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells.
The INPP4B paradox: Like PTEN, but different.
The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.
The introduction of systematic genomic testing for patients with non-small-cell lung cancer.
The KEAP1-NRF2 System in Cancer.
The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136.
The Landscape of PIK3CA Mutations in Colorectal Cancer.
The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis.
The merlin interacting proteins reveal multiple targets for NF2 therapy.
The Metabolic Mechanisms of Breast Cancer Metastasis.
The metastasis suppressor protein NM23-H1 modulates the PI3K-AKT axis through interaction with the p110? catalytic subunit.
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.
The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel.
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.
The mutational burdens and evolutionary ages of early gastric cancers are comparable to those of advanced gastric cancers.
The mutational landscape of head and neck squamous cell carcinoma.
The mutational landscape of the SCAN-B real-world primary breast cancer transcriptome.
The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia.
The Occurrence of Genetic Alterations during the Progression of Breast Carcinoma.
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
The Opposing Roles of PIK3R1/p85? and PIK3R2/p85? in Cancer.
The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation.
The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion.
The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN.
The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis.
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes quiescent but not proliferating MG-63 human osteosarcoma cells to radiation.
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
The phosphoinositide 3-kinase pathway and cancer.
The phosphoinositide 3-kinase pathway and therapy resistance in cancer.
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.
The Phosphoinositide 3-Kinase Pathway Is Crucial for the Growth of Canine Mast Cell Tumors.
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.
The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck.
The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression.
The phosphoinositide 3-kinase/akt1/par-4 axis: a cancer-selective therapeutic target.
The PI3K inhibitor arsenal: choose your weapon!
The PI3K pathway at the crossroads of cancer and the immune system: strategies for next generation immunotherapy combinations.
The PI3K Pathway in Human Disease.
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.
The PI3K/AKT Pathway as a Target for Cancer Treatment.
The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma.
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.
The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.
The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the ?-catenin/SIRT3 signaling pathway in cervical cancer.
The PIK3CA gene as a mutated target for cancer therapy.
The PIK3CA gene is mutated with high frequency in human breast cancers.
The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells.
The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer.
The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
The prevalence of PIK3CA mutations in gastric and colon cancer.
The Prognostic Value of PIK3CA Copy Number Gain in Penile Cancer.
The promise of combining inhibition of PI3K and PARP as cancer therapy.
The PTEN and Myotubularin Phosphoinositide 3-Phosphatases: Linking Lipid Signalling to Human Disease.
The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells.
The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity.
The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling.
The PTEN-PI3K pathway: of feedbacks and cross-talks.
The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene.
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.
The Ras-association domain family (RASSF) members and their role in human tumourigenesis.
The Rational Design of Selective Benzoxazepin Inhibitors of the ?-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB.
The relation between PI3K/AKT signalling pathway and cancer.
The role of aspirin in colorectal cancer chemoprevention.
The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma.
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.
The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells.
The Role of PI3K Inhibition in Lymphoid Malignancies.
The roles of microbial products in the development of colorectal cancer: a review.
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State.
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.
The Specificity of EGF-Stimulated IQGAP1 Scaffold Towards the PI3K-Akt Pathway is Defined by the IQ3 motif.
The stem cell factor (SCF)/c-KIT signalling in testis and prostate cancer.
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
The suppressive effect of Rho kinase inhibitor, Y-27632, on oncogenic Ras/RhoA induced invasion/migration of human bladder cancer TSGH cells.
The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors.
The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.
The transcriptional landscape and mutational profile of lung adenocarcinoma.
The transforming functions of PI3-kinase-gamma are linked to disruption of intercellular adhesion and promotion of cancer cell invasion.
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.
The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma.
Therapeutic benefit of selective inhibition of p110? PI3-kinase in pancreatic neuroendocrine tumors.
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.
Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR.
Therapeutic potential of nvp-bkm120 in human osteosarcomas cells.
Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
Therapeutic targets for cancer: current concepts with PI 3-K, Akt, & mTOR.
Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.
TIMP-3 and Phosphatidylinositol 3-kinase genes were found to be related to the progression of colon cancer in a comparison of pneumoperitoneum and laparotomy in a murine model.
Tks5-dependent formation of circumferential podosomes/invadopodia mediates cell-cell fusion.
Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.
TPIP: a novel phosphoinositide 3-phosphatase.
Tracking the Evolution of Non-Small-Cell Lung Cancer.
Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
TRAF6 interacts with and ubiquitinates PIK3CA to enhance PI3K activation.
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).
Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer.
Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment.
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer.
Transforming acidic coiled coil 1 promotes transformation and mammary tumorigenesis.
Transient Inhibition of PI3K? Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus.
Translational control by oncogenic signaling pathways.
Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models.
Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.
Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate.
Triggering PIK3CA mutations in PI3K/AKT/mTOR axis: Exploration of newer inhibitors and rational preventive strategies.
Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.
TTF-1 Positive Primary Small Cell Carcinoma of the Breast: A Case Report and Review of the Literature.
Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours.
Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.
Tumor expression of calcium sensing receptor and colorectal cancer survival: Results from the nurses' health study and health professionals follow-up study.
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.
Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.
Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival.
Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan.
Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.
Tumor Necrosis Factor-? Promotes Phosphoinositide 3-Kinase Enhancer A and AMP-Activated Protein Kinase Interaction to Suppress Lipid Oxidation in Skeletal Muscle.
Tumor necrosis factor-alpha inhibits differentiation of myogenic cells in human urethral rhabdosphincter.
Tumor necrosis factor-alpha protects synovial cells from nitric oxide induced apoptosis through phosphoinositide 3-kinase Akt signal transduction.
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
Tumor SQSTM1 (p62) expression and T cells in colorectal cancer.
Tumor suppression and promotion by autophagy.
Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer.
Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer.
Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.
Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function.
Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.
Type I to Type II Ovarian Carcinoma Progression: Mutant Trp53 or Pik3ca Confers a More Aggressive Tumor Phenotype in a Mouse Model of Ovarian Cancer.
Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.
Ultra-selection of metastatic colorectal cancer patients using Next Generation Sequencing to improve clinical efficacy of anti-EGFR therapy.
Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry.
Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers.
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
Understanding PTEN regulation: PIP2, polarity and protein stability.
Understanding the relative affinity and specificity of the pleckstrin homology domain of protein kinase B for inositol phosphates.
Undetectable Tumor Cell-Free DNA in a Patient With Metastatic Breast Cancer With Complete Response and Long-Term Remission.
Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis.
Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
Unique clinicopathologic and genetic alteration features in early onset colorectal carcinoma (CRC) compared to age-related CRC: large cohort next generation sequence analysis.
Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes.
Up-regulation of ras-GAP genes is reversed by a MEK inhibitor and doxorubicin in v-Ki-ras-transformed NIH/3T3 fibroblasts.
Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer.
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Upregulation of microRNA-31 targeting integrin ?5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells.
Upregulation of pAKT(Ser473) expression is involved in progression of HPV-positive oropharyngeal squamous cell carcinoma.
Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis.
Use of mutation profiles to refine the classification of endometrial carcinomas.
Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting a treatment outcomes of non-small cell lung cancer.
Using isoform-specific inhibitors to target lipid kinases.
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
V-ATPase controls tumor growth and autophagy in a Drosophila model of gliomagenesis.
Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study.
Vanillin suppresses metastatic potential of human cancer cells through PI3K inhibition and decreases angiogenesis in vivo.
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.
VIP induces NF-?B1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.
Von Hippel-Lindau tumor suppressor (VHL) stimulates TOR signaling by interacting with phosphoinositide 3-kinase (PI3K).
VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-?B activity in B cell precursor-acute lymphoblastic leukemia.
Vulvar Pilomatrix Carcinoma: Morphologic and Molecular Features.
Vulvar squamous cell carcinoma (VSCC) as two diseases: HPV status identifies distinct mutational profiles including oncogenic fibroblast growth factor receptor 3.
Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets.
Water extract from Pleurotus pulmonarius with antioxidant activity exerts in vivo chemoprophylaxis and chemosensitization for liver cancer.
Water-soluble HPMA copolymer-wortmannin conjugate retains phosphoinositide 3-kinase inhibitory activity in vitro and in vivo.
Weight Loss via exercise with controlled dietary intake may affect phospholipid profile for cancer prevention in murine skin tissues.
What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.
What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?
Whole exome sequencing of adenoid cystic carcinoma.
Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma.
Whole-exome sequencing identified mutational profiles of high-grade colon adenomas.
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Will Kinase Inhibitors Make it as Glioblastoma Drugs?
WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
Worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer: A systematic review and meta-analysis.
XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis.
Yeast-based methods to assess PTEN phosphoinositide phosphatase activity in vivo.
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
YM155 exerts a growth inhibitory effect on human osteosarcoma in vitro and in vivo.
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms.
[11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers.
[18F]-FLT Positron Emission Tomography can be used to image the response of sensitive tumors to PI3-Kinase inhibition with the novel agent GDC-0941.
[Activation of phosphatidylinositol 3-kinase in human breast carcinoma]
[Androgen receptor-positive triple negative breast cancer: From biology to therapy].
[Aspirin and colorectal cancer].
[BRAF-positive paucicellular variant of anaplastic carcinoma in the presence of tall cell variant papillary thyroid cancer].
[Ca2+ is involved in tumor necrosis factor-alpha induced cardiomyocyte hypertrophy through PI3-kinase pathway in rats].
[Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
[Correlation between the incidence of PIK3CA mutations in breast cancer and histopathological characteristics of the tumor].
[Current Possibilities for Predicting Responses to EGFR Blockade in Metastatic Colorectal Cancer].
[Ductal adenocarcinoma of the pancreas: subtypes and molecular pathology].
[Effect of moxa-burning heat stimulating Liangmen (ST 21) and Zusanli (ST 36) on proliferation and apoptosis signaling proteins in rats with stress-induced gastric ulcer].
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
[Molecular analysis of sporadic colon cancer].
[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
[PI3 kinases and the control of autophagia]
[PIK3CA mutation analysis in isolated macrodactyly].
[PIK3CA mutations in the most common types of cancer].
[Point somatic mutations in bladder cancer: key carcinogenesis events, diagnostic markers and therapeutic targets].
[Scanning for KRAS, NRAS, BRAF, and PIK3CA mutations by DNA melting analysis with TaqMan probes].
[Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma]
[Signal transduction in urothelial cancer : How exactly do we know the targets for targeted therapy?]
[The expression of PIK3CA in nasopharyngeal carcinoma].
Neoplasms, Basal Cell
CTNNB1 mutations in basal cell adenoma of the salivary gland.
Neoplasms, Germ Cell and Embryonal
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Neoplasms, Neuroepithelial
PIK3CA mutation in a mixed dysembryoplastic neuroepithelial tumor and rosette forming glioneuronal tumor, a case report and literature review.
Neoplasms, Second Primary
PI3K/Akt/mTOR signalling pathway activation in patients with ER-positive, metachronous, contralateral breast cancer treated with hormone therapy.
Neoplasms, Squamous Cell
Associations of PI3KR1 and mTOR Polymorphisms with Esophageal Squamous Cell Carcinoma Risk and Gene-Environment Interactions in Eastern Chinese Populations.
Carcinogenesis of PIK3CA.
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors.
Upregulation of pAKT(Ser473) expression is involved in progression of HPV-positive oropharyngeal squamous cell carcinoma.
Neoplastic Cells, Circulating
Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
miR?10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Neoplastic Processes
Riedel's thyroiditis - a case report with genes' expression studies.
Nephritis
Signal transduction involved in protective effects of 15(R/S)-methyl- lipoxin A(4) on mesangioproliferative nephritis in rats.
[Protective effects of 15-methyl-lipoxin A4 on mesangioproliferative nephritis in rats]
Nervous System Diseases
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.
Neuralgia
Celecoxib reverts oxaliplatin-induced neuropathic pain through inhibiting PI3K/Akt2 pathway in the mouse dorsal root ganglion.
ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain.
Resveratrol inhibits paclitaxel-induced neuropathic pain by the activation of PI3K/Akt and SIRT1/PGC1? pathway.
Treatment With the Delta Opioid Agonist UFP-512 Alleviates Chronic Inflammatory and Neuropathic Pain: Mechanisms Implicated.
Neurilemmoma
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L.
Neuritis
Class I PI3K inhibitor ZSTK474 attenuates experimental autoimmune neuritis by decreasing the frequency of Th1/Th17 cells and reducing the production of proinflammatory cytokines.
Neuritis, Autoimmune, Experimental
Class I PI3K inhibitor ZSTK474 attenuates experimental autoimmune neuritis by decreasing the frequency of Th1/Th17 cells and reducing the production of proinflammatory cytokines.
Neuroblastoma
Activation of Akt predicts poor outcome in neuroblastoma.
Activation of phosphatidylinositol 3-kinase by cellular prion protein and its role in cell survival.
Actovegin reduces the hydrogen peroxide-induced cell apoptosis of SK-N-SH neuroblastoma by means of p38MAPK and PI-3K inhibition.
Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas.
Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway.
Childhood tumors of the nervous system as disorders of normal development.
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Cofilin activity during insulin-like growth factor I-stimulated neuroblastoma cell motility.
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Cypermethrin Activates Autophagosome Formation Albeit Inhibits Autophagy Owing to Poor Lysosome Quality: Relevance to Parkinson's Disease.
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours.
Expression of CD44 isoforms in neuroblastoma cells is regulated by PI 3-kinase and protein kinase C.
FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma.
GDNF family receptor alpha 2 promotes neuroblastoma cell proliferation by interacting with PTEN.
Genetic alterations in lung adenocarcinoma with a micropapillary component.
Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody.
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Hydrogen Sulfide-Induced Processing of the Amyloid Precursor Protein in SH-SY5Y Human Neuroblastoma Cells Involves the PI3-K/Akt Signaling Pathway.
Hypothalamic serotonin-insulin signaling cross-talk and alterations in a type 2 diabetic model.
Inhibition of neuroblastoma cell phosphatidylinositol 3-kinase by CDP-diacylglycerol and phosphatidate.
Inhibition of transforming growth factor-beta/Smad signaling by phosphatidylinositol 3-kinase pathway.
Insulin-like growth factor-I-dependent signal transduction pathways leading to the induction of cell growth and differentiation of human neuroblastoma cell line SH-SY5Y: the roles of MAP kinase pathway and PI 3-kinase pathway.
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.
Mutations in PIK3CA are infrequent in neuroblastoma.
Oestradiol regulates ?-catenin-mediated transcription in neurones.
OncomiRs: the discovery and progress of microRNAs in cancers.
Phosphoinositide 3-kinase is required for bombesin-induced enhancement of fear memory consolidation in the hippocampus.
PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
PKC and Raf-1 inhibition-related apoptotic signalling in N2a cells.
Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition.
Silencing Intersectin 1 Slows Orthotopic Neuroblastoma Growth in Mice.
Targeting PI3K in neuroblastoma.
Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.
VEGF-mediated survivin expression in neuroblastoma cells.
Neurocutaneous Syndromes
Ophthalmic Alterations in the Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome, and the Phakomatosis Pigmentovascularis: An Independent Group of Conditions?
Neurodegenerative Diseases
A pilot study on the effect of lactoferrin on Alzheimer's disease pathological sequelae: Impact of the p-Akt/PTEN pathway.
Driving neural regeneration through the mammalian target of rapamycin.
Erythropoietin: new directions for the nervous system.
Flavonoids Isolated from Flowers of Lonicera japonica Thunb. Inhibit Inflammatory Responses in BV2 Microglial Cells by Suppressing TNF-? and IL-? Through PI3K/Akt/NF-kb Signaling Pathways.
Neuroprotective effects of estrogens: cross-talk between estrogen and intracellular insulin signalling.
Novel compounds for the modulation of mTOR and autophagy to treat neurodegenerative diseases.
Oxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade.
Phosphatidylinositol 3-kinase: increased activity and protein level in amyotrophic lateral sclerosis.
Phosphoinositide 3-kinase inhibitor AS605240 ameliorates streptozotocin-induced Alzheimer's disease like sporadic dementia in experimental rats.
Neuroectodermal Tumors, Primitive
Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.
Neuroendocrine Tumors
Therapeutic benefit of selective inhibition of p110? PI3-kinase in pancreatic neuroendocrine tumors.
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Updates and management algorithm for neuroendocrine tumors of the uterine cervix.
Neurofibroma
Neurofibromin-deficient Schwann cells have increased lysophosphatidic acid dependent survival and migration-implications for increased neurofibroma formation during pregnancy.
Neurofibromatoses
"Wild type" GIST: Clinicopathological features and clinical practice.
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Neurofibromatosis 1
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Neurofibrosarcoma
CXCR4/CXCL12 Mediate Autocrine Cell- Cycle Progression in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
Targeting the PI3K/mTOR Axis, Alone and in Combination with Autophagy Blockade, for the Treatment of Malignant Peripheral Nerve Sheath Tumors.
Neuroinflammatory Diseases
Impact of ambient temperature on inflammation-induced encephalopathy in endotoxemic mice-role of phosphoinositide 3-kinase gamma.
Induction of Neuronal PI3K? Contributes to Endoplasmic Reticulum Stress and Long-Term Functional Impairment in a Murine Model of Traumatic Brain Injury.
p110? PI 3-kinase inhibition perturbs APP and TNF? trafficking, reduces plaque burden, dampens neuroinflammation and prevents cognitive decline in an Alzheimer's disease mouse model.
Phosphoinositide 3-Kinase ? Restrains Neurotoxic Effects of Microglia After Focal Brain Ischemia.
PI3K? inhibition reduces TNF secretion and neuroinflammation in a mouse cerebral stroke model.
Neuroma
Congenital infiltrating lipomatosis of the face with lingual mucosal neuromas associated with a PIK3CA mutation.
Somatic PIK3CA mutations are present in multiple tissues of facial infiltrating lipomatosis.
Neuroma, Acoustic
Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.
Nevus
Analysis of mutations in the PIK3CA and FGFR3 genes in verrucous epidermal nevus.
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Clonality of basal cell carcinoma arising in an epidermal nevus. New insights provided by molecular analysis.
Cloves Syndrome: A Rare Disorder of Overgrowth with Unusual Features - An Uncommon Phenotype?
Giant congenital melanocytic nevus with vascular malformation and epidermal cysts associated with a somatic activating mutation in BRAF.
Keratinocytic epidermal nevus with ipsilateral breast hypoplasia.
Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS.
Molecular heterogeneity of the cerebriform connective tissue nevus in mosaic overgrowth syndromes.
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.
PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum.
Sonographic screening for Wilms tumor in children with CLOVES syndrome.
[PIK3CA-related overgrowth syndrome (PROS)].
Nevus, Pigmented
The absence of BRAF, FGFR3, and PIK3CA mutations differentiates lentigo simplex from melanocytic nevus and solar lentigo.
Nevus, Sebaceous of Jadassohn
Analysis of mutations in the PIK3CA and FGFR3 genes in verrucous epidermal nevus.
Niemann-Pick Disease, Type C
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Niemann-Pick Diseases
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Non-alcoholic Fatty Liver Disease
Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease.
Noonan Syndrome
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Obesity
Attenuated Pik3r1 Expression Prevents Insulin Resistance and Adipose Tissue Macrophage Accumulation in Diet-Induced Obese Mice.
Changes in DNA Methylation and Gene Expression of Insulin and Obesity-Related Gene PIK3R1 after Roux-en-Y Gastric Bypass.
Deficiency of phosphoinositide 3-kinase enhancer protects mice from diet-induced obesity and insulin resistance.
Dysfunction of human subcutaneous FAT arterioles in obesity associated or not with Type 2 diabetes.
Enhanced insulin-stimulated activation of phosphatidylinositol 3-kinase in the liver of high-fat-fed rats.
Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance.
Inhibition of phosphoinositide 3-kinase ? attenuates inflammation, obesity, and cardiovascular risk factors.
Meta-analysis approach identifies candidate genes and associated molecular networks for type-2 diabetes mellitus.
Obesity, insulin resistance and hepatic perfusion.
Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice.
Phosphoinositide-specific inositol polyphosphate 5-phosphatase IV inhibits inositide trisphosphate accumulation in hypothalamus and regulates food intake and body weight.
Rapid depot-specific activation of adipocyte precursor cells at the onset of obesity.
Selective impairment of insulin signalling in the hypothalamus of obese Zucker rats.
Specific knockout of p85? in brown adipose tissue induces resistance to high-fat diet-induced obesity and its metabolic complications in male mice.
The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage.
The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance.
The PI3K pathway preserves metabolic health through MARCO-dependent lipid uptake by adipose tissue macrophages.
Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity and dyslipidaemia by increased energy expenditure.
Obesity, Morbid
Attenuated Pik3r1 Expression Prevents Insulin Resistance and Adipose Tissue Macrophage Accumulation in Diet-Induced Obese Mice.
Oculocerebrorenal Syndrome
The phosphoinositide 3-kinase inhibitor alpelisib restores actin organization and improves proximal tubule dysfunction in vitro and in a mouse model of Lowe syndrome and Dent disease.
Oligodendroglioma
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.
Oncogene Addiction
Emerging therapeutic targets in endometrial cancer.
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Oropharyngeal Neoplasms
High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer.
Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers.
Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer.
Osteoarthritis
Overexpression of microRNA-634 suppresses survival and matrix synthesis of human osteoarthritis chondrocytes by targeting PIK3R1.
TNF-? increases the expression of inflammatory factors in synovial fibroblasts by inhibiting the PI3K/AKT pathway in a rat model of monosodium iodoacetate-induced osteoarthritis.
Osteoarthritis, Knee
A treatment combined prussian blue nanoparticles with low-intensity pulsed ultrasound alleviates cartilage damage in knee osteoarthritis by initiating PI3K/Akt/mTOR pathway.
Osteolysis
Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
The USP14-NLRC5 pathway inhibits titanium particle-induced osteolysis in mice by suppressing NF-?B and PI3K/AKT activities.
Osteosarcoma
Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway.
Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma.
HGK-sestrin 2 signaling-mediated autophagy contributes to antitumor efficacy of Tanshinone IIA in human osteosarcoma cells.
Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha.
Knockdown of autophagy-related protein 6, Beclin-1, decreases cell growth, invasion, and metastasis and has a positive effect on chemotherapy-induced cytotoxicity in osteosarcoma cells.
MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA.
Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy.
Phosphatidylinositol 3-kinase translocation to the nucleus is induced by interleukin 1 and prevented by mutation of interleukin 1 receptor in human osteosarcoma Saos-2 cells.
PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma in a Chinese population.
Probable hereditary familial overlap syndrome with multiple synchronous lung tumors.
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Short Hairpin RNA (shRNA) Ether à go-go 1 (Eag1) Inhibition of Human Osteosarcoma Angiogenesis via VEGF/PI3K/AKT Signaling.
VEGF silencing inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via PI3K/AKT signaling pathway.
VEGF Silencing Inhibits Human Osteosarcoma Angiogenesis and Promotes Cell Apoptosis via PI3K/AKT Signaling Pathway.
Ovarian Cysts
PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy.
Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer.
Ovarian Neoplasms
(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.
Aberrant methylation of breast and ovarian cancer susceptibility gene 1 in chemosensitive human ovarian cancer cells does not involve the phosphatidylinositol 3'-kinase-Akt pathway.
Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma.
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Activation of the MEK-S6 Pathway in High-grade Ovarian Cancers.
Amplification of USP13 drives ovarian cancer metabolism.
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.
beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase.
Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer.
Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-?B-TNF?-PIK3CA loop.
Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Comparative genomic hybridization for the analysis of unbalanced chromosomal abnormalities in ovarian tumors.
Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment.
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer.
Detection of PIK3R1 (L449S) Mutation in a Patient with Ovarian Cancer: A Case Report.
Dihydroartemisinin selectively inhibits PDGFR?-positive ovarian cancer growth and metastasis through inducing degradation of PDGFR? protein.
Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene.
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via ?-catenin-Egr1-mediated PTEN expression.
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Epithelial Mutations in Endometriosis: Link to Ovarian Cancer.
Establishment of a New Ovarian Cancer Cell Line CA5171.
Eupatilin Promotes Cell Death by Calcium Influx through ER-Mitochondria Axis with SERPINB11 Inhibition in Epithelial Ovarian Cancer.
Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation.
Expression of Concern: Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.
Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer.
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma.
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gene expression and prognostic significance in ovarian cancer.
Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells.
Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene.
Hepatocyte growth factor modulates motility and invasiveness of ovarian carcinomas via ras mediated pathway.
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer.
In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer.
Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
Mechanism for the Decision of Ovarian Surface Epithelial Stem Cells to Undergo Neo-Oogenesis or Ovarian Tumorigenesis.
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.
miR-214 targets the PTEN-mediated PI3K/Akt signaling pathway and regulates cell proliferation and apoptosis in ovarian cancer.
MiR?381 regulates cell motility, growth and colony formation through PIK3CA in endometriosis?associated clear cell and endometrioid ovarian cancer.
MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.
Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer.
Mutation of the PIK3CA gene in anaplastic thyroid cancer.
Mutation of the PIK3CA gene in ovarian and breast cancer.
Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer.
Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models.
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.
Ovarian cancer in endometriosis: an update on the clinical and molecular aspects.
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations.
PIK3CA alterations in Middle Eastern ovarian cancers.
PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
PIK3CA is implicated as an oncogene in ovarian cancer.
PIK3CA mutations in ovarian cancer.
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors.
PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
PIK3CA: determining its role in cellular proliferation and ovarian cancer.
PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer.
Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer.
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression.
RNA Interference-Mediated Silencing of the Phosphatidylinositol 3-Kinase Catalytic Subunit Attenuates Growth of Human Ovarian Cancer Cells in vitroand in vivo.
Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Screening for PIK3CA mutations among Saudi women with ovarian cancer.
Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer.
Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
Single nucleotide polymorphism of PIK3CA and its interaction with the environment are risk factors for Chinese Han ovarian cancer.
Somatic mutation profiling in BRCA-negative breast and ovarian cancer patients by multigene panel sequencing.
Tanshinone IIA induces apoptosis of ovarian cancer cells in vitro and in vivo through attenuation of PI3K/AKT/JNK signaling pathways.
Targeting a common collaborator in cancer development.
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment.
Type I to Type II Ovarian Carcinoma Progression: Mutant Trp53 or Pik3ca Confers a More Aggressive Tumor Phenotype in a Mouse Model of Ovarian Cancer.
Paget Disease, Extramammary
Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget's disease.
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Pancreatic Cyst
A combination of molecular markers and clinical features improve the classification of pancreatic cysts.
Pancreatic Neoplasms
A genetic variant in PIK3R1 is associated with pancreatic cancer survival in the Chinese population.
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Abnormal expression of PTEN and PIK3CA in pemetrexed-resistant human pancreatic cancer cell line Patu8988.
Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells.
Anticancer effect of HOTTIP regulates human pancreatic cancer via the metabotropic glutamate receptor 1 pathway.
Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells.
Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers.
Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer.
Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer.
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Genetic progression of pancreatic cancer.
Growth-inhibitory effect of phosphatidylinositol 3-kinase inhibitor on human pancreatic cancer cells and expression of Bcl-2 family.
Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?
In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.
Induction of necrosis in human myeloma cells by kigamicin.
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells.
Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.
KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.
miR?142?5p inhibits pancreatic cancer cell migration and invasion by targeting PIK3CA.
Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.
Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
Molecular landscape of pancreatic cancer: implications for current clinical trials.
Molecular mechanism(s) of actinomycin-D induced sensitization of pancreatic cancer cells to CD95 mediated apoptosis.
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.
OPENchip: an on-chip in situ molecular profiling platform for gene expression analysis and oncogenic mutation detection in single circulating tumour cells.
Oridonin induces autophagy-mediated cell death in pancreatic cancer by activating the c-Jun N-terminal kinase pathway and inhibiting phosphoinositide 3-kinase signaling.
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo.
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.
Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer.
Pancreatitis
Effect of hydrogen sulfide on PI3K-AKT pathway and on caerulein- induced cytokine production in isolated mouse pancreatic acinar cells.
Role of phosphoinositide 3-kinase in the pathogenesis of acute pancreatitis.
Papilloma
Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission.
IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.
Juvenile papillomatosis of the breast (Swiss cheese disease) has frequent associations with PIK3CA and/or AKT1 mutations.
KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC).
Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components.
Overexpression of PTEN/MMAC1 and decreased activation of Akt in human papillomavirus-infected laryngeal papillomas.
Progression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix.
Papilloma, Intraductal
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.
Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components.
PIK3CA and AKT1 mutations in hidradenoma papilliferum.
Papillomavirus Infections
APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma.
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.
Integrated analysis of oral tongue squamous cell carcinoma identifies key variants and pathways linked to risk habits, HPV, clinical parameters and tumor recurrence.
Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations.
Streptomyces sp metabolite(s) promotes Bax mediated intrinsic apoptosis and autophagy involving inhibition of mTOR pathway in cervical cancer cell lines.
Paraganglioma
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Paralysis
Measles virus induces expression of SIP110, a constitutively membrane clustered lipid phosphatase, which inhibits T cell proliferation.
Parathyroid Diseases
PIK3CA Mutational Analysis of Parathyroid Adenomas.
Parathyroid Neoplasms
PIK3CA Mutational Analysis of Parathyroid Adenomas.
Parkinson Disease
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.
Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways.
Targeting disease through novel pathways of apoptosis and autophagy.
Penile Neoplasms
PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer.
PIK3CA, HRAS and KRAS Gene Mutations in Human Penile Cancer.
The Prognostic Value of PIK3CA Copy Number Gain in Penile Cancer.
Perinatal Death
Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha.
Periodontitis
Large-scale investigation of genomic markers for severe periodontitis.
Peripheral Nerve Injuries
Control of Axonal Growth and Regeneration of Sensory Neurons by the p110delta PI 3-Kinase.
Peritoneal Neoplasms
Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.
Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
Peritonitis
Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinasegamma.
Pharyngeal Neoplasms
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma.
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Pheochromocytoma
Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12W cells.
Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells.
Growth factor-dependent survival of rodent fibroblasts requires phosphatidylinositol 3-kinase but is independent of pp70S6K activity.
HIV-1 Tat induces tyrosine phosphorylation of p125FAK and its association with phosphoinositide 3-kinase in PC12 cells.
Insulin-like growth factor and potassium depolarization maintain neuronal survival by distinct pathways: possible involvement of PI 3-kinase in IGF-1 signaling.
The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.
phosphatidylinositol-4,5-bisphosphate 3-kinase deficiency
Important roles of PI3Kgamma in osteoclastogenesis and bone homeostasis.
Leukocyte PI3Kgamma and PI3Kdelta have temporally distinct roles for leukocyte recruitment in vivo.
Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcgamma receptor activation and immune complex-induced inflammation.
PI3K{gamma} regulates cartilage damage in chronic inflammatory arthritis.
Pituitary ACTH Hypersecretion
Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
Pituitary Neoplasms
Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors.
Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas.
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Pityriasis
Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.
Plasmacytoma
Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth.
Pleural Effusion
Targeted next-generation sequencing in cytology specimens for molecular profiling of lung adenocarcinoma.
Pneumococcal Infections
Panax ginseng aqueous extract prevents pneumococcal sepsis in vivo by potentiating cell survival and diminishing inflammation.
Pneumonia
Blockade of class IA phosphoinositide 3-kinase in neutrophils prevents NADPH oxidase activation- and adhesion-dependent inflammation.
Dose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor.
Effects of phosphoinositide 3-kinase in protease-induced acute and chronic lung inflammation, remodeling and emphysema in rats.
Phosphoinositide 3-kinase {gamma} plays a critical role in bleomycin-induced pulmonary inflammation and fibrosis in mice.
Phosphoinositide 3-kinase-? regulates fungus-induced allergic lung inflammation through endoplasmic reticulum stress.
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Polycystic Kidney, Autosomal Dominant
Inhibition of HER-2(neu/ErbB2) restores normal function and structure to polycystic kidney disease (PKD) epithelia.
Polycystic Ovary Syndrome
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Polymorphism in postinsulin receptor signaling pathway is not associated with polycystic ovary syndrome.
Polycythemia Vera
Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3-Kinase pathway activation.
Polydactyly
The Fetus with Ganglionic Eminence Abnormality: Head Size and Extracranial Sonographic Findings Predict Genetic Diagnoses and Postnatal Outcomes.
Polymicrogyria
Polymicrogyria in association with hypoglycemia points to mutation in the mTOR pathway.
The Fetus with Ganglionic Eminence Abnormality: Head Size and Extracranial Sonographic Findings Predict Genetic Diagnoses and Postnatal Outcomes.
Pre-Eclampsia
Diagnostic Significance of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Complex 1 in Preeclampsia.
Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1.
Partial least squares-based gene expression analysis in preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A novel germline variant in PIK3R1 results in SHORT syndrome associated with TAL/LMO T-cell acute lymphoblastic leukemia.
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
Bioinformatics analysis of gene expression profiles in childhood B-precursor acute lymphoblastic leukemia.
Calming down T cell acute leukemia.
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia.
NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways.
Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.
Targeting nonclassical oncogenes for therapy in T-ALL.
VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-?B activity in B cell precursor-acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival.
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels.
High accuracy mutation detection in leukemia on a selected panel of cancer genes.
Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing.
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
PI3K?/? and NOTCH1 cross-regulate pathways that define the T-cell acute lymphoblastic leukemia disease signature.
Targeting nonclassical oncogenes for therapy in T-ALL.
Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells.
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).
Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2.
[Screening and verification of key genes in T-cell acute lymphoblastic leukemia].
Primary Immunodeficiency Diseases
An updated review on activated PI3 kinase delta syndrome (APDS).
Cracking the context-specific PI3K signaling code.
Phenotypic characterization of patients with activated PI3K? syndrome 1 presenting with features of systemic lupus erythematosus.
Primary immunodeficiency disorder caused by phosphoinositide 3-kinase ? deficiency.
The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-? (PI3K?) Syndrome (APDS).
Primary Myelofibrosis
Osteitis fibrosa is mediated by platelet-derived growth factor-a via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chronic hyperparathyroidism.
Prostatic Intraepithelial Neoplasia
A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.
Prostatic Neoplasms
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells.
An inverted CAV1 (caveolin 1) topology defines novel autophagy-dependent exosome secretion from prostate cancer cells.
Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/protein kinase B.
Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer.
Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells.
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-Tumour Potency on Prostate Cancer Cells.
Cytokine effects on cell viability and death of prostate carcinoma cells.
Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Development of a peptide-drug conjugate for prostate cancer therapy.
Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells.
Differential role of PTEN in transforming growth factor ? (TGF-?) effects on proliferation and migration in prostate cancer cells.
Disruptive events in the life of prostate cancer.
Dual inhibition of autophagy and the AKT pathway in prostate cancer.
E17K substitution in AKT1 in prostate cancer.
Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades.
Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin.
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.
ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.
Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1? and sphingosine kinase 1.
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.
Expression of TGF?3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement of PI3-kinase/AKT signaling pathway.
FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis.
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes.
Genetic Alterations in the PI3K Pathway in Prostate Cancer.
Genetic Analysis and Targeted Therapy Using Buparlisib and MK2206 in a Patient with Triple Metachronous Cancers of the Kidney, Prostate, and Squamous Cell Carcinoma of the Lung: A Case Report.
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with Pten loss to accelerate progression and castration-resistant growth.
Impact of E6-associated protein on the proliferation and invasion of prostate cancer cells in bone metastasis.
Improving the genetic signature of prostate cancer, the somatic mutations.
Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells.
Inducible shRNA expression for application in a prostate cancer mouse model.
Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target.
Liquid Biopsy to Identify Actionable Genomic Alterations.
Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells.
miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA.
miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1.
Mitogenic and anti-apoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells.
MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase.
Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.
Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response.
MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.
MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors.
NF-kappaB activation upregulates fibroblast growth factor 8 expression in prostate cancer cells.
Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
P110? Inhibition Reduces Histone H3K4 Di-Methylation in Prostate Cancer.
Perspectives on mTOR Inhibitors for Castration-Refractory Prostate Cancer.
Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
PLZF mediates the PTEN/AKT/FOXO3a signaling in suppression of prostate tumorigenesis.
Prostate cancer, PI3K, PTEN and prognosis.
Prostate Power Play: Does Pik3ca Accelerate Pten-Deficient Cancer Progression?
Protein kinase inhibitors for the treatment of prostate cancer.
Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3).
Recent Advances in Prostate Cancer Treatment and Drug Discovery.
REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase.
Role of focal adhesion kinase and phosphatidylinositol 3'-kinase in integrin fibronectin receptor-mediated, matrix metalloproteinase-1-dependent invasion by metastatic prostate cancer cells.
Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Starving PTEN-deficient prostate cancer cells thrive under nutrient stress by scavenging corpses for their supper.
Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition.
Targeting Fibroblast Growth Factor Pathways in Prostate Cancer.
The Androgen Receptor Induces Integrin {alpha}6{beta}1 to Promote Prostate Tumor Cell Survival via NF-{kappa}B and Bcl-xL Independently of PI3K Signaling.
The interaction of PKN3 with RhoC promotes malignant growth.
The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells.
The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells.
Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.
TP53, SPOP and PIK3CA Genes Status in Prostate Cancer.
TRB3 is a PI 3-kinase dependent indicator for nutrient starvation.
Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice.
VIP induces NF-?B1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.
[Obesity and prostate cancer : Role of adipocytokines and clinical implications].
[P2Y purinergic receptor activated PI-3K/Akt signaling pathway in regulation of growth and invasion of prostatic cancer]
Protein Deficiency
Clinicopathological, molecular features and prognosis of colorectal cancer with mucinous component.
Early-onset colorectal cancer: A distinct entity with unique genetic features.
Proteinuria
Divergent roles of Smad3 and PI3-kinase in murine adriamycin nephropathy indicate distinct mechanisms of proteinuria and fibrogenesis.
Signal transduction involved in protective effects of 15(R/S)-methyl- lipoxin A(4) on mesangioproliferative nephritis in rats.
[Protective effects of 15-methyl-lipoxin A4 on mesangioproliferative nephritis in rats]
Proteus Syndrome
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Fibroadipose Hyperplasia versus Proteus Syndrome: Segmental Overgrowth with a Mosaic Mutation in the PIK3CA Gene.
Molecular heterogeneity of the cerebriform connective tissue nevus in mosaic overgrowth syndromes.
Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway.
PIK3CA c.3140A>G mutation in a patient with suspected Proteus Syndrome: a case report.
Psoriasis
Differential regulation of IGF-II-induced IL-8 by extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinases in human keratinocytes.
Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach.
Up-regulation of phosphatidylinositol 3-kinase in psoriatic lesions.
Pulmonary Disease, Chronic Obstructive
A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition.
A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease.
Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
An Inhaled PI3K? Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial.
Cathelicidin LL-37 restoring glucocorticoid function in smoking and lipopolysaccharide-induced airway inflammation in rats.
Cigarette Smoke Exposure Alters mSin3a and Mi-2alpha/beta Expression; implications in the control of pro-inflammatory gene transcription and glucocorticoid function.
Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease.
Ectopic expressed miR-203 contributes to chronic obstructive pulmonary disease via targeting TAK1 and PIK3CA.
Exploring PI3K? Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials.
Histone deacetylase-2 and airway disease.
Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
PI 3-kinase inhibition: a therapeutic target for respiratory disease.
PI3K signaling in chronic obstructive pulmonary disease: mechanisms, targets, and therapy.
PI3K signalling in chronic obstructive pulmonary disease and opportunities for therapy.
PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Pulmonary administration of phosphoinositide 3-kinase inhibitor is a curative treatment for chronic obstructive pulmonary disease by alveolar regeneration.
Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib.
Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals.
Pulmonary Edema
Elucidation of the Mechanism of Action of Ginseng Against Acute Lung Injury/Acute Respiratory Distress Syndrome by a Network Pharmacology-Based Strategy.
Pulmonary Embolism
Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo.
Pulmonary Emphysema
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
Pulmonary Fibrosis
A phosphoinositide 3-kinase-gamma inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats.
LncRNA MEG3 Involved in NiO NPs-Induced Pulmonary Fibrosis via Regulating TGF-?1-Mediated PI3K/AKT Pathway.
Pulmonary Valve Stenosis
PIK3R1 mutations in two patients with SHORT syndrome and pulmonary stenosis.
Purpura, Thrombocytopenic, Idiopathic
Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of PIK3CD-encoded phosphoinositide 3-kinase ?.
Rectal Neoplasms
Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Do rectal cancer patients with PIK3CA mutations benefit from preoperative radiotherapy with regard to local recurrences?
Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses.
Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential.
Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.
KRAS Mutation Status and Clinical Outcome of Preoperative Chemoradiation With Cetuximab in Locally Advanced Rectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
Monitoring colorectal cancer following surgery using plasma circulating tumor DNA.
Mucinous Adenocarcinoma of the Rectum: A Whole Genome Sequencing Study.
PIK3CA mutations predict local recurrences in rectal cancer patients.
Renal Insufficiency, Chronic
Investigation of the effects of indoxyl sulfate, a uremic toxin, on the intracellular oxidation level and phagocytic activity using an HL-60-differentiated human macrophage cell model.
Reperfusion Injury
Ischaemic Preconditioning Protects Cardiomyocytes from Anthracycline-Induced Toxicity via the PI3K Pathway.
JAK Redux - A Second Look at the Regulation and Role of JAKs in the Heart.
miR-10a overexpression aggravates renal ischemia-reperfusion injury associated with decreased PIK3CA expression.
PI3Kgamma protects from myocardial ischemia and reperfusion injury through a kinase-independent pathway.
Reduction in Renal Ischemia-Reperfusion Injury in Mice by a Phosphoinositide 3-Kinase p110gamma-Specific Inhibitor.
Sevoflurane postconditioning protects chronically-infarcted rat hearts against ischemia-reperfusion injury by activation of pro-survival kinases and inhibition of mitochondrial permeability transition pore opening upon reperfusion.
T-588 inhibits astrocyte apoptosis via mitogen-activated protein kinase signal pathway.
Respiratory Distress Syndrome
ARDS Neutrophils Have a Distinct Phenotype and are Resistant to Phosphoinositide 3-kinase Inhibition.
Respiratory Hypersensitivity
Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations.
Respiratory Syncytial Virus Infections
Adenovirus vectors activate survival pathways in lung epithelial cells.
Respiratory Tract Infections
Gain-of-function mutation in PIK3R1 in a patient with a narrow clinical phenotype of respiratory infections.
The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-? (PI3K?) Syndrome (APDS).
Reticuloendotheliosis, Avian
Advances and highlights in primary immunodeficiencies in 2017.
Retinoblastoma
Involvement of cyclin D1/CDK4 and pRb mediated by PI3K/AKT pathway activation in Pb2+ -induced neuronal death in cultured hippocampal neurons.
Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells.
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
MicroRNA?363?3p inhibits cell proliferation and induces apoptosis in retinoblastoma cells via the Akt/mTOR signaling pathway by targeting PIK3CA.
Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress.
Molecular targeted therapy of glioblastoma.
Mutational analysis of merkel cell carcinoma.
p55PIK Transcriptionally Activated by MZF1 Promotes Colorectal Cancer Cell Proliferation.
PI3K Stimulates DNA Synthesis and Cell-Cycle Progression via Its p55PIK Regulatory Subunit Interaction with PCNA.
PI3K/Akt pathway mutations in Retinoblastoma.
Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Retinoblastoma protein phosphorylation via PI 3-kinase and mTOR pathway regulates adipocyte differentiation.
Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity.
TGF-? regulates the proliferation of lung adenocarcinoma cells by inhibiting PIK3R3 expression.
Vitamin D inhibits growth of human airway smooth muscle cells through growth factor-induced phosphorylation of retinoblastoma protein and checkpoint kinase 1.
Rhabdomyosarcoma
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
Construction and characterization of a conditionally active construct of the insulin-regulated forkhead transcription factor FKHR.
MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing Rhabdomyosarcoma.
MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
Rhabdomyosarcoma, Embryonal
Germline ATM mutation and somatic PIK3CA and BCOR mutations found in an infant with aggressive orbital embryonal rhabdomyosarcoma.
MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma.
Rhinitis, Allergic
PI3-Kinase Regulates Eosinophil and Neutrophil Degranulation in Patients with Allergic Rhinitis and Allergic Asthma Irrespective of Allergen Challenge Model.
Rhinitis, Allergic, Seasonal
Evaluation of the anti-allergic activity of Citrus unshiu using rat basophilic leukemia RBL-2H3 cells as well as basophils of patients with seasonal allergic rhinitis to pollen.
Salmonella Infections
Multiple Host Kinases Contribute to Akt Activation during Salmonella Infection.
Sarcoma
Acetylcholine-dependent upregulation of TASK-1 channels in thalamic interneurons by a smooth muscle-like signalling pathway.
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer.
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
Distinct genetic profiles of extracranial and intracranial acral melanoma metastases.
EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas.
Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
Genetic alterations in Japanese extrahepatic biliary tract cancer.
Genetic alterations in lung adenocarcinoma with a micropapillary component.
Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy.
High co-expression of PD-L1 and HIF-1? correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Hsa_circ_0012152 and Hsa_circ_0001857 Accurately Discriminate Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia.
Human sensory neuron-specific Mas-related G protein-coupled receptors-X1 sensitize and directly activate transient receptor potential cation channel V1 via distinct signaling pathways.
Identification of protein kinase C as an intermediate in Na,K-ATPase Beta-subunit mediated lamellipodia formation and suppression of cell motility in carcinoma cells.
Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population.
Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Measurement of Telomere Length in Colorectal Cancers for Improved Molecular Diagnosis.
Molecular association of functioning stroma with carcinoma cells in the ovary: A preliminary study.
Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma.
Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas.
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase.
Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases: Report of 3 cases, with morphological and molecular analysis.
Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma.
Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma.
PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.
Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells.
Searching for molecular targets in sarcoma.
Simultaneous Knockdown of Sprouty2 and PTEN Promotes Axon Elongation of Adult Sensory Neurons.
Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.
Targeted therapies in development for non-small cell lung cancer.
Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments.
The Hippo signal transduction pathway in soft tissue sarcomas.
The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer.
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Triiodothyronine stimulates steroid and VEGF production in murine Leydig cells via cAMP-PKA pathway.
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
[Correlation between expression of TUBB3/STMN1 and EGFR signaling pathway in non-small cell lung cancer].
Sarcoma, Avian
The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity.
Sarcoma, Ewing
Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects.
Sarcoma, Kaposi
Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
Sarcopenia
Frailty and sarcopenia: The potential role of an aged immune system.
Scrapie
Tunneling-nanotube: A new way of cell-cell communication.
Seizures
4E-BP2-dependent translation in parvalbumin neurons controls epileptic seizure threshold.
Filamin A inhibition reduces seizure activity in a mouse model of focal cortical malformations.
Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat.
Wortmannin reduces insulin signaling and death in seizure-prone Pcmt1-/- mice.
Sepsis
ARDS Neutrophils Have a Distinct Phenotype and are Resistant to Phosphoinositide 3-kinase Inhibition.
Ceramide regulates lipopolysaccharide-induced phosphatidylinositol 3-kinase and Akt activity in human alveolar macrophages.
Downregulation of PI3K-? in a mouse model of sepsis-induced myocardial dysfunction.
Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis.
Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury.
Phosphorylation of endothelial nitric-oxide synthase is diminished in mesenteric arteries from septic rabbits depending on the altered phosphatidylinositol 3-kinase/Akt pathway: reversal effect of fluvastatin therapy.
Stimulation of the ?7 Nicotinic Acetylcholine Receptor Protects Against Sepsis by Inhibiting Toll-like Receptor via Phosphoinositide 3-Kinase Activation.
Targeted delivery of a phosphoinositide 3-kinase ? inhibitor to restore organ function in sepsis.
Severe Combined Immunodeficiency
Advances and highlights in primary immunodeficiencies in 2017.
Shock, Septic
The role of SHIP1 in macrophage programming and activation.
Skin Diseases
FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra.
Skin Neoplasms
A Potent Inhibitor of Phosphoinositide 3-Kinase (PI3K) and Mitogen Activated Protein (MAP) Kinase Signalling, Quercetin (3, 3', 4', 5, 7-Pentahydroxyflavone) Promotes Cell Death in Ultraviolet (UV)-B-Irradiated B16F10 Melanoma Cells.
Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice.
Isorhamnetin Suppresses Skin Cancer through Direct Inhibition of MEK1 and PI3-K.
The P110 subunit of PI3-K is a therapeutic target of acacetin in skin cancer.
Sleep Deprivation
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Small Cell Lung Carcinoma
Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling.
Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report.
EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.
Oncogenic mutation of PIK3CA in small cell lung carcinoma: A potential therapeutic target pathway for chemotherapy-resistant lung cancer.
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
PIK3CA mutations and copy number gains in human lung cancers.
PIK3CA Mutations in Resected Small Cell Lung Cancer.
Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Targeting the phosphoinositide 3-kinase p110-? isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway.
Spinal Cord Injuries
Clustering analysis to identify key genes associated with motor neuron excitability following spinal cord injury.
Spinal Cord Ischemia
Induction of phosphatidylinositol 3-kinase and serine-threonine kinase-like immunoreactivity in rabbit spinal cord after transient ischemia.
Squamous Cell Carcinoma of Head and Neck
A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3K? inhibition in controlling tumor growth.
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer.
A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.
Absence of hotspot mutations in exons 9 and 20 of the PIK3CA gene in human oral squamous cell carcinoma in the Greek population.
AKT3 is a key regulator of head and neck squamous cell carcinoma.
An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma.
Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy.
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Association of PIK3CA gene mutations with head and neck squamous cell carcinomas.
Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signaling.
Combined mutational analysis of RAS, BRAF, PIK3CA, and TP53 genes in Taiwanese patients with oral squamous cell carcinoma.
Comprehensive Mutation Analysis of PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1 Genes is Suggestive of a Non- Neoplastic Nature of Phenytoin Induced Gingival Overgrowth.
Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer.
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR.
Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC.
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance.
Epstein-Barr virus infection is strictly associated with the metastatic spread of sinonasal squamous-cell carcinomas.
Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets.
Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
Genetic alterations of the PIK3CA oncogene in human oral squamous cell carcinoma in an Indian population.
Genetic association between PIK3CA gene and oral squamous cell carcinoma: a case control study conducted in Chongqing, China.
Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection.
Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.
Genomic insights into head and neck cancer.
Genomic landscape of human papillomavirus-associated cancers.
Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Hippo Pathway and YAP Signaling Alterations in Squamous Cancer of the Head and Neck.
Hypoxia-induced epithelial-mesenchymal transition is regulated by phosphorylation of GSK3-? via PI3 K/Akt signaling in oral squamous cell carcinoma.
Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models.
Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways.
LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma.
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications.
Molecular pathways in head and neck cancer.
Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes.
mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma (HNSCC).
Mutation of chromatin regulators and focal hotspot alterations characterize human papillomavirus-positive oropharyngeal squamous cell carcinoma.
Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.
Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma.
New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors.
Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma.
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
p120-Catenin Downregulation and PIK3CA Mutations Cooperate to Induce Invasion through MMP1 in HNSCC.
Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer.
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Phosphoinositide kinase-3 status associated with presence or absence of human papillomavirus in head and neck squamous cell carcinomas.
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
PI3K/PTEN/AKT/mTOR pathway genetic variations are associated with the clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
PIK3CA mutation in HPV-associated OPSCC patients receiving deintensified chemoradiation.
PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.
Prevalence of high-risk human papillomavirus infection and cancer gene mutations in nonmalignant tonsils.
Prevention of Tumor Growth Driven by PIK3CA and HPV Oncogenes by Targeting mTOR Signaling with Metformin in Oral Squamous Carcinomas Expressing OCT3.
Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review.
Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes.
PTEN deficiency contributes to the development and progression of head and neck cancer.
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Search for mutations in signaling pathways in head and neck squamous cell carcinoma.
Sequencing the head and neck cancer genome: implications for therapy.
Silencing of miR-17-5p suppresses cell proliferation and promotes cell apoptosis by directly targeting PIK3R1 in laryngeal squamous cell carcinoma.
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC).
Taselisib (GDC-0032), a Potent ?-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell lines.
The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel.
The molecular pathogenesis of head and neck squamous cell carcinoma.
The mutational landscape of head and neck squamous cell carcinoma.
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]
Starvation
Class III phosphoinositide 3-kinase--Beclin1 complex mediates the amino acid-dependent regulation of autophagy in C2C12 myotubes.
Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway.
Induction of Autophagy by Amino Acid Starvation in Fish Cells.
LL5beta is a phosphatidylinositol (3,4,5)-trisphosphate sensor that can bind the cytoskeletal adaptor, gamma-filamin.
Modulation of Src homology 3 proteins by the proline-rich adaptor protein Shb.
Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
TRB3 is a PI 3-kinase dependent indicator for nutrient starvation.
Stomach Neoplasms
A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report.
Activation of EGFR-PI3K-AKT signaling is required for Mycoplasma hyorhinis-promoted gastric cancer cell migration.
An ?-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.
An increase in galectin-3 causes cellular unresponsiveness to IFN-?-induced signal transduction and growth inhibition in gastric cancer cells.
Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer.
Association between PIK3CA alteration and prognosis of gastric cancer patients: a meta-analysis.
Association between telomere length and PIK3CA amplification in gastric cancer.
Association of mast cell infiltration with gastric cancer progression.
Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer.
Baculovirus production of fully-active phosphoinositide 3-kinase alpha as a p85alpha-p110alpha fusion for X-ray crystallographic analysis with ATP competitive enzyme inhibitors.
Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1.
C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Cardia Gastric Cancer Is Associated With Increased PIK3CA Amplifications and HER2 Expression Than Noncardia Gastric Cancer According to Lauren Classification.
Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression.
Class I phosphatidylinositol 3-kinase inhibitor LY294002 activates autophagy and induces apoptosis through p53 pathway in gastric cancer cell line SGC7901.
Clinical significance of PI3K/Akt/mTOR signaling in gastric carcinoma.
Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.
Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer.
Comprehensive molecular characterization of gastric adenocarcinoma.
Concomitant PIK3CA amplification and RASSF1A or PAX6 hypermethylation predict worse survival in gastric cancer.
Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer.
Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization.
Downregulation of miR203 induces overexpression of PIK3CA and predicts poor prognosis of gastric cancer patients.
Effect of dexmedetomidine on the cognitive function of patients undergoing gastric cancer surgery by regulating the PI3K/AKT signaling pathway.
Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice.
Effects of small interfering RNA inhibit Class I phosphoinositide 3-kinase on human gastric cancer cells.
Epithelial-mesenchymal transition in gastric cancer (Review).
Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer.
Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.
Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake.
Gastric Cancer: New Drugs - New Strategies.
Genes Involved in the PD-L1 Pathway Might Associate with Radiosensitivity of Patients with Gastric Cancer.
Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing.
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.
Identification and Validation of SNP-Containing Genes With Prognostic Value in Gastric Cancer via Integrated Bioinformatics Analysis.
Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil.
Identification of PIK3CA multigene mutation patterns associated with superior prognosis in stomach cancer.
LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway.
Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-?B pathway, and MMP-9 expression.
MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells.
Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network.
Molecular Classification of Gastric Cancer among Alaska Native People.
Molecular targets and biological modifiers in gastric cancer.
Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.
Mutations of key driver genes in gastric cancer metastasis risk: a systematic review and meta-analysis.
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Mutations of PIK3CA in gastric adenocarcinoma.
Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer.
Oncogenic mutations in gastric cancer with microsatellite instability.
Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer cells.
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation.
Phosphoinositide 3-kinase/Akt and nuclear factor ?B pathways are involved in tumor necrosis factor-related apoptosis-inducing ligand resistance in human gastric cancer cells.
Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death.
PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.
PIK3CA Mutation Analysis in Iranian Patients with Gastric Cancer
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene.
Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.
Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling pathway.
Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells.
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Signaling components involved in Bcl-w-induced migration of gastric cancer cells.
Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression.
Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
The AKT inhibitor AZD5363 is selectively active in PIK3CA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer.
The Wnt/?-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation.
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.
Up-regulation of PIK3CA promotes metastasis in gastric carcinoma.
Upregulation of microRNA-31 targeting integrin ?5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells.
What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?
[Chitosan/PIK3CA siRNA nanoparticle-mediated PIK3CA gene interference decreases the invasive capacity of gastric cancer cells in vitro].
Stroke
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.
Circulating mRNA and microRNA profiling analysis in patients with ischemic stroke.
Electrical Stimulation of the Cerebral Cortex Exerts Antiapoptotic, Angiogenic, and Anti-Inflammatory Effects in Ischemic Stroke Rats Through Phosphoinositide 3-Kinase/Akt Signaling Pathway.
Ginkgetin aglycone attenuates neuroinflammation and neuronal injury in the rats with ischemic stroke by modulating STAT3/JAK2/SIRT1.
Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor.
Phosphoinositide 3-kinase promotes adult subventricular neuroblast migration after stroke.
Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.
Struma Ovarii
Papillary thyroid cancer in a struma ovarii: a report of a rare case.
Sturge-Weber Syndrome
Ophthalmic Alterations in the Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome, and the Phakomatosis Pigmentovascularis: An Independent Group of Conditions?
Subarachnoid Hemorrhage
Phosphatidylinositol 3-kinase inhibitor failed to reduce cerebral vasospasm in dog model of experimental subarachnoid hemorrhage.
Syndactyly
Somatic mosaicism of the PIK3CA gene identified in a Hungarian girl with macrodactyly and syndactyly.
Synovitis
Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis.
Tauopathies
DHCR24 Knock-Down Induced Tau Hyperphosphorylation at Thr181, Ser199, Thr231, Ser262, Ser396 Epitopes and Inhibition of Autophagy by Overactivation of GSK3?/mTOR Signaling.
Telangiectasia, Hereditary Hemorrhagic
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120.
Telangiectasis
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120.
Roles of cyclin-dependent kinase 4 and p53 in neuronal cell death induced by doxorubicin on cerebellar granule neurons in mouse.
Teratoma
Ovarian clear cell carcinoma with an immature teratoma component showing ARID1A deficiency and an identical PIK3CA mutation.
P53 and PIK3CA Mutations in KRAS/HER2 Negative Ovarian Intestinal-Type Mucinous Carcinoma Associated with Mature Teratoma.
The genetic landscape of 87 ovarian germ cell tumors.
Testicular Neoplasms
Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility.
Thromboembolism
PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.
Thrombosis
Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors.
Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
Circulating microRNA expression and their target genes in deep vein thrombosis: A systematic review and bioinformatics analysis.
Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization.
Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo.
Differential Phosphoinositide 3-Kinase Signaling: Implications for PTCA?
Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3).
In-depth PtdIns(3,4,5)P
Inhibitory Effects of Ginsenoside Ro on Clot Retraction through Suppressing PI3K/Akt Signaling Pathway in Human Platelets.
Naringenin Inhibits Platelet Activation and Arterial Thrombosis Through Inhibition of Phosphoinositide 3-Kinase and Cyclic Nucleotide Signaling.
Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation.
Phosphoinositide 3-kinase p110? negatively regulates thrombopoietin-mediated platelet activation and thrombus formation.
PI 3-kinase p110beta: a new target for antithrombotic therapy.
Platelet PI3K? and GSK3 regulate thrombus stability at a high shear rate.
Regulation of endogenous reactive oxygen species in platelets can reverse aggregation.
Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing.
Signalling through Class I PI3Ks in mammalian cells.
The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis.
The Phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) Binder Rasa3 Regulates Phosphoinositide 3-kinase (PI3K)-dependent Integrin ?IIb?3 Outside-in Signaling.
The PI3K? Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential.
Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.
Type I phosphoinositide 3-kinases: potential antithrombotic targets?
Thrombotic Microangiopathies
Phosphoinositide 3-kinase ? mediates microvascular endothelial repair of thrombotic microangiopathy.
Thymoma
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1, and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.
A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice.
AKT-independent PI3-K signaling in cancer - emerging role for SGK3.
Analysis of differentially expressed genes between endometrial carcinosarcomas and endometrioid endometrial carcinoma by bioinformatics.
Codelivery of Genistein and miRNA-29b to A549 Cells Using Aptamer-Hybrid Nanoparticle Bioconjugates.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence.
Enhanced myeloid differentiation factor 88 promotes tumor metastasis via induction of epithelial-mesenchymal transition in human hepatocellular carcinoma.
Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array.
Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP.
Metastasis suppressor protein 1 regulated by PTEN suppresses invasion, migration, and EMT of gastric carcinoma by inactivating PI3K/AKT signaling.
MicroRNA-10a controls airway smooth muscle cell proliferation via direct targeting of the PI3 kinase pathway.
Mutational analysis of PI3K/AKT and RAS/RAF pathway activation in malignant salivary gland tumours with a new mutation of PIK3CA.
Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
New function of type I IFN: induction of autophagy.
Oncocytoma-like renal tumor with transformation toward high-grade oncocytic carcinoma: a unique case with morphologic, immunohistochemical, and genomic characterization.
Oncogene alterations in endometrial carcinosarcomas.
p28(GANK) overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1? pathways.
p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1? pathways.
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
PIK3CA mutations in mucinous cystic neoplasms of the pancreas.
Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Protection of the Developing Brain with Anthocyanins Against Ethanol-Induced Oxidative Stress and Neurodegeneration.
Protein phosphatase 3 differentially modulates vascular endothelial growth factor- and fibroblast growth factor 2-stimulated cell proliferation and signaling in ovine fetoplacental artery endothelial cells.
Rare frequency of gene variation and survival analysis in thymic epithelial tumors.
Role of Akt Isoforms Controlling Cancer Stem Cell Survival, Phenotype and Self-Renewal.
Sildenafil alleviates bronchopulmonary dysplasia in neonatal rats by activating the hypoxia-inducible factor signaling pathway.
Testosterone up-regulates seladin-1 expression by iAR and PI3-K/Akt signaling pathway in C6 cells.
The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer.
Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.
Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.
Thyroid Cancer, Papillary
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Cribriform-morular variant of papillary thyroid carcinoma: a study of 3 cases featuring the PIK3CA mutation.
Current Concepts in the Molecular Genetics and Management of Thyroid Cancer: An Update for Radiologists.
Deep sequencing of KIT, MET, PIK3CA, and PTEN hotspots in papillary thyroid carcinomas with distant metastases.
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.
MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay.
MicroRNA-363-3p downregulation in papillary thyroid cancer inhibits tumor progression by targeting NOB1.
MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by targeting PIK3CA.
Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.
Next-generation sequencing identified somatic alterations that may underlie the etiology of Chinese papillary thyroid carcinoma.
Relative quantification of PIK3CA gene expression level in fine-needle aspiration biopsy thyroid specimens collected from patients with papillary thyroid carcinoma and non-toxic goitre by real-time RT-PCR.
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
Thyroid Carcinoma, Anaplastic
Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma Identifies RAS and PIK3CA Mutations as Negative Survival Predictors.
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Current Concepts in the Molecular Genetics and Management of Thyroid Cancer: An Update for Radiologists.
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
Mutation of the PIK3CA gene in anaplastic thyroid cancer.
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
Thyroid Diseases
A novel PIK3R1 mutation of SHORT syndrome in a Chinese female with diffuse thyroid disease: a case report and review of literature.
Thyroid Neoplasms
A single nucleotide polymorphism in PIK3CA gene is inversely associated with P53 protein expression in breast cancer.
Antineoplastic Activity of an Old Natural Antidiabetic Biguanoid on the Human Thyroid Carcinoma Cell Line.
Berberine could inhibit thyroid carcinoma cells by inducing mitochondrial apoptosis, G0/G1 cell cycle arrest and suppressing migration via PI3K-AKT and MAPK signaling pathways.
Carcinogenesis of PIK3CA.
Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Current Concepts in the Molecular Genetics and Management of Thyroid Cancer: An Update for Radiologists.
DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells.
Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study.
ETV5 overexpression contributes to tumor growth and progression of thyroid cancer through PIK3CA.
FOXO3a: a novel player in thyroid carcinogenesis?
GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1? (HIF-1?) pathways.
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.
MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
Methodology, criteria and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts.
Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.
Mouse Models as a Tool for Understanding Progression in BrafV600E-Driven Thyroid Cancers.
Mutation of the PIK3CA gene in anaplastic thyroid cancer.
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Overexpression and overactivation of Akt in thyroid carcinoma.
Papillary thyroid cancer in a struma ovarii: a report of a rare case.
Periostin silencing suppresses the aggressive phenotype of thyroid carcinoma cells by suppressing the Akt/thyroid stimulating hormone receptor axis.
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Relative quantification of PIK3CA gene expression level in fine-needle aspiration biopsy thyroid specimens collected from patients with papillary thyroid carcinoma and non-toxic goitre by real-time RT-PCR.
Roles of XB130, a novel adaptor protein, in cancer.
Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification.
Solid Papillary Breast Carcinomas Resembling the Tall Cell Variant of Papillary Thyroid Neoplasms (Solid Papillary Carcinomas with Reverse Polarity) Harbor Recurrent Mutations Affecting IDH2 and PIK3CA: A Validation Cohort.
TGF-?1 induces HMGA1 expression: The role of HMGA1 in thyroid cancer proliferation and invasion.
The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway.
The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.
Thyroid Carcinoma in a Child with Activated Phosphoinositide 3-Kinase ? Syndrome: Somatic Effect of a Germline Mutation.
Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers.
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
Whole-genome sequencing of follicular thyroid carcinomas reveal recurrent mutations in microRNA processing subunit DGCR8.
XB130 Mediates Cancer Cell Proliferation and Survival through Multiple Signaling Events Downstream of Akt.
Thyroid Nodule
Relationship between TSHR, BRAF and PIK3CA gene copy number variations and thyroid nodules.
Thyroiditis
Riedel's thyroiditis - a case report with genes' expression studies.
The role of phosphoinositide 3-kinase subunits in chronic thyroiditis.
Tics
BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
Tongue Neoplasms
Molecular prognosticators in clinically and pathologically distinct cohorts of head and neck squamous cell carcinoma-A meta-analysis approach.
PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells.
Toxoplasmosis
Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase ? Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
Toxoplasmosis, Congenital
Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase ? Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
Triple Negative Breast Neoplasms
Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer.
Clinical outcomes based on multigene profiling in metastatic breast cancer patients.
Enhanced immortalization, HUWE1 mutations and other biological drivers of breast invasive carcinoma in Black/African American patients.
Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology.
Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers.
MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women.
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.
PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report.
PIK3CA mutations and downstream effector p-mTOR expression: implication for prognostic factors and therapeutic targets in triple negative breast cancer.
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
Targeted Treatment of Triple-Negative Breast Cancer.
Targeting the PI3-kinase pathway in triple-negative breast cancer.
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.
Tuberculosis
1alpha,25-Dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase.
Differential regulation of interleukin-12 and tumour necrosis factor-alpha by phosphatidylinositol 3-kinase and ERK 1/2 pathways during Mycobacterium tuberculosis infection.
Hydrogen sulfide-induced GAPDH sulfhydration disrupts the CCAR2-SIRT1 interaction to initiate autophagy.
M. tuberculosis PknG manipulates host autophagy flux to promote pathogen intracellular survival.
PI3-Kinase ?? Catalytic Isoforms Regulate the Th-17 Response in Tuberculosis.
Susceptibility to Tuberculosis Is Associated With PI3K-Dependent Increased Mobilization of Neutrophils.
Tuberous Sclerosis
14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation site(s).
A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation.
Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
Macropinocytosis, mTORC1 and cellular growth control.
mTOR mutations in Smith-Kingsmore syndrome: four additional patients and a review.
Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of rapamycin.
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases.
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs.
Targeting phosphoinositide 3-kinase: moving towards therapy.
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.
Tubular Sweat Gland Adenomas
PIK3CA and AKT1 mutations in hidradenoma papilliferum.
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Urinary Bladder Neoplasms
Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells.
Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
High Resolution Melting Analysis for Rapid Detection of PIK3CA Gene Mutations in Bladder Cancer: A Mutated Target for Cancer Therapy.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells.
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.
Integrated gene network analysis and text mining revealing PIK3R1 regulated by miR-127 in human bladder cancer.
Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
Knockdown of KNTC1 Inhibits the Proliferation, Migration and Tumorigenesis of Human Bladder Cancer Cells and Induces Apoptosis.
Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells.
Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer.
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells.
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
PI3K/AKT pathway genetic alterations and dysregulation of expression in bladder cancer.
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
PIK3CA Is Regulated by CUX1, Promotes Cell Growth and Metastasis in Bladder Cancer via Activating Epithelial-Mesenchymal Transition.
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy.
Retraction note: Integrated gene network analysis and text mining revealing PIK3R1 regulated by miR-127 in human bladder cancer.
Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.
Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder.
The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
[Point somatic mutations in bladder cancer: key carcinogenesis events, diagnostic markers and therapeutic targets].
Urticaria
Critical Signaling Events in the Mechanoactivation of Human Mast Cells through p.C492Y-ADGRE2.
Uterine Cervical Neoplasms
Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
Chemo-preventive and therapeutic effect of the dietary flavonoid kaempferol: A comprehensive review.
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia.
Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.
Corrigendum to 'clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome'.
Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration.
Genetic alterations and PIK3CA gene mutations and amplifications analysis in cervical cancer by racial groups in the United States.
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway.
Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women.
MGL Ligand Expression Is Correlated to Lower Survival and Distant Metastasis in Cervical Squamous Cell and Adenosquamous Carcinoma.
MiR-125b inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting phosphoinositide 3-kinase catalytic subunit delta.
miR-92a promotes cervical cancer cell proliferation, invasion, and migration by directly targeting PIK3R1.
Mutational profiles of marker genes of cervical carcinoma in Bangladeshi patients.
Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
PIK3CA as an oncogene in cervical cancer.
PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences.
PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer.
PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
PIK3CA Mutations and Their Impact on Survival Outcomes of Patients with Cervical Cancer: A Systematic Review.
PIK3CA pathway mutations predictive of poor response following Standard radio chemotherapy +/- Cetuximab in cervical cancer patients.
PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro.
Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
S100A6 promotes the proliferation and migration of cervical cancer cells via the PI3K/Akt signaling pathway.
Streptomyces sp metabolite(s) promotes Bax mediated intrinsic apoptosis and autophagy involving inhibition of mTOR pathway in cervical cancer cell lines.
Targeting of ?-Catenin Reverses Radioresistance of Cervical Cancer with the PIK3CA-E545K Mutation.
Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer.
The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the ?-catenin/SIRT3 signaling pathway in cervical cancer.
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
Translating Imaging Results into Tumor Biology: FDG-PET and The Response to Chemoradiation in Human Cervical Carcinoma.
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Uterine Neoplasms
Activated Mutant p110? Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion.
PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences.
Vascular Malformations
CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations.
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Cloves Syndrome: A Rare Disorder of Overgrowth with Unusual Features - An Uncommon Phenotype?
CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations.
Managing Vascular Anomalies in the Era of Genetics and Precision Medicine: An Opportunity or a Challenge?
Menstrual disorders associated with sirolimus treatment.
Molecular analysis of a uterine broad ligament leiomyoma in a patient with CLOVES syndrome.
Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations.
New and Emerging Targeted Therapies for Vascular Malformations.
PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
PIK3CA mutations in vascular malformations.
PIK3CA vascular overgrowth syndromes: an update.
PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution.
PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum.
Somatic PIK3R1 variation as a cause of vascular malformations and overgrowth.
Sonographic screening for Wilms tumor in children with CLOVES syndrome.
Targeted therapy in patients with PIK3CA-related overgrowth syndrome.
Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.
Utility of clinical high-depth next generation sequencing for somatic variant detection in the PIK3CA-related overgrowth spectrum.
[PIK3CA-related overgrowth syndrome (PROS)].
Vascular System Injuries
Matrine attenuates high-fat diet-induced in vivo and ox-LDL-induced in vitro vascular injury by regulating the PKC?/eNOS and PI3K/Akt/eNOS pathways.
The role of Rac1 in glycoprotein Ib-IX-mediated signal transduction and integrin activation.
Vasculitis
Activated phosphoinositide 3-kinase delta syndrome misdiagnosed as anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report.
L-selectin: an emerging player in chemokine function.
Ventilator-Induced Lung Injury
Lack of phosphoinositide 3-kinase-gamma attenuates ventilator-induced lung injury.
Vesicular Stomatitis
Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production.
Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages.
Stable lentiviral vector-mediated gene silencing in human monocytic cell lines.
Viremia
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
Virus Diseases
A Peptide Derived from Phosphoinositide 3-kinase Inhibits Endocytosis and Influenza Virus Infection.
A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity).
Adenovirus vectors activate survival pathways in lung epithelial cells.
Exhaustion of the CD8
GSK-3-associated signaling is crucial to virus infection of cells.
Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Phosphatidylinositol 3-kinase binding to polyoma virus middle tumor antigen mediates elevation of glucose transport by increasing translocation of the GLUT1 transporter.
Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages.
Progression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix.
Use of a tandem affinity purification assay to detect interactions between West Nile and dengue viral proteins and proteins of the mosquito vector.
Waldenstrom Macroglobulinemia
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
West Nile Fever
Use of a tandem affinity purification assay to detect interactions between West Nile and dengue viral proteins and proteins of the mosquito vector.
Whooping Cough
A lysophosphatidic acid receptor lacking the PDZ-binding domain is constitutively active and stimulates cell proliferation.
Acetylcholine leads to free radical production dependent on K(ATP) channels, G(i) proteins, phosphatidylinositol 3-kinase and tyrosine kinase.
Activation of HIF-1? by ?-Opioid Receptors Induces COX-2 Expression in Breast Cancer Cells and Leads to Paracrine Activation of Vascular Endothelial Cells.
Activation of p21-activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells.
Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation.
Activation of phosphoinositide 3-kinases by the CCR4 ligand macrophage-derived chemokine is a dispensable signal for T lymphocyte chemotaxis.
Activation of PI 3-kinase by G protein betagamma subunits.
ADP-ribosylation factor and Rho proteins mediate fMLP-dependent activation of phospholipase D in human neutrophils.
Aldosterone inhibits apical NHE3 and HCO3- absorption via a nongenomic ERK-dependent pathway in medullary thick ascending limb.
Alpha1 adrenergic receptors activate phosphatidylinositol 3-kinase in human vascular smooth muscle cells. Role in mitogenesis.
Angiotensin AT(1) receptor phosphorylation and desensitization in a hepatic cell line. Roles of protein kinase c and phosphoinositide 3-kinase.
Bradykinin B2 receptors activate Na+/H+ exchange in mIMCD-3 cells via Janus kinase 2 and Ca2+/calmodulin.
C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro.
C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase.
Characterization of the migration of lung and blood T cells in response CXCL12 in a three-dimensional matrix.
Chemotactic peptide fMetLeuPhe induces translocation of the TRPV2 channel in macrophages.
Contrasting signaling pathways of alpha1A- and alpha1B-adrenergic receptor subtype activation of phosphatidylinositol 3-kinase and Ras in transfected NIH3T3 cells.
Critical Signaling Events in the Mechanoactivation of Human Mast Cells through p.C492Y-ADGRE2.
CysLT1 receptor-induced human airway smooth muscle cells proliferation requires ROS generation, EGF receptor transactivation and ERK1/2 phosphorylation.
Determinants Present in the Receptor Carboxy Tail Are Responsible for Differences in Subtype-Specific Coupling of beta-Adrenergic Receptors to Phosphoinositide 3-Kinase.
Differences in CXCR4-mediated signaling in B cells.
Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells.
Erk1/2- and p38 MAP kinase-dependent phosphorylation and activation of cPLA2 by m3 and m2 receptors.
Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30.
Expression and functional role of formyl peptide receptor in human bone marrow-derived mesenchymal stem cells.
Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway.
G protein-coupled estrogen receptor 1 (GPER1)/GPR30 increases ERK1/2 activity through PDZ motif-dependent and -independent mechanisms.
Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy.
Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways.
Heme induces neutrophil migration and reactive oxygen species generation through signaling pathways characteristic of chemotactic receptors.
Human catestatin enhances migration and proliferation of normal human epidermal keratinocytes.
Identification of a structural element in phospholipase C beta2 that interacts with G protein betagamma subunits.
Identification of two isoforms of mouse neuropeptide Y-Y1 receptor generated by alternative splicing. Isolation, genomic structure, and functional expression of the receptors.
Independent activation of endogenous p21-activated protein kinase-3 (PAK3) and JNK by thrombin in CCL39 fibroblasts.
Insulin-like growth factor binding protein-3 stimulates phosphatidylinositol 3-kinase in MCF-7 breast carcinoma cells.
Interleukin-1 inhibits angiotensin II-stimulated protein kinase B pathway in renal mesangial cells via the inducible nitric oxide synthase.
Involvement of MAP kinase signal transduction pathway in UVB-induced activation of macrophages in vitro.
Involvement of phosphatidylinositol 3-kinase in stromal cell-derived factor-1 alpha-induced lymphocyte polarization and chemotaxis.
Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors.
Lithium activates mammalian Na+/H+ exchangers: isoform specificity and inhibition by genistein.
Lysophosphatidic acid and receptor-mediated activation of endothelial nitric-oxide synthase.
Lysophosphatidic acid induces alpha1B-adrenergic receptor phosphorylation through G beta gamma, phosphoinositide 3-kinase, protein kinase C and epidermal growth factor receptor transactivation.
Lysophosphatidylserine Stimulates L2071 Mouse Fibroblast Chemotactic Migration via a Process Involving Pertussis Toxin-Sensitive Trimeric G-Proteins.
Mechanisms of kringle fragment of urokinase-induced vascular smooth muscle cell migration.
MIP-3alpha induces human eosinophil migration and activation of the mitogen-activated protein kinases (p42/p44 MAPK).
Molecular determinants and feedback circuits regulating type 2 CRH receptor signal integration.
Novel role of Gi?2 in cell migration: Downstream of PI3-kinase-AKT and Rac1 in prostate cancer cells.
Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages.
Phosphorylation, desensitization and internalization of human alpha1B-adrenoceptors induced by insulin-like growth factor-I.
PI3 kinase-dependent stimulation of platelet migration by stromal cell-derived factor 1 (SDF-1).
Platelet microparticles induce angiogenesis in vitro.
Potentiation of chemotactic peptide-induced superoxide generation by CD38 ligation in human myeloid cell lines.
Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein.
Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1.
Recruitment of pleckstrin and phosphoinositide 3-kinase gamma into the cell membranes, and their association with G beta gamma after activation of NK cells with chemokines.
Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms.
Requirement of phosphatidylinositol 3-kinase activation and calcium influx for leukotriene B4-induced enzyme release.
Requirement of phosphatidylinositol 3-kinase activity for bradykinin stimulation of NF-kappaB activation in cultured human epithelial cells.
Resistin: a newly identified chemokine for human CD4-positive lymphocytes.
Role of phosphatidylinositol 3-kinase in the binding of Bordetella pertussis to human monocytes.
Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells.
Sphingosine 1-phosphate and control of vascular tone.
Stimulation of extracellular signal-regulated kinases and proliferation in the human gastric cancer cells KATO-III by obestatin.
Stromal cell-derived factor-1alpha induces tube-like structure formation of endothelial cells through phosphoinositide 3-kinase.
Synergistic activation of phospholipases Cgamma and Cbeta: A novel mechanism for PI3K-independent enhancement of FcepsilonRI-induced mast cell mediator release.
The acute and chronic stimulatory effects of endothelin-1 on glucose transport are mediated by distinct pathways in 3T3-L1 adipocytes.
The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase.
The CXC chemokine stromal cell-derived factor activates a Gi-coupled phosphoinositide 3-kinase in T lymphocytes.
The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B.
The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8.
Thrombin-promoted release of UDP-glucose from human astrocytoma cells.
Thromboxane A(2) receptor mediated activation of the mitogen activated protein kinase cascades in human uterine smooth muscle cells.
Toxoplasma gondii triggers Gi-dependent PI 3-kinase signaling required for inhibition of host cell apoptosis.
Wortmannin-sensitive activation of p70s6k by endogenous and heterologously expressed Gi-coupled receptors.
Wilms Tumor
Correspondence to Gripp et al. nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation.
Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation.
Wiskott-Aldrich Syndrome
A phosphatidylinositol 3-kinase-independent insulin signaling pathway to N-WASP/Arp2/3/F-actin required for GLUT4 glucose transporter recycling.
N-WASP activation by a beta1-integrin-dependent mechanism supports PI3K-independent chemotaxis stimulated by urokinase-type plasminogen activator.